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Abstract
Streptococcus pyogenes is adapted for persistence in humans. It typically colonizes the
tonsils and skin, and humans are the only known reservoir. S. pyogenes can cause a wide
range of mild to serious infections. Most streptococci-related deaths are due to
complications of rheumatic fever and invasive infections. S. pyogenes produces virulence
factors that contribute to the pathogen’s ability to colonize and cause disease, including
streptococcal superantigens (SAgs), also known as streptococcal pyrogenic exotoxins
(Spes). SAgs function by cross-linking T cells and antigen presenting cells (APC) which
may cause a massive inflammatory response, and as such have been found to contribute
to streptococcal toxic shock syndrome (STSS). The role of SAgs in adaptation of S.
pyogenes to its target niche has not been investigated.
colonizes mouse complete nasal turbinates (cNT).

S. pyogenes experimentally

Murine models of streptococcal

infection are imperfect systems due to inherent host-specific tropism. In this thesis, the
colonization potential of S. pyogenes MGAS8232, associated with rheumatic heart
disease, and S. pyogenes MGAS5005, associated with invasive infections, were assessed
to explore the contribution of SAgs to nasal colonization in a mouse model. Colonization
was tested in multiple mouse strains expressing human or mouse major histocompatibility
complex (MHC) class II.

C57BL/6 (B6) mice expressing human leukocyte antigen

(HLA) transgenes showed enhanced colonization, up to ~100,000-fold at 48 hours postinoculation. Individual and combined SAg deletions were assessed for nasal colonization.
S. pyogenes MGAS8232 deletion colonization in mice expressing HLA-DR4 and HLADQ8 (DR4/DQ8) determined that SpeA was the major contributing SAg to the
establishment of colonization, with minor contributions from SpeL and streptococcal
mitogenic exotoxin Z (SmeZ). Colonization of S. pyogenes MGAS5005 was assessed in
FVB mice, which express murine MHC class II q (H-2q), and SpeJ and SmeZ were the
main contributing SAgs to the establishment of nasal colonization. SAgs contribute to 48hour streptococcal recovery, but do not change the kinetics of bacterial clearance from
cNT. These findings support the hypothesis that SAgs play an important role in niche
adaptation and the establishment of colonization in mild or asymptomatic streptococcal
infections in a murine model of nasal infection.

iii

Keywords
Superantigen, Streptococcus pyogenes, streptococcal pyrogenic exotoxin, colonization,
transgenic mice, mouse models, pharyngitis, group A Streptococcus

iv

Acknowledgements
I would like to thank all of the wonderful staff and students who have joined The
Department of Microbiology and Immunology and the McCormick lab throughout my
tenure. I wish that I could thank everyone personally, your friendship, trips for coffee,
sushi nights, card making classes, yoga, dinners, pubs, shopping trips, phone calls,
suggestions and advice have made a huge difference to the quality of my research and my
life, thank you for including me in your lives, I am richer for having known you. I would
like to thank Kelcey, Stacey and Catherine for editing this thesis in its various
incarnations. I would like to thank A. K. M. Nur-ur Rahman for sharing the road with me
from our first days in the McCormick lab to my last. Your friendship is invaluable.
I would like to thank our collaborators Dr. M. Kotb from the University of Illinois
in Cincinnati for the transgenic HLA DR4/DQ8 mice, Dr. P. P. Cleary from the
University of Minnesota in Minneapolis for inviting me to your laboratory to learn the
nasal turbinate surgery, and to Dr. T. Dileepan and A. Gillman for teaching me their
methods. I would like to thank Dr. E. Cairns for the transgenic HLA DR4 mice, and Dr.
Ian Welch for his assistance analyzing the histology data. I would like to additionally
thank Dr. S. M. Haeryfar for the use of his flow cytometer, and antibodies, and for being
a sounding board for my science, as well as for reviewing and editing my thesis. I admire
your thorough, detailed and organized approach to research and I appreciate your passion
for science, it has been inspiring working with you. I would like to thank Delfina
Mazzuca Siroen for her assistance in submission of animal ethics protocols, her
instruction on the finer points of animal husbandry, her feedback on protocol design,
helping me with histology processing and staining and the million other things that she
has assisted me with, both personal and professional. Thank you.
I would like to thank my committee members Dr. David E. Heinrichs and Dr. S.
Mansour Haeryfar for their sound advice and assistance in meeting my scientific goals.
I would like to thank my supervisor Dr. John McCormick for his continued
support of my work. The joy that you express with each new result presented to you
makes it all worth it. Thank you for giving me the freedom to pursue this work, and other
research over the years. I have truly enjoyed working with you.

v

I would like to thank Mr. Al Lawrence who taught me high school biology. The
concepts that I learned from him have served me well throughout most of my time at
university. If it were not for his infectious passion for science, I would have become an
artist.
Thank you to my family and friends for understanding why for a good portion of
my PhD that I could not leave the mice or the bacteria for more than 24-36 hours at a
time. I appreciate your love and unconditional patience. I would not have finished
without it.
Finally, I would like to thank my husband Mark Phipps, who not only suggested
that I undertake my PhD, and has patiently waited for me to complete it. It is very rare to
have the opportunity to pursue your passion; I am deeply grateful and humbled that Mark
has offered me the opportunity to do so. Thank you for tolerating the late nights and 5 am
starts that were sometimes necessary, for the lack of weekends and the distraction.
Finally, thank you for not divorcing me during any part of this process. I love you.

vi

Table of Contents

Page
Title Page

i

Certificate of Examination

ii

Abstract

iii

Acknowledgements

v

Table of Contents

vii

List of Tables

xiii

List of Figures

xiv

List of Appendices

xvii

List of Abbreviations

xviii

Chapter 1: Introduction

1

1.1.

Group A Streptococcus

2

1.2.

Infections by Streptococcus pyogenes

3

1.2.1.

Infection versus colonization versus asymptomatic

3

colonization
1.2.2.

Severe streptococcal infections

3

1.2.3.

Mild to moderate streptococcal infections

8

1.2.4.

Asymptomatic colonization by Streptococcus pyogenes

9

1.2.5.

Treatment of streptococcal infections

10

1.3.

Genetic diversity in Streptococcus pyogenes

11

1.4.

Regulation of streptococcal virulence factors

13

1.5.

Superantigens

15

1.5.1.

Superantigen structure

15

1.5.2.

Staphylococcal superantigens

19

1.5.3.

Streptococcal superantigens

19

1.6.

Streptococcal strains

20

1.6.1.

Streptococcus pyogenes MGAS5005

21

1.6.2.

Streptococcus pyogenes MGAS8232

21

vii

Page
1.7.

Murine strains as experimental tools in investigating

22

Streptococcus pyogenes
1.8.

Pathophysiological structure of the murine nose and

22

oropharynx
1.8.1.

Pathophysiological comparison of nasal tissue between

25

mice and humans
1.8.2.

Nasal-associated lymphoid tissue

25

1.8.3.

Streptococcal colonization and the murine nasal infection

26

model
1.9.

Rationale and hypothesis

27

Chapter 2: Materials and Methods

28

2.1.

Bacterial growth conditions

29

2.1.1.

Escherichia coli growth conditions

29

2.1.2.

Streptococcus pyogenes growth conditions

29

2.2.

Genetic isolation

33

2.2.1.

Plasmid isolation from Escherichia coli

33

2.2.2.

Isolation of genomic deoxyribonucleic acid from

33

Streptococcus pyogenes
2.3.

Deoxyribonucleic acid visualization

33

2.3.1.

Agarose gel electrophoresis

33

2.3.2.

Deoxyribonucleic acid agarose gel extraction

34

2.4.

Polymerase chain reaction

34

2.4.1.

Standard polymerase chain reaction methods

34

2.4.2.

Escherichia coli colony screening by polymerase chain

40

reaction
2.4.3.

Deoxyribonucleic acid sequencing

40

2.5.

Molecular cloning

40

2.5.1.

Restriction digestions

40
viii

Page
2.5.2.

Deoxyribonucleic acid ligations

41

2.5.3.

Deoxyribonucleic acid ethanol precipitation

41

2.5.4.

Preparation of rubidium chloride competent Escherichia

41

coli
2.5.5.

Escherichia coli transformations

42

2.5.6.

Preparation of electrocompetant Streptococcus pyogenes

42

2.5.7.

Electroporation of Streptococcus pyogenes

42

2.5.8.

Streptococcal genome mutagenesis

43

2.5.9.

Complementation of speA into the superantigen deletion

50

strain of Streptococcus pyogenes MGAS8232
2.6.

Protein visualization

50

2.6.1.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

50

2.6.2.

Western blots

51

2.7.

Protein expression and purification

51

2.7.1.

Histidine-tagged superantigen purification

51

2.7.2.

Trichloroacetic acid streptococcal supernatant protein

52

precipitation
2.8.

Antibody generation

53

2.8.1.

Antibody production

53

2.8.2.

Antibody titres

53

2.9.

Mouse housing and breeding

54

2.9.1.

Housing

54

2.9.2.

Mice

54

2.9.3.

Genotyping

56

2.10.

Streptococcal colonization and persistence in a mouse model 56

2.10.1.

Bacterial preparation

56

2.10.2.

Mouse nasal inoculation

57

2.10.3.

Endpoint surgery

57

2.10.4.

Tissue processing and plating

58

2.11.

Histology

61
ix

Page
2.11.1.

Organ isolation

61

2.11.2.

Histology tissue processing

61

2.11.3.

Cassetting, embedding and sectioning fixed tissues

62

2.11.4.

Haematoxylin and eosin staining of processed tissue

62

2.11.5.

Histology evaluation

63

2.12.

Flow cytometry

63

2.12.1.

Tissue isolation and processing

63

2.12.2.

Flow cytometry

63

2.13.

Cytokine analysis

64

2.13.1.

Human peripheral blood mononuclear cell activation assay

64

2.13.2.

Mouse splenocyte activation assay

64

2.13.3.

Enzyme-linked immunosorbant assay

67

2.13.4.

Multiplex cytokine analysis

67

Chapter 3: Results

68

3.1.

69

Establishment of a murine model of nasal colonization by
Streptococcus pyogenes

3.1.1.

Surgical removal of the complete nasal turbinates of mice

69

3.1.2.

Bacterial dose determination for streptococcal colonization

75

in mice
3.1.3.

Streptococcal nasal colonization varies depending on murine 78
transgenic expression of human MHC class II

3.1.4.

Streptococcal colonization is not dependant on the source of

78

mice
3.1.5.

Nasal colonization by S. pyogenes in mice expressing

79

different murine MHC class II is variable and S. pyogenes
strain-dependant
3.1.6.

Streptococcal superantigenic sensitivity varies with murine
expression of MHC class II

x

79

Page
3.2.

Streptococcus pyogenes MGAS8232 and MGAS5005

87

superantigen isogenic deletion strain creation and
characterization
3.2.1.

Superantigen production by Streptococcus pyogenes

87

3.2.2.

Construction of Streptococcus pyogenes MGAS5005

91

and Streptococcus pyogenes MGAS8232 superantigen
deletion mutants
3.2.3.

Complementation of speA into the S. pyogenes

91

MGAS8232 complete superantigen deletion strain.
3.2.4.

Superantigen deletion did not induce significant growth

98

defects
3.2.5.

Superantigen protein production by in vitro cultured

98

isogenic streptococcal deletion mutants confirms
superantigen deletion
3.3.

Role of superantigens in nasal colonization of

98

Streptococcus pyogenes MGAS5005 of FVB mice.
3.3.1.

Streptococcal superantigens influence the colonization

103

of S. pyogenes MGAS5005 in the nasal passage of
FVB mice
3.4.

Role of superantigens in nasal colonization of

103

Streptococcus pyogenes MGAS8232 in DR4/DQ8 mice
3.4.1.

Streptococcal superantigens produced by S. pyogenes

103

MGAS8232 contributed to the colonization of the nasal
passage at 24 hours post-inoculation
3.4.2.

Streptococcal burden in the organs of Streptococcus

113

pyogenes MGAS8232-infected transgenic DR4/DQ8
mice
3.4.3.

Superantigen deletion impacts streptococcal burden at 48
hours, but not the persistence of S. pyogenes in
DR4/DQ8 nasal passage
xi

113

Page
3.4.4.

Infection with a superantigen-competent strain of S.

117

pyogenes MGAS8232 results in greater mucus
production and cellular debris in the nasopharyngeal
meatus
3.4.5.

Immunophenotyping of splenic, lymph node, and nasal

117

cells in S. pyogenes MGAS8232-treated mice

Chapter 4: Discussion

133

Chapter 5: References

147

Chapter 6: Appendices

159

Curriculum Vitae

174

xii

List of Tables
Page
Table 1.

Jones criteria for diagnosis of rheumatic fever

7

Table 2.

Bacterial strains used in this study

30

Table 3.

Plasmids used in this study

32

Table 4.

Primers used in this study

35

Table 5.

Mouse strains used in this study

55

Table 6.

Antibodies for flow cytometry

65

Table 7.

Flow cytometry staining panels

66

Table 8.

Summary of mouse strain-specific superantigen sensitivity

82

Table 9.

Antibodies used for Western blot analysis

88

xiii

List of Figures

Page
Figure 1.

Streptococcal superantigen structure and immunoreceptor

16

interactions
Figure 2.

The physiological location of the ethmoid turbinates,

23

nasal-associated lymphoid tissue and the maxillary sinuses
Figure 3.

Streptococcus pyogenes MGAS5005 superantigens in

44

genomic context
Figure 4.

Streptococcus pyogenes MGAS8232 superantigens in

46

genomic context
Figure 5.

Markerless mutagenesis in Streptococcus pyogenes

48

Figure 6.

Surgical removal of the murine complete nasal turbines

59

Figure 7.

Histological transition in the haematoxylin and eosin-stained 70
murine head cross sections from T4 to T3

Figure 8.

Haematoxylin and eosin-stained section of transected

73

murine head indicating the position of the NALT from a
wild type S. pyogenes MGAS8232-infected mouse
Figure 9.

Efficient nasal colonization in humanized mice by S.

76

pyogenes is dependent on human MHC class II
Figure 10.

Streptococcus pyogenes colonization variability in mice

80

expressing murine MHC class II
Figure 11.

Splenocyte activation of B6 and transgenic HLA-mice by

83

recombinant streptococcal superantigens
Figure 12.

Splenocyte activation of BALB/c and FVB mice by

85

recombinant streptococcal SAgs
Figure 13.

Anti-streptococcal superantigen antibodies are specific

89

for their target proteins
Figure 14.

Streptococcal superantigen deletion strategy for individual
and entire superantigen deletion strains

xiv

92

Page
Figure 15.

Strategy to evaluate the superantigen deletion strains.

94

Figure 16.

Confirmation of superantigen deletions in mutant strains

96

of Streptococcus pyogenes
Figure 17.

Assessment of the growth of isogenic streptococcal

99

superantigen deletion strains
Figure 18.

Expression analysis of streptococcal superantigens in the

101

isogenic superantigen deletion strains
Figure 19.

Specific superantigens are critical for successful

104

colonization of cNT by Streptococcus pyogenes MGAS5005
in FVB mice
Figure 20.

Piloerection of FVB mice in Streptococcus pyogenes

106

MGAS5005-treated mice
Figure 21.

Streptococcus pyogenes MGAS5005 recovered from the

108

organs of nasally-treated FVB mice
Figure 22.

Nasal colonization by isogenic superantigen deletion

110

strains of Streptococcus pyogenes MGAS8232
Figure 23.

Streptococcus pyogenes MGAS8232 recovered from the

113

organs of nasally-treated DR4/DQ8 mice
Figure 24.

Kinetics of nasal colonization by Streptococcus pyogenes

115

MGAS8232 wild-type and SAg strains in DR4/DQ8 mice
Figure 25.

Histological assessment of nasal tissue sections

119

Figure 26.

Splenocyte gating strategies to assess the proportions of

121

immune cells in mice treated with S. pyogenes
Figure 27.

Nasal infection with wild type and superantigen deletion

123

strains of Streptococcus pyogenes MGAS8232 does not result
in changes in the lymphocyte population in the spleen
Figure 28.

Lymph node gating strategies to assess the proportions of
immune cells in mice treated with S. pyogenes

xv

125

Page
Figure 29.

Nasal infection with wild type and superantigen deletion

127

strains of Streptococcus pyogenes MGAS8232 results in
significantly more macrophage in the pooled lymph nodes
Figure 30.

Gating strategies to assess the proportions of immune cells

129

in mice treated with S. pyogenes in the complete nasal
turbinates
Figure 31.

Nasal infection with wild type deletion strains of
Streptococcus pyogenes MGAS8232 results in a decrease in
CD11c+ cells in the cNT

xvi

131

List of Appendices
Page
Appendix 1. Cytokine analysis of complete nasal turbinate tissue

160

homogenate supernatants from FVB mice inoculated
with Streptococcus pyogenes MGAS5005 at 48 hours
Appendix 2. Cytokine analysis of complete nasal turbinate tissue

162

homogenate supernatants from DR4/DQ8 mice infected
with Streptococcus pyogenes MGAS8232 at 24 hours
Appendix 3. Cytokine analysis of complete nasal turbinate tissue

164

homogenate supernatants from DR4/DQ8 mice inoculated
with Streptococcus pyogenes MGAS8232 taken at 48 hours
Appendix 4. Activation of human PBMCs and murine splenocytes by

166

Streptococcus pyogenes wild type and isogenic deletion
bacterial culture supernatants
Appendix 5. Human PBMC stimulated with isogenic Streptococcus

168

pyogenes mutant supernatants
Appendix 6. Animal protocol ethics approval

170

Appendix 7. Human ethics approval

172

xvii

List of Abbreviation


Ohms

C

Degrees Celsius

F

Microferridae

g

Microgram

l

Microliter

M

Micromolar

g

Times gravity



Deletion

A

Deletion of speA

AJZ

Deletion of speA, speJ, and smeZ

C

Deletion of speC

G

Deletion of speG

J

Deletion of speJ

LM

Deletion of speL and speM

SAg

Deletion of all streptococcal SAgs

SAg + A

Deletion of all streptococcal SAgs complemented with speA

Z

Deletion of smeZ

Amp

Ampicillin

APC

Antigen presenting cell

APS

Ammonium persulfate

ARF

Acute rheumatic fever

B

Brain

BHI

Brain heart infusion media

bp

Base pair

CBB

Coomassie brilliant blue

CD

Cluster of differentiation

cfu

Colony forming unit

cNT

Complete nasal turbinates

xviii

cRPMI

Complete media, supplemented Rosewell Park Memorial Institute tissue
culture media

DC

Dendritic cells

DNA

Deoxyribonucleic acid

DNase

Deoxynuclease

dNTP

Deoxyribonucleotide triphosphate

DQ8

Mice transgenically expressing MHC class II HLA-DQ8

DR4

Mice transgenically expressing MHC class II HLA-DR4

DR4/DQ8

Mice transgenically expressing MHC class II HLA-DR4 and HLA-DQ8

EDTA

Ethylenediaminetetraacetic acid

ELISA

Enzyme linked immunosorbant assay

Erm

Erythromycin

ET

Ethmoid turbinate

FBS

Fetal bovine serum

FVB

Friend leukemia virus B-type mice

HBSS

Hanks balanced saline solution

HF

High-fidelity buffer, for Phusion polymerase

HLA

Human leukocytic antigen

HP

Human plasma

HPLC

High power liquid chromatography

HRP

Horseradish peroxidase

ICE

Integrative conjugative element

IFN

Interferon gamma

IL

Interleukin

IPTG

Isopropyl -D-1-thiogalactopyranoside

Kan

Kanamycin

Kb

Kilobase

kDa

Kilo dalton

L

Liter

LB

Luria-Bertani media

Mb

Mega base
xix

MCP-1

Monocyte chemotactic protein-1

MDSC

Myeloid-derived suppressor cells

MHC

Major histocompatibility complex

MIP-1

Macrophage inflammatory protein-1 alpha

ml

Milliliter

mM

Millimolar

mm

Millimeters

NALT

Nasal-associated lymphoid tissue

NF

Necrotizing fasciitis

NK

Natural killer cells

No

Nose

OD

Optical density

PBMC

Peripheral blood mononuclear cells

PBS

Phosphate-buffered saline

PBST

Phosphate-buffered saline with tween-20

PCR

Polymerase chain reaction

pM

Picomolar

PVDF

Polyvinylidene fluoride

RF

Rheumatic fever

RHD

Rheumatic heart disease

RNA

Ribonucleic acid

RNaseA

Ribonuclease A

RPM

Revolutions per minute

RPMI

Roswell Park Memorial Institute medium

rSAg

Recombinant superantigen

SDS

Sodium dodecyl sulfate

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SEA

Staphylococcal enterotoxin A

SmeZ

Streptococcal mitogenic exotoxin Z

Spe

Streptococcal pyrogenic exotoxin

SSA

Streptococcal superantigen
xx

STSS

Streptococcal toxic shock syndrome

TE

Tris-EDTA buffer

TAE

Tris-acetate EDTA buffer

TCA

Trichloroacetic acid

TCR

T cell receptor

TEMED

Tetramethylenediamine

TGF-

Transforming growth factor beta

THY

Todd-Hewitt and yeast extract

TMB

3,3’,5,5’ tetramethylbenzidine, ELISA substrate reagent

TNF

Tumor necrosis factor alpha

TSST-1

Toxic shock syndrome toxin-1

U

Units

V

Volts

V

Variable beta chain

v/v

Volume per volume

w/v

Weight per volume

xxi

1

Chapter 1: Introduction

2

1.1. Group A Streptococcus
Streptococcus pyogenes are Gram-positive, -haemolytic cocci that are
aerotolerant anaerobes [1-2], and obligate human pathogens [3]. Although S. pyogenes is
known to cause a wide range of active infections, they may also persist asymptomatically
in the human population by colonizing the human oropharynx, specifically in the tonsils
[4].
Streptococcal infections are contracted from direct, indirect or droplet contact
with oral or wound secretions from an infected individual [5-7], and can be transmitted
orally to cause streptococcal disease in atypical sites [8-9]. Casual contact rarely leads to
disease [6]. The incubation period for streptococcal disease is one to three days postexposure and the infection is communicable until seven days after the start of antibiotic
treatment [6].
S. pyogenes produces infections of varying clinical severities which may be
generally separated into diseases of two categories, namely severe streptococcal
infections and mild or moderate infections. S. pyogenes is associated with significant
morbidity and mortality globally and was ranked ninth among individual pathogens
causing highest estimated deaths as reported by the World Health Organization in 2002
[10].

In high-income countries, the S. pyogenes diseases that are of the greatest

significance are pharyngitis and invasive diseases, whereas in low-income countries
rheumatic fever, rheumatic heart disease and glomerulonephritis are the most major S.
pyogenes diseases with endemic incidences of impetigo [11]. The greatest burden of
streptococcal diseases is encountered in low-income countries [11].

Streptococcal

infections also result in a significant economic burden ranging in the hundreds of millions
of dollars a year in the United States [12]. Genetically identical strains can cause both
severe and non-severe disease, indicating an important role for host factors in determining
the clinical outcome of streptococcal infections [13].
Serotypic classification of S. pyogenes has traditionally relied on variable surface
antigens such as the M protein and the T antigen [14]. The M-protein is an antiphagocytic surface protein and the T antigen is a pilus protein that binds fibronectin and
collagen [15] and is resistant to trypsin digestion [16]. At any given time, there are
multiple serotypic lineages of S. pyogenes circulating within the human population.

3

Differences in the distribution of S. pyogenes serotypes vary both by year and
geographically [17]. There are molecular differences in the M type of strains of S.
pyogenes that circulate in Africa and in the Pacific region compared to high-income
countries [11]. Certain M serotypes of S. pyogenes have been linked to the prevalence of
certain types of infections.

1.2. Infections by Streptococcus pyogenes
1.2.1. Infection versus colonization versus asymptomatic colonization
Strictly by definition within the context of bacteriology colonization means that
there is a presence of bacteria in a given area. The implication of colonization may be
that the bacteria will not cause disease. Asymptomatic colonization specifically means
that the presence of the bacteria within the host results in no appreciable or detectable
symptoms of infection and may additionally imply variable lengths of colonization, either
transient or persistent infection.

Finally, the definition of bacterial infection is the

proliferation of a bacterium within a tissue which results in cellular injury and is
symptomatic.

1.2.2. Severe streptococcal infections
Severe streptococcal disease includes necrotizing fasciitis (NF), streptococcal
toxic shock syndrome (STSS) and chronic post-infection sequelae such as
glomerulonephritis, streptococcal arthritis, and rheumatic fever (RF), which may
ultimately lead to rheumatic heart disease (RHD). Severe streptococcal infections can be
the result of a previous streptococcal infection by S. pyogenes, nosocomial infections, or
in up to 50% of cases there is no obvious portal of entry for the streptococcal infection
[18]. Severe streptococcal diseases can be further sub-classified as being either invasive
disease or post-infection sequelae. Invasive diseases are defined as infections in which
streptococci are isolated from an otherwise sterile site, whereas post-infection sequelae
are defined as a severe consequence of a streptococcal infection. Monitoring of invasive
streptococcal diseases over an 8-year period in Ontario, Canada revealed that 12% of
invasive streptococcal cases were hospital-acquired, and that the common modes of
transmission were from patient to patient or by a staff carrier [19]. The major risk factors

4

for severe and invasive streptococcal infections are pre-existing wounds, chicken pox, use
of immunosuppressive drugs, pregnancy and underlying illnesses [6, 18, 20].

In

developing countries, half of the patients with severe streptococcal diseases have an
underlying disease or chronic illness such as human immunodeficiency virus infections,
cancer, diabetes, alcohol abuse, or chicken pox [21].
It is estimated that there are approximately 18.1 million cases of severe
streptococcal infections, including post-infection sequelae, and an additional 1.78 million
new cases annually globally [10]. In the United States, there are 9,600-9,700 cases of
invasive streptococcal diseases each year that result in 1,100-1,300 deaths [17]. In Halton
Region in the province of Ontario, there were between 1 to 5 cases of severe streptococcal
disease per 100,000 individuals between 1997 and 2009 [22-23].
Necrotizing fasciitis is an infection of the subcutaneous tissue, fascia, and fat that
can lead to tissue necrosis, severe illness, streptococcal toxic shock syndrome (STSS) and
mortality [24]. S. pyogenes is the most common cause of NF [25], and is diagnosed by a
positive culture for S. pyogenes from an otherwise sterile site such as blood, connective
tissue, or fascial tissue with either gross cutaneous necrosis or histopathology that
demonstrates necrosis and polymorphonuclear cell infiltration in the fascia, reticular
dermis or subcutaneous fat [19, 25]. NF most commonly presents with localized pain
described to be disproportionate to the size of injury, chills, fever, sore throat, and
respiratory symptoms, rash and vomiting [25]. The incidence of NF in children in
Canada has been reported to be between 1.3 and 2.93 cases per million [25-27] and is
associated with up to 20% mortality, which occurs in a shorter timeframe than any other
severe streptococcal disease [25, 28] and is often preceded by a Varicella infection
(chicken pox) [25-26].
Streptococcal toxic shock syndrome is a host immune-mediated systemic disease
that is induced by superantigens (SAgs; described below) [29]. STSS is very severe in
nature with a rapid onset that can result in hypotension and multiple organ failure [30].
Streptococcal SAgs have been detected in patients with STSS and a lack of anti-SAg
antibodies has been associated with an increased risk of STSS [31-32]. STSS often
occurs in conjunction with other invasive streptococcal diseases such as cellulitis,
bacteremia and necrotizing fasciitis, and can be the result of a tegumentary breech [29,
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32], or have no apparent source. The diagnostic criteria for STSS include hypotension,
renal function impairment, disseminated coagulopathy, adult respiratory distress
syndrome, erythematous macular rash, tissue necrosis and central nervous system
disorders [33]. The early symptoms of STSS are flu-like with fever, swollen lymph
nodes, irritated throat, vomiting, diarrhea, rash, and muscle and joint pain, which may be
disproportionately severe [18, 32]. Resulting intravascular coagulation can result in
circulatory impairment which may lead to gangrene and may require surgical intervention
[18]. Mortality rates in patients with STSS have been estimated to be up to 81% [21].
Glomerulonephritis is the immune-mediated swelling of and subsequent damage
to the kidneys which may ultimately result in kidney failure. This condition has been
linked to preceding streptococcal infection, and typically occurs in children or young
adults [34]. Symptoms of post-streptococcal glomerulonephritis are edema, hypertension,
hematuria, urinary sediment abnormalities, fever and decreased serum complement levels
[34].

Glomerulonephritis occurs after a latency period of an average of ten days

following streptococcal infection for acute glomerulonephritis, and within three to six
weeks for glomerulonephritis [34]. Nephrogenicity seems to be related to M protein
serotypes, in particular with M49 serotype strains in instances of skin infection [35], but
all strains within the same M serotype are not necessarily nephrogenic [34].

The

incidence of skin infections and glomerulonephritis is seasonal, and peaks in the summer
months in temperate climates, and is pharyngitis-associated acute glomerulonephritis in
northern climates [34].

The median incidence of acute post-streptococcal

glomerulonephritis in children in less developed countries was 24.3 cases per 100,000
[10]. It is estimated that there are 470,000 global cases annually with deaths in about 1%
of all cases, mostly in adults [10]. The incidence of glomerulonephritis has continually
declined globally, but there are still parts of the world that have a high incidence such as
Africa, the Caribbean, South America, New Zealand, and Kuwait [34].
Rheumatic fever is a disease linked to poverty which is a post-streptococcal infection
sequelae that may develop 2-5 weeks after the initial streptococcal infection [36-38].
Each year there are 470,000 estimated new cases of RF and 233,000 deaths attributable to
RF or RHD [10]. A decrease in the incidence of RF in the developed world has been in
part attributed to the lower incidence of streptococcal infection due to good nutrition,
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good hygiene, and treatment with antibiotics [10, 39].

In developing countries S.

pyogenes is the most common cause of invasive bacterial disease in young infants during
the first two months of life [40]. This is due to both the greater incidence of any type of
streptococcal infection, and the chances that infections are more likely to go untreated
[38]. S. pyogenes are rarely recovered in RF cases because the preceding streptococcal
infection occurs well before the first signs of RF . Clinical diagnosis of RF is made
according to updated Jones criteria [41] (Table 1).

The symptoms of RF are due to

antibody cross-reactivity against shared epitopes from the streptococcal M-protein similar
to epitopes found in cardiac myosin, synovial, and neuronal tissues, which ultimately
results in autoimmunity [42-43].

Sera in patients with RF frequently have high

concentrations of myosin-reactive antibodies [34]. This autoimmune reaction ultimately
results in synovial inflammation (polyarthritis), neuronal tissue reactivity (Sydenham’s
chorea) and inflammation of the heart. Carditis is the most serious manifestation of RF
with polyarticular arthritis being the most common manifestation. RF-associated carditis
is associated with permanent valve damage [34].

S. pyogenes M-serotypes that are

associated with the development of RF are found to have increased virulence, higher M
protein expression and form mucoid colonies with upregulated capsule production to
prevent phagocytosis [38].
RHD follows RF autoimmune reactivity to the heart resulting in lesions and
inflammation in the heart valves that may lead to permanent and progressive cardiac
damage [42]. The mitral valve is the most common valve affected, followed by the
aortic, tricuspid, and occasionally the pulmonary valve [38]. With 15.6 million cases,
RHD is the most common cause of heart disease in children worldwide and is the leading
cause of cardiovascular death in the first five decades of life in developing countries [10,
36, 44]. RHD can sometime cause strokes; it is estimated that 3-7.5% of strokes in all
developed countries are due to underlying RHD, which results in 108,000-269,000 deaths
due to strokes per year in developing countries [10]. There are an estimated 2.39 million
cases of RHD globally in children aged five to fourteen years, and it is estimated that one
and a half percent of those cases will result in death each year [10]. Mortality due to
RHD varies geographically with the total number of deaths being approximately 23,877
in more developed countries, and 468,164 in less developed countries [10]. The highest
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Table 1. Jones criteria for the diagnosis of rheumatic fever. The diagnosis of RF requires
the co-presence of either two major criteria, or one major criterion and two minor criteria,
together with supporting evidence of a preceding infection with S. pyogenes [41].
Major Criteria

Minor Criteria

Migratory polyarthritis

Fever

Carditis

Elevated acute-phase reactants

Subcutaneous nodules

Arthralgia

Chorea

Prolonged PR interval on
electrocardiography

Erythema marginatum
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prevalence of RHD is found in sub-Saharan Africa where there are 5.7 cases per 1,000,
approximately five times higher compared to developed countries [10]. It is estimated
that two to three percent of children in Cambodia and Mozambique have RHD which is
often undiagnosed [39], and that 60% of RF patients will develop RHD [10], which is
why prophylaxis is often used to prevent subsequent cardiac damage.

1.2.3. Mild-to-moderate streptococcal infections
Aside from serious, severe and invasive streptococcal diseases, S. pyogenes can
also be the causative agent of less severe, mild-to-moderate infections such as scarlet
fever, impetigo, and streptococcal pharyngitis. These infections are more common than
severe streptococcal infections and are more likely to go unreported and untreated. Mildto-moderate S. pyogenes infections are often considered to be inconsequential, despite the
potential complications of developing severe streptococcal disease.
Scarlet fever is a SAg-mediated streptococcal disease [45] that is characterized by
the swelling of the tongue that gives it a strawberry colour and appearance, a distinctive
sandpaper rash on the trunk of the body, fever, and exudative pharyngitis [46]. The
incubation period for scarlet fever is one to two days. The rash may persist for more than
a week and as it fades may result in desquamation [46].
Impetigo is a topical skin infection, often caused by S. pyogenes, that results in
skin abrasions which most often form around the mouth [47]. Estimates of the prevalence
of impetigo in the global population vary based on the study. Studies done in Brazil,
Ghana, and Mali found impetigo in 9.6-12.3% of the population; other studies have
indicated that the prevalence of impetigo is between 0.2-35%; the range in prevalence
may be due to differences in the definition of cases and bacteriological sampling
techniques between groups [47]. S. pyogenes was isolated from approximately 95% of
impetiginous lesions in studies in Brazil and Africa, which was consistent with previous
American studies [47]. Impetigo is especially prevalent in children between the ages of 2
and six years old, especially those in developing countries. At any given time 111 million
children in developing countries are estimated to have streptococcal pyoderma globally
[10].
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Streptococcal pharyngitis, otherwise known as ‘strep throat’, is a common illness
in which a streptococcal infection of the pharynx results in swelling of the tonsular tissue
and mucus production over the tonsils, and is often accompanied by fever.

Large

numbers of S. pyogenes are isolated from the saliva of convalescents [7] and droplets
containing infected saliva can be passed by sneezing, coughing or talking [5].
Pharyngeal infections are some of the most common streptococcal infections with
an estimated 616 million pharyngeal infections globally each year [10]. It is estimated
that annually in developed countries, approximately 15% of school-aged children and
four to ten percent of the population will suffer from a symptomatic episode of
streptococcal pharyngitis [10], and that the average cost in the treatment (both medical
and non-medical) of each case is approximately $200, which amounts to an estimated
224-539 million dollars per year cost for streptococcal pharyngitis in the United States
alone [12]. The incidence of pharyngeal infection in less developed countries are
estimated to be five to ten times greater than in the developed world [10]. Pharyngeal
infections may resolve on their own or with aid of antibiotic treatment. Streptococcal
pharyngitis may potentially precede more severe streptococcal infections or post-infection
sequelae.

1.2.4. Asymptomatic colonization by Streptococcus pyogenes
Streptococcus pyogenes association with humans may also result in asymptomatic
persistence of the bacteria within the human population.

As this association is

asymptomatic, there is no regular monitoring for the detection of S. pyogenes in healthy
populations globally. The prevalence of S. pyogenes carriage varies by age. A general
survey of the throat carriage of S. pyogenes in 2,626 asymptomatic individuals in
Denmark revealed that 2.2% of the population was asymptomatically colonized. The
incidence of colonization was inversely correlated with the age of the individual. The
incidence of streptococcal colonization in individuals less than 14 years of age was
between 10.9-12% [48-49], and the prevalence of streptococcal asymptomatic
colonization in children under 5 was 24% [49]. The lowest incidence of streptococcal
carriage was in individuals older than 45 years (0.6%) [48].

10

Asymptomatic carriers of S. pyogenes can be the cause of severe streptococcal
infection in a healthcare environment [19]. There have been reported incidences of
asymptomatic carriage of the same strains of S. pyogenes which were the cause of severe
and invasive infections in an outbreak in healthcare and household contacts [21]. A study
of 46 patients with invasive streptococcal infection in Ontario, Canada determined that
the rate of streptococcal colonization in household contacts was 12% in throat cultures
approximately 5-12 days after the onset of illness in the index patient. It was determined
that household contacts were more likely to be colonized if they had 4 or more hours of
contact daily with the index patient, and if they were younger in age [21].

The

asymptomatic persistence of a streptococcal serotype within the population, regardless of
the previous association with an infectious disease outbreak, likely plays a role in the
overall incidence of streptococcal disease, either mild or severe.

1.2.5. Treatment of streptococcal infections
Effective resolution of non-severe S. pyogenes infections (such as pharyngitis or
impetigo) can prevent the potential complications of severe streptococcal disease or the
development of post-infection sequelae.

Resolution of streptococcal infection is

dependent on a fast and accurate diagnosis and effective treatment with antibiotics and,
where necessary, supportive therapy [28].

S. pyogenes is most often treated with

penicillin or amoxicillin, or alternatively in the case of penicillin allergy with clindamycin
or macrolide antibiotics [25, 36, 50].

Prophylaxis is recommended in cases of

colonization of healthcare workers carrying an outbreak strain of S. pyogenes [6].
Treatment of RF involves a two-pronged approach involving the treatment of the
streptococcal infection with antibiotics and anti-inflammatory medications to treat the
symptoms of RF. Intravenous immunoglobulin (IVIG) has also been used as a treatment
for carditis [38]. The best prevention of RF is primary prophylaxis to prevent subsequent
streptococcal infections. Long-term prophylaxis is recommended by the World Health
Organization and the American Heart Association guidelines for people with a history of
RF every three to four weeks until the age of 21 to prevent subsequent rheumatogenic
incidents [10, 39]. When left untreated, episodes of RF resolve on their own within three
months, but may ultimately result in cardiac damage. Sixty-five to seventy-five percent
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of patients recover from the carditis without any further consequences; this recovery rate
decreases if there are subsequent RF occurrences or if the carditis is severe [38].
There have been some reported cases of macrolide and multi-drug resistance in S.
pyogenes including resistance to azithromycin, tetracycline, clindamycin, lincomycin,
streptogramin, chloramphenicol and erythromycin [36, 51-52].

There are different

incidences of antibiotic resistance reported in geographically distinct outbreaks that range
from 1-48% [36], and antibiotic resistance has been considered to be a contributing factor
to outbreaks of streptococcal disease [53].

Specifically, a recent report of a 2011

outbreak of scarlet fever in Hong Kong, China reported that the causative strain of S.
pyogenes had acquired resistance to macrolide-lincomycin-streptogramin and tetracycline
and encoded a MATE efflux pump, which is thought to be associated with antimicrobial
resistances [53-54]. Nevertheless, despite the long-term use of -lactam antibiotics to
treat S. pyogenes infection, there has never been a documented case of penicillin
resistance for this organism.

1.3. Genetic diversity in Streptococcus pyogenes
Streptococcal strains vary in genome size from 1.33 to 1.94 Mb in size. The
variable size is due to the insertion of mobile genetic elements into the base streptococcal
genome (NCBI genome sequence database). A large part of the genetic diversity in S.
pyogenes is attributed to differences in the mobile genetic elements that are integrated
into a base genome [55]. There is very little genetic change in the base genome between
S. pyogenes serotypes [55]. There is limited variability in the clonal populations of S.
pyogenes isolated in an outbreak.

On average, there are 49 single nucleotide

polymorphisms and 11 insertion and deletion events in the core genome of surveyed
clonal S. pyogenes strains that were surveyed over the course of fifteen years [56].
Critically, the streptococcal population is not genetically static, but made of distinct sub
clones that appear in each epidemic group [56].
Streptococci can acquire bacteriophage, transposons and integrative conjugative
elements that often contain virulence factors and antibiotic resistance determinants [57].
The acquisition or loss of virulence factors and antimicrobial resistance encoding
deoxyribonucleic acids (DNA) has been linked with changes in infectious properties and
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outbreaks [53, 58]. Integrative conjugative elements (ICE) have been associated with the
acquisition of antibiotic resistance in streptococcal populations, but do not encode SAgs
[53]. ICE differ in their GC content more than bacteriophage, which may suggest that
they originate from organisms that are not streptococci [57].
Bacteriophages are viral particles that may infect and introduce foreign DNA into
a bacterial host. All sequenced strains of S. pyogenes are polylysogenic [55] and many of
these bacteriophage elements encode virulence factors including SAgs [59]. Acquisition
of a bacteriophage can change the infective properties of the streptococci due to the
acquisition of new virulence factors. Often there is excision and reintegration of the
bacteriophage DNA during normal growth (Kasper and McCormick, Unpublished data)
and this movement may be a method regulating gene expression in S. pyogenes [60]. The
phage-associated hypermutation is growth phase dependent and may allow the bacteria to
better adapt to a new or changing environment [60].
Lysogenic bacteriophages found in S. pyogenes are mosaic in nature and may
have pieces in common with other phages [61]. Bacteriophages that carry streptococcal
SAgs can be transferred between different strains of S. pyogenes, and are not restricted by
M serotypes.

Transfer has been detected between group A, group C and group G

streptococci, indicating a potentially common pool of bacteriophage [62-64]. This body
of work also indicated that toxigenic conversion can happen by lysogenic transfer [61].
This lysogenic transfer, including the transfer of virulence factors, can provide plasticity
that could be advantageous for adapting to a host challenge and may possibly result in
increases in virulence. A bacteriophage can be induced to enter the lytic cycle in the
presence of mammalian cells, including in a mouse nasopharyngeal model [55], which
may indicate that phages can be transferred in vivo in the host. Toxin encoding lysogenic
bacteriophages can be considered as early pathogenicity islands, which eventually
undergo mutagenesis and selective pressure to alter sequences such that the island can no
longer excise or enter the lytic cycle. This may be due to the selective advantage provided
by the presence of the mobile genetic element and thus, pathogenicity islands and
prophage can represent varying points of evolution, and depending on the stringency of
the search criterion, may become indistinguishable from the surrounding genome [65].
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The acquisition of bacteriophages that encode novel virulence factors may
contribute to the increased fitness. The resurgence of the M1 strain of S. pyogenes that is
widely circulating globally, is thought to be, in part, due to the acquisition of a
bacteriophage encoding speA [2, 14]. The presence of the speA gene may also be a major
contributing factor in the resurgence of severe and invasive streptococcal infections
reported in the 1980s and 1990s [14]. It stands to reason that the introduction of a novel
bacteriophage that encodes a SAg, or other phage-encoded virulence factor, could
increase the efficiency of asymptomatic carriage, although this has yet to be shown
experimentally.

1.4. Regulation of streptococcal virulence factors
Gene expression in S. pyogenes is dependent on two main types of regulatory
proteins: stand-alone regulators and two component regulatory systems [66-67]. A two
component regulatory system is comprised of a sensory histidine kinase that
autophosphorylates in response to an environmental signal, and transfers the phosphate to
a response regulator, which then affects gene transcription [68]. A stand-alone regulator
is a regulatory protein that does not have an identified sensory kinase associated with it
[66]. There are currently thirteen two-component systems described in S. pyogenes and
multiple stand-alone regulators. The two best-studied virulence regulators in S. pyogenes
are the stand-alone regulator mga operon and the covRS two-component system.
mga was the first positive acting gene regulator of a virulence network discovered
in S. pyogenes [66]. All S. pyogenes have the mga operon which is required for the
adaptation into new tissue sites and controls the expression of surface associated
molecules such as the M protein, and secreted factors like C5a peptidase and the secreted
inhibitor of complement, which are each necessary for immune evasion [66]. The mga
operon controls genes in response to environmental conditions, such as the upregulation
of C5a peptidase in response to elevated carbon dioxide levels, changes in osmolarity,
temperature and iron restriction [66]. mga is encoded on what is believed to be an ancient
pathogenicity island with the M-protein, whose integration into the streptococcal genome
likely occurred prior to speciation [65]. Regulation by the mga regulon reaches its peak
during the exponential phase of bacterial growth, which implies that mga regulated
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proteins are necessary for adaptation of S. pyogenes to new tissue sites at early stages of
infection [66].
Regulatory systems are very sensitive to the introduction of single nucleotide
polymorphisms. It has been observed that there is an overabundance of single nucleotide
polymorphisms in transcriptional regulators between streptococcal strains [56]. Modest
polymorphisms in regulatory genes can result in considerable differences in the
streptococcal transcriptome which can result in differences in pathogenicity [56].
The covRS two-component system influences the transcription of approximately
15% of genes in S. pyogenes, including genes involved in stress adaptation, gene
regulation, pathogenesis, and suppresses surface and secreted proteins. Regulation by
covRS is growth condition-dependent [69] and regulates many streptococcal virulence
factors including the hyaluronic acid synthesis operon, streptokinase, cysteine protease,
mitogenic factor, capsule and streptolysin S [70-74]. CovRS detects stressful conditions
endogenous to the human body such as low iron, temperature of 39C, pH, exogenous
Mg2+, and growth in the presence of saline [75-76], and is required for the adhesion to
keratinocytes [70]. Single nucleotide polymorphisms in the covS gene have been linked
to the ability of streptococcal strains to transition from causing pharyngeal infections to
being more apt to cause invasive infections [77-79]. However, the reported mutations
that are linked to invasive disease protein profile were reported to be present in both
pharyngeal and invasive isolates; conversely, the pharyngeal covS mutations protein
expression profile were also found in both pharyngeal and invasive isolates [80]. S.
pyogenes isolated from a patient with scarlet fever from a 2011 outbreak in Hong Kong
failed to switch to the covRS mutant SpeB-negative form 3 days post infection [53], as
was reported to be characteristic. This may indicate that mutations in covRS may not be
the key determinant of the severity of streptococcal infections in all strains.
Other regulatory systems have been identified and characterized to play a role in
the regulation of virulence genes, often in response to external stimuli such as bacterial
growth phase, temperature, gas concentrations, iron concentration and nutritional
availability. One example is the regulator CodY which regulates the production of
DNases, protease, and hyaluronidase, in response to growth phase and the abundance of

15

nutrients, which may contribute to the dissemination of S. pyogenes and the hydrolysis of
host macromolecules [81].
There is surprisingly little known about the regulation of superantigens in
Streptococcus pyogenes.

There is evidence that streptococcal superantigens are

upregulated early on in infection [82].

In vitro streptococcal superantigens are

upregulated in late log phase or stationary phase [83]. The rgg (also known as ropB)
regulon upregulates transcription is higher in pharyngeal infections, and in general is
affected by growth phase, pH, NaCl concentration and carbohydrate-poor and peptiderich nutrient environments. Recently, chromatin immunoprecipitation revealed that Rgg
binds upstream of speH [84].

1.5. Superantigens
SAgs are a family of proteins that are produced by a limited number of bacterial,
and viral species. Staphylococcal enterotoxin A (SEA) was the first SAg to be identified
and it was purified and characterized in 1966 [85], although it was not known to be a SAg
at the time. The term ‘superantigen’ was coined in 1989 when it was determined that the
mitogenic capability of these toxins resulted in a massive expansion of T cells that
occurred in a T cell receptor (TCR) variable -chain (V)-dependent manner [86]. SAgs
stimulate both cluster of differentiation (CD) 4+ and CD8+ T cells polyclonally [87-88],
and have been reported to stimulate contact-dependent T regulatory cells and invariant
natural killer T cells in a concentration-dependent manner [87, 89]. Although they
typically bind select TCR V families and major histocompatibility complex (MHC)
class II molecules (Figure 1C-D), their binding selectivity can be less stringent at higher
SAg concentrations [87, 90].

1.5.1. Superantigen structure
Staphylococcal and streptococcal SAgs are between 22 and 31 kilodaltons (kDa)
in size. Although the SAg family vary greatly in their amino acid similarity, between
15.5% to 90% amino acid sequence homology, they all share the same general ternary
structure.

Staphylococcal and streptococcal SAgs may have evolved from a single

ancestral SAg [31] and a recent phylogenic tree has outlined the relatedness of all known
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Figure 1. Streptococcal superantigen structures and immunoreceptor interactions. (A)
Cartoon representations of all of the available streptococcal superantigen crystal
structures including SpeA (PDB 1HA5) [91], SpeC (PDB 1KTK) [92], SpeH (PDB
1ET9) [93], SpeI (PDB 2ICI) [94], SpeJ (PDB 1TY0) [95], SmeZ (PDB 1EU3) [93], and
SSA (PDB 1BXT) [96]. (B) Cartoon representation of conventional antigen presentation
[97] in which the TCR V (green) and V (yellow) chains recognize the specific peptide
antigen presented by MHC class II (PDB IJ8W [98]. (C) Cartoon representation of a
streptococcal superantigen which only has a low-affinity MHC class II binding site, such
as SpeA and SSA. The superantigen (grey) interacts with the TCR V chain (yellow) and
the MHC class II -chain (blue) in a manner that is less-specific than conventional
antigen presentation. The V chain of the TCR makes contact with the  chain of MHC
class II (red). This model was constructed by superimposition of SEB-MHC class II
(PDB 1D6E [99]) with SEB-TCR  chain (PDB 1SBB [100]), a mouse TCR was used to
align the V chain

of the TCR (PDB 1U3H) [101]).

(D) The majority of the

streptococcal superantigens have a zinc-mediated high-affinity MHC class II binding site
in addition to a low-affinity MHC class II binding site. These superantigens bind the V
chain of the TCR and the -chain of the MHC class II in a manner similar to Panel C, and
have an additional zinc-mediated high-affinity MHC class II binding site which binds to
the -chain of the MHC class II binding site (red). The model was constructed as detailed
in [102] by superimposition of the SpeC-TCR structure (PDB 1KTK [92]) with the
SEC3-MHC class II (low-affinity) structure (PDB 1JWM [103]), and the SpeC-MHC
class II (high-affinity) structure (PDB 1HQR [104]), and with TCR-MHC class II
structure (PDB 1FYT [97]) to align the -chain of the TCR. (E) Despite significant
differences in their primary amino acid sequences, all SAgs share a conserved ternary
structure. In red at the C-terminal end of the superantigen is a -grasp domain which is
the site of the zinc-mediated high-affinity MHC class II binding site in SAgs. In blue, at
the N-terminal of the protein is a -barrel domain which is the site of the low-affinity
MHC class II binding site. In yellow is the T cell receptor binding site. In the center of
the superantigen structure in grey is an -helix that connects to two domains.
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bacterial SAgs [105]. Each SAg contains a C-terminal -grasp domain, and an Nterminal -barrel domain, arranged around a long central -helix (Figure 1A, 1E). SAgs
bind directly to the V-chain of the TCR [27, 81], and it has been demonstrated that the
TCR -chain plays an important role in the stabilization of the ternary complex between
some of the TCR-SAg-MHC class II complexes [106-107].
The human MHC class II locus is a collection of genes known as the human
leukocytic antigen (HLA) complex [108]. MHC class II molecules are heterodimeric
glycoproteins with - and -chains that are expressed on the surface of macrophages,
dendritic cells and B cells, and present peptides for recognition by CD4+ T cells. MHC
class II molecules associate with antigens before being expressed on the surface of the
cell. Human MHC class II has three loci, HLA-DR, -DQ, and –DP, and each individual
has a maternal and paternal copy of each allele; 90% of all individuals are heterozygous
for HLAs at each locus [108]. There are multiple allotypic forms of HLA-DR, HLA-DQ,
and HLA-DP [109-110]. HLA haplotypes are expressed on the cell surface of APCs in
different proportions, in the following general pattern: DR>DQ>DP [111].
Superantigens associate with MHC class II and TCRs simultaneously which can
result in a massive immune response. Streptococcal SAgs have been reported to, in
general, bind to HLA-DQ better than HLA-DR and –DP [32], and isotypic and allotypic
variations can influence the immune response and the response to SAgs [88] in in vitro
binding and proliferation assays [112], and can result in different clinical outcomes in
streptococcal infection [112-114].

The MHC class II polymorphisms have been

demonstrated to contribute to the magnitude and quality of the T cell response to SAgs
[112], and protective MHC class II haplotypes are associated with higher IL-10
production and lower levels of pro-inflammatory cytokines [115].
Streptococcal SAgs bind to MHC class II through their two MHC class II binding
sites. Streptococcal SAgs can either bind to MHC class II through a low-affinity MHC
class II -chain binding site (as is the case for SpeA and SSA) [116] (Figure 1C), or
through both the low-affinity interaction, and an additional zinc-mediated high-affinity
MHC class II -chain binding site [117] (Kasper and McCormick, unpublished) (Figure
1D). Streptococcal SAgs have a higher affinity for human MHC class II than for mouse

19

MHC class II, explaining why they are more potent in activating human T cells as
compared to mouse T cells [31].

1.5.2. Staphylococcal Superantigens
Staphylococcal enterotoxins (SEs) were initially characterized based on their
emetic ability at concentrations less than 1 g, which causes diarrhea and vomiting in
staphylococcal food poisoning [31]. However, many of the staphylococcal SAgs do not
possess emetic activity, or have not been tested, and these are referred to as the SAg-like
toxins (SE-like or SEl). Staphylococcal SAgs are associated with illnesses such as
staphylococcal food poisoning, toxic shock syndrome (both menstrual and non-menstrual)
and are potentially also linked to diseases in which SAgs may play a contributing role
such as Kawasaki disease, chronic rhinosinusitis, atopic dermatitis and guttate psoriasis
[105]. The toxic shock syndrome toxin-1 (TSST-1) SAg is associated with menstrual and
non-menstrual toxic shock syndrome and is fairly unique among the superantigen family.
TSST-1 is both evolutionarily distinct [118-119], and engages both TCR V and MHC
class II with a unique architecture by making peptide-contacts [120-121]. Staphylococcal
enterotoxin B (SEB), and sometimes SEC, are also historically associated with the nonmenstrual form of toxic shock syndrome [122]. The role of staphylococcal SAgs in
colonization is unclear [105]. The work presented in this study focuses exclusively on
streptococcal SAgs, and further information on the staphylococcal SAgs can be found in a
recent review by Xu and McCormick [105].

1.5.3. Streptococcal Superantigens
There are currently eleven known SAgs that have been characterized from S.
pyogenes: streptococcal pyrogenic exotoxin SpeA, SpeC, SpeG-M, streptococcal
mitogenic exotoxin Z (SmeZ), and streptococcal SAg (SSA) [116, 123-125].
Streptococcal SAgs that have been crystallized are shown in Figure 1 [91-93, 95-96].
SpeB and SpeF were previously labelled as SAgs, but have since been found to encode a
cysteine protease and deoxyribonuclease (DNase), respectively. All sequenced strains of
S. pyogenes encodes multiple SAgs within their genomes, and distinct streptococcal
strains express different compliments of SAgs [126]. Although, there is no common SAg
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profile linked to a particular strain or to invasive diseases such as STSS [2, 127], SpeA
has historically been associated with STSS [128-129], and has been detected in the serum
of mice infected with an invasive streptococcal infections at microgram (g) levels [130],
and in the serum of acute phase patients at pictogram levels [130-132].
Although SAgs have been associated with severe diseases like STSS, many
healthy adults who have not previously developed severe SAg-mediated diseases,
produce antibodies against these toxins, suggesting that SAgs are also made during mild
or asymptomatic streptococcal infections [133-134].

Streptococcal superantigens are

upregulated in pharyngeal infections in a macaque model of pharyngeal infection [82],
which also indicates that streptococcal superantigens may play a role in mild infections or
asymptomatic colonization by Streptococcus pyogenes.
Certain streptococcal superantigens have been found to preferentially bind HLADR or –DQ such as SpeA, which preferentially bind HLA-DQ [59], but that SpeA did not
react differently to allotypic variations between HLA-DQ6 and –DQ8 [88]. SpeC was
better-presented by HLA-DR than –DQ alone [135]. Streptococcal superantigens also
have the ability to stimulate different immune system responses depending on the
concentration of superantigens [87].

At high concentrations superantigens stimulate

inflammatory responses and low stimulating concentrations of superantigens at the
picogram and femtogram levels stimulate the production of IL-10 which can stimulate the
suppression of co-stimulatory ligands on APCs such as activated B cells and monocytes
[87].
The true evolutionary function of SAgs within S. pyogenes is not understood,
however it is likely that these toxins have evolved in the context of asymptomatic
persistence of S. pyogenes within the human population.

1.6. Streptococcal strains
There are many serotypes of S. pyogenes circulating in the human population at
any given time. The specialization of S. pyogenes as an obligate human pathogen is
thought to be due to a lack of biosynthetic genes, and the expression of a large number of
scavenging systems which are thought to be typical of human specialization [136]. The
efficiency of S. pyogenes to persist within a human host is largely thought to be due to the
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inherent virulence factors produced by the bacteria, in combination with the sensitivity of
the host immune system to streptococcal infections. Closely related streptococci, such as
Streptococcus canis and Streptococcus dysgalactiae, lack host specific adaptation which
indicates that the ancestor to S. pyogenes was unlikely to be human-specific [137]. This
further suggests that a primary feature in the evolution of S. pyogenes was the stringent
adaptation to humans.

1.6.1. Streptococcus pyogenes MGAS5005
Streptococcus pyogenes MGAS5005 serotype was isolated from the cerebrospinal
fluid in 1996 from a patient in Toronto, Ontario, Canada, and is an M1 serotype which
has been indicated to be the most widely-circulating cause of invasive streptococcal
infections in North America, and Western Europe [138]. This specific strain was
originally isolated from a patient with an invasive case of S. pyogenes in Ontario, Canada
[138]. The total size of the S. pyogenes MGAS5005 genome is 1.838554 megabases
(Mb).

The strain contains 4 mobile genetic elements including three bacteriophage

elements and one ICE and encodes four SAgs. The gene for speA is encoded on the
bacteriophage 5005.1. This lineage of S. pyogenes has persisted globally for more than
25 years and has been isolated from both severe and mild cases [14]. Genetically
identical M1 isolates can cause both severe and non-severe disease [13].

1.6.2. Streptococcus pyogenes MGAS8232
Streptococcus pyogenes MGAS8232 is an M18 serotype of S. pyogenes and this
strain was isolated from a patient with ARF in 1987 [136].

The M18 serotype strains are

often associated with incidences of ARF in the USA. The genome is 1.895017 Mb, and
contains five bacteriophages and no ICE. Of the six SAgs encoded in the MGAS8232
genome, four are encoded on bacteriophage. The 8232.1 bacteriophage encodes speA1;
speC is encoded on 8232.2; and speL and speM are encoded close together on 8232.3
[136]. Streptococcus pyogenes MGAS8232 has a common genetic backbone to other
streptococcal strains with some large regions of insertion but no major rearrangements
[136].
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1.7. Murine strains as experimental tools in investigating Streptococcus pyogenes
In order to study the role of virulence factors in the context of colonization, mild
infections and disease, it is important to use a model system that is sensitive to the
virulence factors produced by the pathogen being assessed.

It is also important to

reiterate that most mouse MHC class II molecules do not interact efficiently with
streptococcal SAgs [139], and thus many experiments have utilized exogenous or
chemical agents, such as the liver damaging agent D-galactosamine to sensitize mice to
SAg-mediated responses [140]. These agents can also potentially mask or exaggerate
significant pathogenic effects of the bacterial infection on the animal [140].
Mice expressing transgenic human MHC class II molecules have been described
to have a greater sensitivity to SAg activation and are considered to be better models for
the study of SAg-mediated pathogenesis [112-113, 141]. These transgenic mice have
been used to determine the impact that various human MHC class II molecules could
potentially have on the clinical outcomes of severe and invasive infections [112-113,
141].

1.8. Pathophysiological structure of the murine nose and oropharynx
In mice, as in all mammals, the nose is both a portal of entry into the respiratory
system and the sensory organ for olfaction. Nasally inspired air is passed through the
nasal passage which extends, bi-laterally divided by the septum, from the nostrils to the
nasopharynx [142] (Figure 2). The complex folding of the nasal structure warms and
conditions the air before it enters the lungs [143]. The nasal passage is lined by ciliated
nasal mucosa, which beat to move nasal mucus, produced by goblet cells, distally to the
oropharynx where it is swallowed [142].
There are five types of epithelia in the nose: neuroepithelium, respiratory
epithelium, squamous epithelium, lymphoepithelium, and transitional epithelium.
Squamous epithelium is located in the nasal vestibule just inside the nostrils and is similar
to the epidermis in the skin.

The translational epithelium is situated between the

squamous epithelium and the respiratory epithelium. Respiratory epithelium is more
distal from the nares and makes up the majority of the non-olfactory epithelium.
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Figure 2.

The physiological location of the ethmoid turbinates, nasal-associated

lymphoid tissue and the maxillary sinuses. A cross-section drawing of the head of a
mouse indicates where standard sections are taken for histological analysis at T3 and T4.
The nose (No), and brain (B) are identified for orientation. The T3 section is located
anterior of the T4 section and slices through the ethmoid turbinate (ET) ahead of both the
molar teeth and the eye (E). The NALT (N) is located bilaterally at the base of the
ethmoid turbinates. Lateral to the NALT in the T3 section is the maxillary sinus (MS).
The T4 section cuts through both the brain and the eye. The ethmoid turbinate is betterseparated and the NALT is located bilaterally at the base of the ethmoid turbinates.
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Respiratory epithelium and neuroepithelium are both ciliated, although the cilia beat more
slowly to locomote the mucus distally over the neuroepithelium than the respiratory
epithelium. The fifth type of nasal epithelium is the lymphoepithelium; this epithelium
covers the discrete foci of nasal-associated lymphoid tissue (NALT) that run bilaterally
on the ventral face of the nasopharyngeal meatus, which is otherwise lined with
respiratory epithelium.

1.8.1. Pathophysiological comparison of nasal tissue between mice and humans
Although there are many similarities in the function and structure of the nasal
epithelia between mice and humans, there are also some notable differences [143]. The
nasal passage in both mice and humans is separated by a septum and the nasal passage
extends from the nostrils to the nasopharynx. Unlike humans and other primates who are
able to breathe orally and nasally, mice are obligate nose breathers [142].
Physiologically, mice lack hair in the vestibule just inside the nasal opening [142] and
have more complicated nasal turbinates in their folding and branching patterns [143]. In
particular, the extremely complex folded shape of the ethmoid turbinates which are lined
with olfactory neuroepithelium, and respiratory epithelium in mice [143] are thought to
be designed for acute, more sensitive olfaction [142].

1.8.2. Nasal-associated lymphoid tissue
Human tonsils, otherwise known as Waldeyer’s ring, are composed of the human
adenoid, bilateral tubule, palatine, and lingual tonsils [142]. Similar analogous structures
have been reported in monkeys, horses, cattle, rats, and mice [144-145]. The tonsular
surface is highly invaginated which increases the surface area of the tonsils and aids in
the capture of foreign materials for immune surveillance [146]. The human tonsils are the
primary site of streptococcal colonization.

Tonsils that were excised from healthy

individuals due to recurrent pharyngotonsillitis had a carrier rate for S. pyogenes of 25%,
and in healthy individuals with hypertrophic tonsils, this carrier rate for S. pyogenes was
7%, which suggests that the tonsils are an important reservoir for asymptomatic carriage
of S. pyogenes, which may seek refuge intracellularly [147]. The NALT in mice has been
reported to correlate functionally to Waldeyer’s ring in humans [142]. The location of the
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NALT within the nasal passage is strategic in that all antigenic-laden inspired air must
pass across the area [142].
The NALT is overlaid by the lymphoepithelium, which includes cuboidal cells
with luminal microvilli called membranous cells (M cells) that are involved in the uptake
and translocation of inhaled antigens to the underlying lymphoid structures [142-143].
The NALT and the nasal mucosa drains directly to the cervical lymph nodes and is a
major mucosal inductive site [148]. It is an organized tissue with T lymphocyte- and B
lymphocyte-enriched zones [149]. NALT is an immune inductive and tolerogenic site
which contains T cell precursors which are thought to downregulate T cell activation. It
has been suggested that NALT may be capable of both mucosal and systemic immune
response [142, 150].

1.8.3. Streptococcal colonization and the murine nasal infection model
Streptococcal colonization of the nasal passage in mice is thought to be analogous
to tonsular asymptomatic colonization or mild pharyngeal infection and has been
previously described in papers from the Cleary laboratory [149, 151-153]. It has been
determined that BALB/c mice infected with 5  108 colony forming units (cfu) of S.
pyogenes remained infected with detectable concentrations of bacteria for seven days in
the nasal cavity, and that the greatest concentration of streptococci was located in the
NALT at 48 hours post-inoculation [154]. Kinetically, it was observed that after an initial
clearance of the bacteria, as imaged at four and a half hours, the streptococcal burden
recovered at 24 hours and reached the maximum concentration at 48 hours [154].
Streptococci are indicated to survive intracellularly in NALT infection models as
indicated by antibiotic protection assays of infected NALT tissue with S. pyogenes
resulted in about 1-10% bacterial recovery [154]. Similar studies done with excised
human tonsils also observed S. pyogenes existing intracellularly [147]. The uptake of S.
pyogenes into the NALT was downregulated by pre-treatment with UEA-1 lectin which
indicates that the portal of entry into the NALT is via the M cells [149]. Streptococcal
induction of TGF- upregulates the expression of 51 integrins and fibronectin in
tonsular fibroblasts which are necessary for S. pyogenes internalization into the host cells
[155], additionally it also increases Th17 and T regulatory cells which may dampen
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cellular responses to antigens and increases the infiltration of neutrophils and
macrophages into infected host tissues [155]. Similar Th17 response was observed in
both mouse nasal and tonsular tissue [155].

1.9. Rationale and hypothesis
Scientific and clinical studies in the literature are largely focused on the
examination of severe and invasive streptococcal infections. There are relatively fewer
clinical papers, however, that examine mild streptococcal infections or asymptomatic
persistence of S. pyogenes within the human population [49, 156-158]. It can be argued
that although severe streptococcal diseases are dramatic and important, mild or
asymptomatic infections occur much more frequently and are thus of greater significance
for streptococcal persistence within the host, and within the human population as a whole,
as well as for the mechanisms of evolution of these bacteria. Streptococcal superantigens
have been shown to be upregulated in a pharyngeal infection model in Cynomolgus
macaques, which implies that streptococcal superantigens play a role in mild
streptococcal infection or streptococcal colonization [82], however the relationship and
contribution of streptococcal superantigens to the establishment of mild infection and
colonization has not been systematically assessed. As a result, the study of the
mechanisms that S. pyogenes will use to persist within the population are extremely
important. Although the role of streptococcal SAgs in severe disease such as STSS is
clear, the natural niche of S. pyogenes is in a state of colonization or mild infection, and
as such we hypothesize that these toxins have likely evolved within the context of mild
infection or colonization. Therefore, the hypothesis of this thesis is that SAgs play an
important role in the course of colonization of S. pyogenes in an appropriate SAgsensitive nasal mouse model.
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Chapter 2: Materials and Methods
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2.1. Bacterial growth conditions
2.1.1. Escherichia coli growth conditions
Escherichia coli strains used in this study are listed in Table 2. All E. coli were
grown aerobically at 37C in either Difco Luria-Bertani (LB) broth (Becton, Dickinson
and Company, Sparks, MD, USA) or Brain Heart Infusion (BHI) medium (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA) or on solid LB or BHI media
supplemented with 1.5% agar (BD, Franklin Lakes, NJ, USA). The media were prepared
to contain antibiotics appropriate to the plasmids within those strains (Table 3).
Ampicillin (Amp) (EMD, Darmstadt, Germany) was used at a concentration of 150
g/ml, and kanamycin (Kan) (Sigma Aldrich, St. Louis, MO, USA) at a concentration of
50 g/ml. Erythromycin (Erm) (Acros Organics, NJ, USA) was used at a concentration
of 150 g/ml in. All antibiotics were filter sterilized through a 0.2 m syringe filter (Pall
Life Sciences, Ann Arbor, MI, USA). Viable stocks of E. coli were maintained and
stored in LB or BHI containing the appropriate antibiotics and 20% (v/v) glycerol at 80C.

2.1.2. Streptococcus pyogenes growth conditions
S. pyogenes strains used in this study are listed in Table 2. All S. pyogenes
cultures were grown without aeration at either 30C, 37C, or 40C in Todd Hewitt media
(Becton, Dickinson, and Company, Sparks, MD, USA) supplemented with 1% (w/v) with
yeast extract (EMD Chemicals Inc., Darmstadt, Germany) (THY). Media was prepared
to contain 1 g/ml Erm for growth with plasmids as necessary (Table 3). After the SAg
genes were inactivated (described below), of all of the S. pyogenes were grown in THY
media supplemented with 10% human plasma (HP) to restore the streptococcal capsule
[159]. Human plasma was collected after being diluted 1:1 in Roswell Park Memorial
Institute medium (RPMI) 1640 and reserved from peripheral blood mononuclear cells
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Table 2. Bacterial strains used in this study
Strain

Description

Escherichia coli XL1 Blue

recA1 endA1 gyrA96 thi-1 supE44 relA1 lac
q

Source
Novagen

r

[F’proABlacl Z∆M15 Tn10 (Tet )]
Stratagene
Escherichia coli BL21 (DE3)

F- ompT[lon] hsdSB with λDE3 prophage

Novagen

carrying the T7 RNA polymerase gene

Streptococcal strains
Sumby et al. [138]
Streptococcus

pyogenes

MGAS5005 wild type
Streptococcus

M1 streptococcal strain isolated from an
invasive case in Ontario

pyogenes

S. pyogenes MGAS5005 with speA disrupted

This study

pyogenes

S. pyogenes MGAS5005 with speG disrupted

This study

pyogenes

S. pyogenes MGAS5005 with speJ disrupted

This study

pyogenes

S. pyogenes MGAS5005 with smeZ disrupted

This study

pyogenes

S. pyogenes MGAS5005 with speA, speJ, and

This study

MGAS5005 speA
Streptococcus
MGAS5005 speG
Streptococcus
MGAS5005 speJ
Streptococcus
MGAS5005 smeZ
Streptococcus

MGAS5005 speA/speJ/smeZ

smeZ disrupted

Streptococcus

M18 streptococcal serotype associated with

pyogenes

MGAS8232 wild type

Smoot et al. [136]

acute rheumatic fever outbreaks in USA.
Isolated from a patient with acute rheumatic
fever.

Streptococcus

pyogenes

S. pyogenes MGAS8232 with speA disrupted

This study

pyogenes

S. pyogenes MGAS8232 with speC knocked

This study

MGAS8232 speA
Streptococcus
MGAS8232 speC
Streptococcus

out
pyogenes

S. pyogenes MGAS8232 with speG disrupted

This study

pyogenes

S. pyogenes MGAS8232 with speL and speM

This study

MGAS8232 speG
Streptococcus

MGAS8232 speL/speM

disrupted

Streptococcus

S. pyogenes MGAS8232 with smeZ disrupted

MGAS8232 smeZ

pyogenes

This study
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Streptococcus

pyogenes

MGAS8232 SAg
Streptococcus

S. pyogenes MGAS8232 with speA, speC,

This study

speG, speL, speM, and smeZ disrupted
pyogenes

MGAS8232 SAg + speA

S. pyogenes MGAS8232 SAg complemented

This study

with speA

Superantigen expression strains
Escherichia coli BL21 with SpeA

pET28a::TEV::speA wild type

[160]

Escherichia coli BL21 with SpeC

pET41a::TEV::speC wild type

[161]

Escherichia coli BL21 with SpeG

pET28::TEV::speG wild type

[160]

Escherichia coli BL21 with SpeJ

pET28::TEV::speJ wild type

[160]

Escherichia coli BL21 with SpeL

pET28::TEV::speL wild type

Shipa Gupta,
unpublished

Escherichia coli BL21 with

pET28::TEV::speM wild type

SpeM
Escherichia coli BL21 with
SmeZ

Shipa Gupta,
unpublished

pET41a::TEV::smeZ wild type

Christine Herfst,
unpublished
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Table 3. Plasmids used in this study
Plasmid

Description

Source

pG+host5

Erythromycin resistance, Gram-negative

Appligene,

origin of replication, Gram-positive

[162]

temperature-sensitive origin of replication
pG+host5::I-SceI

pG+host5 base plasmid with I-SceI restriction

This study

enzyme cut site
pG+host5::I-SceI::MGAS8232 speA

Plasmid to knock out speA in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS8232 speC

Plasmid to knock out speC in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS8232 speG

Plasmid to knock out speG in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS8232

Plasmid to knock out speL and speM in S.

speL/M

pyogenes MGAS8232

pG+host5::I-SceI::MGAS8232 smeZ

Plasmid to knock out smeZ in S. pyogenes

This study

This study

MGAS8232
pG+host5::I-SceI::MGAS5005 speA

Plasmid to knock out speA in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS5005 speG

Plasmid to knock out speG in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS5005 speJ

Plasmid to knock out speJ in S. pyogenes

This study

MGAS8232
pG+host5::I-SceI::MGAS5005 smeZ

Plasmid to knock out smeZ in S. pyogenes

This study

MGAS5005
pG+host5::I-SceI::Int MGAS5005

pG+host5::I-SceI containing sequence for

This study

homologous recombination between tsf and
pepO of S. pyogenes MGAS5005 with
multiple cloning site
pG+host5::I-SceI::Int MGAS8232

pG+host5::I-SceI containing sequence for

This study

homologous recombination between tsf and
pepO of S. pyogenes MGAS8232 with
multiple cloning site
pG+host5::I-SceI::Int MGAS8232 speA

Plasmid for complementation of speA

Comp

between tsf and pepO of S. pyogenes
MGAS8232

This study
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(PBMC) isolation. THY media with 10% HP was filtered in 0.2 m filters (Pall Life
Sciences, Ann Arbor, MI, USA) into sterile bottles. Viable stocks of S. pyogenes were
maintained and stored in THY with 20% (v/v) glycerol at -80C.

2.2. Genetic isolation
2.2.1. Plasmid isolation from Escherichia coli
Plasmid DNA was isolated using the QIAprep spin miniprep kit (QIAGEN
Sciences, MD, USA) as per manufacturer instructions. Plasmid DNA was eluted in
distilled water and was stored at -20C.

2.2.2. Isolation of genomic deoxyribonucleic acid from Streptococcus pyogenes
Genomic DNA was isolated by pelleting 1-2 ml of an overnight culture of S.
pyogenes. The bacterial pellet was washed in 1 ml of 0.2 M sodium acetate (Sigma
Chemical Company, St. Louis, MO, USA) and resuspended in 350 l of S. pyogenes lysis
buffer [50 mM ethylenediaminetetraacetic acid (EDTA; Sigma Chemical Company, St.
Louis, MO, USA), 0.2% sodium dodecyl sulfate (SDS; Sigma Chemical Company, St.
Louis, MO, USA)] and incubated at 75C for 30-40 minutes. Lysed streptococci were
treated 100 l with 5 M potassium acetate (EMD Chemicals Inc., Darmstadt, Germany)
and placed in the -20C for 1 hour. The frozen lysate was spun at 21,130  g for 10
minutes.

Supernatant was drawn off and added to 1 ml of -20C 100% ethanol

(Commercial Alcohols, Brampton, Canada) and placed in the -20C freezer for 30-40
minutes. DNA was spun at 21,130  g for 10 minutes. Ethanol is poured off and 1 ml of
-20C 70% ethanol was added and spun at 21,130  g for 1 minute. The ethanol was
poured off and the pellet was dried. To isolate total genetic material (DNA and RNA) the
pellet was resuspended in distilled water. To isolate DNA alone the pellet was
resuspended in tris-EDTA buffer (TE) 10 mM Tris, 1 mM EDTA with 10 g/ml
ribonuclease A (RNaseA) (Sigma-Aldrich Company, St. Louis, MO, USA), pH 8.0).

2.3. Deoxyribonucleic acid visualization
2.3.1. Agarose gel electrophoresis
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DNA was visualized on ethidium bromide-stained tris-acetate EDTA buffer
(TAE) (40 mM Tris-acetate, 1 mM EDTA) agarose gels. DNA loading dye (5% glycerol,
0.04% (w/v) bromophenol blue (International Biotechnologies, New Haven, CT, USA),
0.04% xylene cyanol) was mixed with the samples prior to loading the gel. A 1 kilobase
(Kb) standard DNA molecular weight ladder (Invitrogen, Burlington, ON, Canada) was
included in the gels as a size standard. Agarose (Invitrogen, Burlington, ON, Canada)
gels were prepared at concentrations from 0.8% to 2% depending on the desired
resolution of a given product. Gels were stained in 0.05% (w/v) ethidium bromide
(EMD, Darmstadt, Germany) in 1  TAE for 10-20 minutes before being rinsed in water
and visualized and photographed under ultraviolet light.

2.3.2. Deoxyribonucleic acid agarose gel extraction
DNA fragments were purified from agarose gels by excising the DNA band of the
appropriate size from the gel with a fresh scalpel blade. The gel fragment was placed in a
microfuge tube and frozen at -20C for at least an hour or -80C for at least 20 minutes.
The gel fragment was centrifuged at 21,130  g for 10 minutes. The supernatant was
drawn off and retained and the agarose pellet was spun a second time. The pooled
supernatant was purified by a QIAquick PCR purification kit (QIAGEN Sciences, MD,
USA) as specified by manufacturers instructions for DNA purification. Samples were
eluted in 20-50 l of distilled water.

2.4. Polymerase chain reaction
2.4.1. Standard polymerase chain reaction methods
Polymerase chain reaction (PCR) products were amplified in a Peltier
Thermocycler PTC-200 (MJ Research, Waterdown, MA, USA). All oligonucleotide
primers were obtained from Sigma-Genosys and are described in Table 4. Reactions
were prepared in 100 l reaction volumes or master mixes containing 1  high fidelity
(HF) buffer (New England Biolabs, Ipswich, MA, USA), 100 mM deoxyribonucleotide
triphosphate (dNTP) mixture (Roche Diagnostics, Mannheim, Germany), 2 mM MgSO4
(Sigma Chemical Company, St. Louis, MO, USA), 200 pM of each of the forward or
reverse primers, 1 l of template DNA and 1 Unit of Phusion polymerase (New England
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Table 4. Primers used in this study
Primer

Sequence (5’-3’)a

Purpose

Sequencing and screening primers
M13 For

GTAAAACGACGGCCAGTGAG

Sequencing and screening

M13 Rev

CAGGAAACAGCTATGACCATG

Sequencing and screening

Int/Screen speA 5005

GCAAGCTACGGTTACGAAATTG

Integration, screening and

For
Int/Screen speA 5005

sequencing
CAGGTTTGGGATAAGGACACAC

Rev
speA Screen II 8232

sequencing
CCATCCTTTTTTGATTCTCC

Rev
speC Int II For

Integration, screening and

Integration, screening and
sequencing

GCAAAGCACTGGTTCGATGT

Integration, screening and
sequencing

speC Int II Rev

GGATAACCTTAACCGCGCTAC

Integration, screening and
sequencing

speG 5005 Int/Screen

GAAGCCGGCGTCAAACTG

II For
speG 5005 Int/Screen

sequencing
CAGCTTCTGTTACTTGGCCTTG

II Rev
speG int II For

Integration, screening and

Integration, screening and
sequencing

GCCCTCGTCAGAATGACTGT

Integration, screening and
sequencing

speG Screen II Rev

CCGATACCGATCACCACAAG

Integration, screening and
sequencing

Int/Screen speJ 5005

GACGCTAGCCGGTACTGTC

For
Int/Screen speJ 5005

sequencing
CCTTATGGTACCCAACATAC

Rev
speL/M Int II For

Integration, screening and

Integration, screening and
sequencing

GGCTTGAGTTATGTGTCTTTA

Integration, screening and
sequencing

speL/M Screen II

GTTTGGTGGTATAGATGTAGCAAGG

Rev
smeZ Int II For

Integration, screening and
sequencing

CATGCCTGCTCAAACAAGATT

Integration, screening and
sequencing

smeZ Screen II Rev

ATACGACTCCATCTCATTATAGC

Integration, screening and
sequencing

Plasmid construction
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I-SceI OH 1

CTAGTTAGGGATAACAGGGTAATT

Construction of pG+host5::I-SceI

I-SceI OH 2

CTAGAATTACCCTGTTATCCCTAA

Construction of pG+host5::I-SceI

KpnI-tsf For

GGGGGGGGTACCACTTGCTCAATTG

Constructing pG+host5::Int

AACCACG

complementation plasmid

TTTTTTGAATTCGATATCAAGCTTAT

Constructing pG+host5::Int

CGATACCGTCGACCTCGAGGGGGGG

complementation plasmid

EcoRI-MCS-tsf Rev

CCCTCCGTTTGACACAACAAAAAGA
EcoRI-MCS-pepO

GGGGGGGAATTCCTGCAGCCCGGG

Constructing pG+host5::Int

For

GGATCCACTAGTTCTAGACACCAAT

complementation plasmid

AAGGAAGCAAAAA
NotI-pepO Rev

GGGGGGGCGGCCGCAGCCTAAATG

Constructing pG+host5::Int

ATTGGTGGA

complementation plasmid

BamHI-upstream

CCCGGATCCTTATCTAGCACACAGG

Superantigen deletion construct

speA5005 For

CTGATGTG

KpnI-downstream

CCCGGTACCGGACGTGGGTTCGACT

speA 5005Rev

CCC

BamHI-upstream

CCCGGATCCGCCAAGTTATGCCATT

speA MGAS8232

ACTGTGTTG

Superantigen deletion construct

Superantigen deletion construct

For
PstI-upstream speA

CCCCTGCAGGAAGTCTACCTAACAA

MGAS8232 Rev

CCAAGTAA

PstI-downstream

CCCCTGCAGCAATACTTTTTTATTGT

speA MGAS8232

TTTCCATTAATAT

Superantigen deletion construct

Superantigen deletion construct

For
KpnI-downstream

CCCGGTACCGCAAATGACAAATCGC

speA MGAS8232

TATATCAATAA

Superantigen deletion construct

Rev
SpeI-speA Comp For

GGGGGGACTAGTATTTTATAATAAA

Superantigen complementation

ATTATTAATATAAGTTAA

construct

GGGGGGGTCGACAAAACCGCTCATC

Superantigen complementation

AAATGA

construct

PstI-downstream

CCCCTGCAGTTTGATGATGTTAATCT

Superantigen deletion construct

speC MGAS8232

TTTTCAT

SalI-speA Comp Rev

For
KpnI-downstream

CCCGGTACCCGGATATCAATTTTGT

speC

GGATTAAACG

MGAS8232Rev

Superantigen deletion construct
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BamHI-upstream

CCCGGATCCCGGTTACACCATGCGC

speC MGAS8232

ACTGTCG

Superantigen deletion construct

For
PstI-upstream speC

CCCCTGCAGTTCGATATTTATCTTGA

MGAS8232 Rev

AAAATAATTCATC

BamHI-upstream

CCCGGATCCGAATCGGTATTAGAAG

speG MGAS5005

GTTTGCTAGTG

Superantigen deletion construct

Superantigen deletion construct

For
PstI-upstream speG

CCCCTGCAGAATTGTCAAAATGTTT

MGAS5005 Rev

GTTTTCATTTAAAA

KpnI-downstream

CCCGGTACCCATGTTGTCCCGCAAA

speG MGAS5005

TGAC

Superantigen deletion construct

Superantigen deletion construct

Rev
BamHI-upstream

CCCGGATCCGCCCAGCTTCAAGACG

speG MGAS8232

TTGGTTAA

Superantigen deletion construct

For
PstI-upstream speG

CCCCTGCAGAAATTCTAAAATGAAC

MGAS8232 Rev

TTAGCCAC

PstI-downstream

CCCCTGCAGGATATCTACTTAAAAA

speG For

CGCACTAG

KpnI-downstream

CCCGGTACCGGAAGATCAAGCCAAC

speG MGAS8232

CCAAGAAA

Superantigen deletion construct

Superantigen deletion construct

Superantigen deletion construct

Rev
BamHI - downstream

CCCGGATCCGATGGAAGAGAGACTC

speJ MGAS5005

TTAGAGAAGC

Superantigen deletion construct

For
PstI-downstream

CCCCTGCAGTACCTTTGGACTAAAT

speJ MGAS5005

AAGATAGGAGC

Superantigen deletion construct

Rev
PstI-upstream speJ

CCCCTGCAGTTTTATTATTCTTTTCA

MGAS5005-For

TACCTCTCCTCG

KpnI-upstream speJ

CCCGGTACCGAGTCACTTTGACATT

MGAS5005-Rev

CAGAGATGAAG

BamHI-upstream

CCCGGATCCCCTATGGACGTAGACA

speL/M MGAS8232

AATATGTTG

Superantigen deletion construct

Superantigen deletion construct

Superantigen deletion construct

For
PstI-upstream

CCCCTGCAGTTATTCACAAACAAAG

Superantigen deletion construct
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speL/M MGAS8232

AAAATTAATTAGTA

Rev
PstI-downstream

CCCCTGCAGCAAAGTCAAGGTATTT

speL/M MGAS8232

TTTTTCAT

Superantigen deletion construct

For
KpnI-downstream

CGCGGTACCCGGTGTATTGACATTG

speL/M MGAS8232

ATGTATTC

Superantigen deletion construct

Rev
BamHI-upstream

GGGGGATCCGGGGAATTATGCCAAT

smeZ MGAS8232

TGTCTCTA

Superantigen deletion construct

For
PstI-upstream smeZ

CCCCTGCAGAAAAATAAGTTTTGTT

MGAS8232 Rev

TTTTTCATAAATAG

PstI-downstream

CCCCTGCAGTTAGATATAGAAATTG

smeZ MGAS8232

ACTCCTAATTC

Superantigen deletion construct

Superantigen deletion construct

For
KpnI-downstream

GGGGGTACCGGGCAATTGTTTAACT

smeZ MGAS8232

GGTTAATTAG

Superantigen deletion construct

Rev

Superantigen internal screening primers
speA RT For

AAAGTTGCCATCTCTTGGTTC

Internal screening primer

speA RT Rev

CAAGAGGTATTTGCTCAACAAGAC

Internal screening primer

speC RT For

TTTGAGCAGGCGTAATTCCT

Internal screening primer

speC RT Rev

TTCAACGACACACACATTAAACA

Internal screening primer

speG RT For

ACCCCATGCGATTATGAAAA

Internal screening primer

speG RT Rev

GGGAGACCAAAAACATCGAC

Internal screening primer

speJ RT For

GCTCTCGACCTCAGAATCAA

Internal screening primer

speJ RT Rev

CTTTCATGGGTACGGAAGTG

Internal screening primer

speL RT For

ATAAGTCAGCACCTTCCTCTTTC

Internal screening primer

speL RT Rev

AAATCTCCCGTTACCTTCCA

Internal screening primer

speM RT For

AACTTCTTCTTCCTTAAAGCGTCT

Internal screening primer

speM RT Rev

TGCTGTGTTGGTTAATAGCGA

Internal screening primer

smeZ RT For

TTTCTCGTCCTGTGATTGGA

Internal screening primer

smeZ RT Rev

AATGGGACGGAGAACATAGC

Internal screening primer

DR4/DQ8 genotyping primers
DQA (1027) For

GAAGACATTGTGGCTGACCATGTTG

Mouse genotype
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CC
DQA (1029) Rev

AGCACAGCGATGTTTGTCAGTGCAA

Mouse genotype

ATTGCGG
DQ8b (vA) For1

AGGATTTGGTGTACCAGTTTAAGGG

Mouse genotype

CAT
DQ8b (vT) For 2

AGGATTTGGTGTTCCAGTTTAAGGG

Mouse genotype

CAT
DQ8b (vii) Rev

TGCAAGGTCGTGCGGAGCTCCAA

Mouse genotype

DR4A (1101) For

GGAGATAGTGGAACTTGCGG

Mouse genotype

DR4A (1104) Rev

CCGATCACCAATGTACCTCC

Mouse genotype

DR4B (1098) For

GTTTCTTGGAGCAGGTTAAACA

Mouse genotype

DR4B (1099) Rev

CTGCACTGTGAAGCTCTCAC

Mouse genotype

a

Underline in primer sequences indicates restriction endonuclease sites used for cloning

purposes.
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Biolabs, Ipswich, MA, USA). General cycle conditions were as follows: 98C for 5
minutes; 98C for 30 seconds; primer-specific annealing temperature which was in
general Tm + 4C for 30 seconds; 72C for a time appropriate for the gene being
amplified at 15 seconds per 1 Kb; steps 2 to 4 were repeated 35 times; 72C for 5
minutes; 4C indefinitely. PCR products were purified using QIAquick PCR purification
kit (QIAGEN Sciences, MD, USA) as per manufacturer’s instructions and were eluted in
20-50 l of distilled water or 10 mM Tris-Cl, pH 8.5.

2.4.2. Escherichia coli colony screening by polymerase chain reaction
To screen for recombinant plasmids in E. coli, colony-screening PCR was
performed on ligation-transformed E. coli colonies. A standard master mix for PCR was
prepared with the exception of added template and aliquoted into 10-20 l across the
number of reaction tubes. Single colonies were picked from the plates and dipped into
the aliquoted master mix before being placed in a snap cap tube with appropriate media
and antibiotics. Resulting PCR products were analyzed by agarose gel electrophoresis.

2.4.3. Deoxyribonucleic acid sequencing
All DNA sequencing was performed at the John P. Robarts Research Institute
Sequencing Facility at Western University in London, Ontario, Canada. Sequencing was
performed with appropriate primers (Table 4).

2.5. Molecular cloning
2.5.1. Restriction digestions
Restriction digestions were performed in a 90 l reaction volume containing 3070 U of each restriction enzyme in 1  the appropriate reaction buffer supplemented with
1 l of bovine serum albumin as indicated, and incubated following the manufacturer’s
recommended temperature. Enzymes were purchased from Invitrogen (Burlington, ON,
Canada), New England Biolabs (Ipswich, MA, USA) or Roche Diagnostics (Mannheim,
Germany). Once the DNA was cut to completion it was purified using the QIAquick
PCR purification kit (QIAGEN Sciences, MD, USA).

Antarctic phosphatase (New
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England Biolabs, Ipswich, MA, USA) was used in stock plasmid digestions to reduce the
incidence of non-specific empty vector ligation.

2.5.2. Deoxyribonucleic acid ligation
All ligations were performed in 25 l reaction volumes containing 40 U of T4
DNA ligase (New England Biolabs, Ipswich, MA, USA) and an excess of insert to vector.
Reactions were incubated at either room temperature for 1 hour or overnight at 17C
before transformation.

2.5.3. Deoxyribonucleic acid ethanol precipitation
Plasmid DNA, previously isolated from a QIAprep spin miniprep kit (QIAGEN
Sciences, MD, USA), was mixed with 2-3 volumes of -20C 99% ethanol supplemented
with 0.1 volumes of 3 M Sodium Acetate (Sigma, St. Louis, MO, USA) and placed at 20C for 1 hour or more. The precipitated DNA was spun at 21,130  g for 10 minutes
before the supernatant was poured off. The pellet was washed with 1 ml of -20C 70%
ethanol without mixing, and spun for 1 minute at 21,130  g and the supernatant was
poured off. The pellet was dried and resuspended in HPLC water (Fisher Scientific, Fair
Lawn, NJ, USA).

2.5.4. Preparation of rubidium chloride competent Escherichia coli
Escherichia coli XL1-Blue and E. coli BL21 (DE3) competent cells were prepared
by growing 100 ml culture in PSI broth (5 g/L Bacto yeast extract, 20 g/L Bacto tryptone,
5 g/L magnesium sulphate, pH 7.6 with KOH) to an OD600 of 0.4. Cells were placed on
ice for 15 minutes and were then centrifuged at 3,000  g at 4C for 5 minutes. The cell
pellet was resuspended in 40 ml of TfbI buffer [30 mM KAc (EMD Chemicals Inc.,
Darmstadt, Germany), 100 mM RbCl2 (Alfa Aesar, Ward Hill, MA, USA), 10 mM CaCl2
(Sigma Chemical Co., St Louis, MO, USA), 50 mM MnCl2 (Sigma-Aldrich Co., St.
Louis, MO. USA), 15% glycerol, pH 5.8] and put on ice for 15 minutes. Cells were again
centrifuged at 3,000  g at 4C resuspended in 4 ml of TfbII buffer [10 mM MOPS
(Sigma Chemical Co., St. Louis, MO, USA), 10 mM RbCl2, 75 mM CaCl2, 15% glycerol,
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pH 6.5]. Cells were aliquoted on ice into 100 l volumes and flash frozen in an ethanol
bath and stored at -80C.

2.5.5. Escherichia coli transformations
Escherichia coli XL1-Blue and E. coli BL21 rubidium chloride competent cells
were thawed on ice for approximately 10 minutes. Plasmid DNA or ligation mixtures
were added to the thawed E. coli cells and were left on ice for up to 30 minutes. The cells
were heat shocked at 42C for 45 seconds and then placed on ice for 2 minutes and 900 l
of LB broth was subsequently added. The cells were then incubated at 37C for 1 hour
with shaking.

The transformation was plated on the appropriate media plates with

antibiotic and grown overnight at 37C.

2.5.6. Preparation of electrocompetent Streptococcus pyogenes
Electrocompetent S. pyogenes was prepared by subculturing 1 ml an overnight
culture into 100 ml of pre-warmed THY + 0.6% glycine (Fisher Scientific, Fair Lawn, NJ,
USA) which was then grown at 37C without shaking.

After 1.5 hours, 8 mg of

hyaluronidase (Sigma Chemical Co., St. Louis, MO, USA) was added and the culture was
returned to the 37C incubator until the OD600 reached 0.21. The culture was pelleted at
6,000  g for 10 minutes. The cells were washed twice in 10-20 ml of ice cold 15%
sterile glycerol. Cells were resuspended after a final wash in 4 ml ice cold 15% glycerol
and aliquoted in 220 l aliquots. Aliquots were flash-frozen in a dry-ice ethanol bath and
stored at -80C.

2.5.7. Electroporation of Streptococcus pyogenes
Plasmids to be electroporated into S. pyogenes were ethanol precipitated and
resuspended in HPLC water (Fisher Scientific, Fair Lawn, NJ, USA). DNA (1-2 g) was
added to ice-thawed electrocompetent S. pyogenes. Cells were electroporated at 2500
volts (V), 600 ohms (), and 25 microfarads (F) in 2 mm electroporation cuvettes
(VWR, Westchester, PA, USA) in a Biorad Gene Pulser XCell electroporator. After
electroporation, cells were immediately transferred to 10 ml THY broth at room
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temperature and placed in a 30C incubator to recover for 1 hour before a sub-inhibitory
concentration of erythromycin (0.01 g/ml) was added. Cells were returned to 30C for
an additional four hours before being pelleted and resuspended in 1 ml THY broth plated
on THY plates with the appropriate antibiotics for the plasmids. Cultures were grown for
up to 3 days at 30C.

2.5.8. Streptococcal genome mutagenesis
In-frame deletions were made of all of the streptococcal SAgs in S. pyogenes
MGAS5005 (Figure 3) and S. pyogenes MGAS8232 (Figure 4). The construction of the
streptococcal SAg mutants was made in a manner similar to the procedure reviewed in
Cho et al. [163].

Briefly, S. pyogenes were electroporated with a pG+host5-based

plasmid (Table 3) [162] including the mutation flanked by the contextual upstream and
downstream homologous regions. The bacterial transformants that grew on THY + 1
g/ml erythromycin (THY Erm1) at 30C were picked and grown in THY Erm1 broth at
30C. A total nucleic acid preparation was made of this culture and the presence of the
plasmid was confirmed by PCR. Transformed bacteria were plated on THY Erm1 plates
and incubated at 40C. Resulting colonies were picked and grown in THY Erm1 broth at
40C. DNA was isolated and the integration of the construct was confirmed by PCR.
Bacteria with confirmed integrations were subcultured into THY broth without antibiotics
and grown at 30C with daily subculturing at 1%. Cultures were screened for the loss of
the pG+host5-based plasmid by replicate plating onto THY, THY Erm1, and TSAII plates
that are supplemented with 5% defibrinated sheep blood [Becton, Dickinson, and
Company, Franklin Lakes, NJ USA; 1.45% pancreatic digest of casein (w/v), 0.5% papaic
digest of soybean meal (w/v), 0.5% NaCl (w/v), 1.4% agar (w/v), 0.15% (w/v) growth
factors, 5% (v/v) sheep blood, defibrinated]. Beta-haemolytic cultures that were sensitive
to erythromycin were grown in THY broth culture and were screened by total nucleic acid
isolation and PCR for excision or insertion of the targeted gene of interest. PCR primers
used for S. pyogenes mutagenesis are listed in Table 4 and the mutagenesis strategy is
depicted in Figure 5. All strains of S. pyogenes were sub-cultured daily at 1% in filtersterilized THY + 10% HP for 5 days before glycerol stocks were made and stored at
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Figure 3. Streptococcus pyogenes MGAS5005 superantigens in genomic context. (A)
The genome of S. pyogenes MGAS5005 contains three bacteriophage like-elements
(triangles), and four SAgs within its 1.839 Mb genome. (B) S. pyogenes MGAS5005encoded SAgs in their immediate genetic context. The speA gene is flanked upstream by
a hypothetical phage protein spy_0995 and downstream by phage proteins spy_0997 and
spy_0998 that are oriented in the opposite direction of the speA2 gene. The speG gene is
flanked upstream by the spy_0180 gene, which is in reverse orientation and is an S-layerlike domain containing protein. Directly upstream of speG in the same orientation is
spy_0181 which is a hypothetical cytoplasmic protein. Downstream of speG are three
genes that are in the same orientation as the speG gene, spy_0183, which is a hypothetical
protein, spy_0184, which is a predicted cytoplasmic proteins and glucose-6-phosphate
isomerase. speJ is flanked by two hypothetical proteins. The upstream protein is in the
same orientation as speJ and the downstream protein is in reverse orientation. The smeZ
gene is flanked upstream by two genes in the same orientation. spy_1700 encodes an
acetyltransferase and spy_1701 encodes a topology modifying protein.

Immediately

downstream of smeZ there is a gene in reverse orientation that is a hypothetical
cytoplasmic protein and beyond that there is a gene in the same orientation that is a
dipeptide binding protein.
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Figure 4. Streptococcus pyogenes MGAS8232 superantigens in genomic context. (A)
The 1.895 MB genome of S. pyogenes MGAS8232 encodes five bacteriophage-like
elements (triangles). Four of the six SAgs encoded in the chromosome of S. pyogenes
MGAS8232 are bacteriophage-encoded including speA1 encoded on 8232.1, speC on
8232.2, and speL and speM are encoded on 8232.3. (B) Within the immediate genetic
context speA is flanked upstream by two genes that are in the opposite orientation to speA
and encode hypothetical proteins, and downstream by spyM18_0391 which encodes Nacetylmuramoyl-L-alanine amidase which is also in reverse orientation. The speC gene is
flanked upstream in the same orientation by mf2 and downstream by a hypothetical
protein in reverse orientation. The speG gene is flanked upstream by spyM18_0199
which is a transposase that is in the reverse orientation. Downstream of speG are two
genes in the same orientation, a hypothetical protein and glucose-6-phosphate isomerase.
The speL and speM genes are encoded beside one another in the same orientation. The
genes directly flanking speL and speM are both hypothetical proteins oriented in the same
orientation. The smeZ gene is flanked by hypothetical proteins in the opposite direction.
Further upstream of smeZ is a topology modulation protein, and further downstream is
dppA which is a surface lipoprotein.
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Figure 5. Markerless mutagenesis in Streptococcus pyogenes. To create precise
markerless deletions of each superantigen, all constructs were generated in
pG+host5::I-SceI (Table 3) by cloning PCR products containing ~500 bp
homologous regions both upstream and downstream of the superantigen gene, but
leaving the first and last three codons of the superantigen intact. S. pyogenes
containing the integration plasmids were grown at 40C with erythromycin to
select for a single cross-over integration of the plasmid within the streptococcal
genome. The integration was confirmed by PCR and bacterial growth was shifted
to the permissive temperature of 30C without antibiotics to allow for the second
cross-over event and eventual clearance of the plasmid. Erythromycin-sensitive S.
pyogenes were screened for the superantigen deletion and clearance of the plasmid
with specific primers by PCR.
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minus 80C. All stocks at -80C were tested for growth defects by doing a computerautomated optical density of 600 nm (OD600) growth curve using a Bioscreen C MBR
(Piscataway, NJ, USA).

2.5.9. Complementation of speA into the superantigen deletion strain of Streptococcus
pyogenes MGAS8232
Streptococcus pyogenes MGAS8232 complete superantigen deletion strain was
complemented with the speA gene with its native promoter as determined by promoter
mapping by PPP software (http://bioinformatics.biol.rug.nl/websoftware/ppp) [164]. The
complementation cassette was created in pG+host5 using homologous recombination
sites for insertion between pepO and tsf. The process by which speA was introduced was
similar to the superantigen deletion protocols outlined in Figure 5 in that it used the
Gram-positive temperature-sensitive origin of replication to ensure integration of the
plasmid into the genome and relied on antibiotic sensitivity to indicate the loss of the
plasmid and PCR screening to confirm each step.

2.6. Protein visualization
2.6.1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
All proteins were visualized by Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE).

Separating gels were made with 12% polyacrylamide

[0.1% (w/v) SDS (Fisher Scientific, Fair Lawn, NJ, USA), 0.25% (v/v), 1.5 M Tris-HCl
(EMD Chemicals Inc., Darmstadt, Germany), pH 8.8, 12% (v/v) acrylamide (EMD
Chemicals Inc., Darmstadt, Germany), 0.1% (w/v) ammonium persulfate (APS) (Sigma
Chemical Co., St. Louis, MO, USA) and 0.15% (v/v) tetramethylenediamine (TEMED)
(EMD Chemicals Inc., Darmstadt, Germany)] with 5% acrylamide stacking gels [1.3%
(w/v) SDS, 25% (v/v), 0.5 M Tris-HCl, pH 6.8, 5% (v/v) acrylamide, 0.1% (w/v) APS
and 0.2% (v/v) TEMED], using a BioRad Mini-PROTEAN 3 system. Laemmli buffer
[125 mM Tris pH 6.8, 50% glycerol, 4% SDS, 5% -mercaptoethanol [Omni Pur,
Calbiochem, EMD Chemicals Inc., Gibbstown, NJ, USA], and 0.1% (w/v) bromophenol
blue] was added to each protein sample before being boiled for five minutes. BroadRange molecular weight marker (New England BioLabs, Ipswich, MA, USA) was used.
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Gels were run in tris-glycine electrophoresis buffer (25 mM Tris, 190 mM glycine, 1%
SDS) for 30 minutes at 85 V and then at 150 V for an additional 90 minutes. Gels were
stained in coomassie [45% methanol, 10% glacial acetic acid (Caledon, Georgetown, ON,
Canada), 0.1% (w/v) coomassie brilliant blue stain R-250) for at least 1 hour and then
destained for visualization (45% methanol (Caledon, Georgetown, ON, Canada), 10%
acetic acid (Caledon, Georgetown, ON, Canada)].

2.6.2. Western blots
Proteins for Western blots were run on 12% SDS-PAGE gels and were then
transferred to a polyvinylidene difluoride (PVDF) Amersham HybondP membranes (GE
Healthcare, Little Chalfont, Buckingshire, UK) using a BioRad Trans-Blot system. A
piece of PVDF membrane was immersed in 100% methanol for 10 minutes and then
equilibriated in transfer buffer (182 mM glycine, 34 mM Tris, 20% methanol) for 10
minutes.

SDS-PAGE gels were also equilibrated in transfer buffer.

The PVDF

membrane was placed on top of the protein gel and sandwiched between 6 pieces of filter
paper and was placed in the transfer apparatus. Proteins were transferred for one hour at
100 V at 4C or overnight at 25 V at 4C. Membranes were subsequently blocked with
5% (w/v) skim milk (Equality) diluted in 1  phosphate buffered saline (PBS) [125 mM
NaCl (BDH, Westchester, PA, USA), 1.5 mM KH2PO4 (Sigma Aldrich Co., St. Louis,
MO, USA), 8 mM Na2HPO4 (EMD Chemicals Inc., Darmstadt, Germany), 2.5 mM KCl
(Sigma Aldrich Co., St. Louis, MO, USA), pH 7.6] for 1 hour at room temperature. The
blocking buffer was replaced with the appropriate dilution of primary antibody diluted in
1% (w/v) skim milk in PBS incubated at room temperature for 1 hour. The membranes
were washed three times for 5 minutes in PBS with 0.01% (v/v) tween20 (PBST) and
then once for 15 minutes in PBS. The secondary antibody was incubated with the
membrane in 1% (w/v) skim milk in PBS for an hour. The membrane was washed as
before. All Western blots were visualized on LI-COR Odyssey (LI-COR Biosciences,
Lincoln, NB, USA).

2.7. Protein expression and purification
2.7.1. Histidine-tagged superantigen purification
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Histidine-tagged SAgs were expressed from pET-based expression plasmids in E.
coli BL21 (DE3). Expression strains of E. coli were grown in LB supplemented with
Kanamycin at 50 g/ml (Kan50). Overnight cultures of bacteria were subcultured (0.1%)
into 1 L of LB Kan50 and grown at 37C with shaking for 3 hours before being induced
with 200 M isopropyl -D-1-thiogalactopyranoside (IPTG) and the culture was returned
to 37C incubator with shaking overnight. Cultures were pelleted at 3,500  g (Avanti J25 centrifuge, Beckman Coulter) for 10 minutes. The pellet was resuspended in 10 ml of
1  hepes buffer [10 mM Hepes (BDH, VWR, West Chester, PA, USA), 150 mM NaCl
(BDH, VWR, West Chester, PA, USA), pH 7.4] with 10 l DNaseI and 50 l of 10
mg/ml lysozyme in a shaking ice bath for 1 hour. Bacteria were sonicated in 3 rounds of
50 pulses of 40% duty cycle, output 4 on Branson Sonifier (Danbury, CT, USA) and
allowed to rest on ice between each round of sonication. Cellular debris was pelleted at
10,000  g at 4C for 10 minutes and the supernatant was passed over a Ni NTA His Bind
Resin nickel affinity chromatography column (Novagen, San Diego, CA, USA) and
histidine-tagged SAgs were eluted in either the 60 mM or 200 mM imidazole in 1  hepes
buffer elution fractions. The proteins were dialyzed 3 times against 1 L of 1  hepes
buffer for 1 hour.

The SAgs were cleaved with either tobacco etch virus protease

(McCormick lab) or thrombin for 24-72 hours at 4C. Cleaved proteins were passed
again over a nickel affinity chromatography column, and eluted from the column in the
15 mM or 30 mM imidazole fractions in 1  hepes buffer. The proteins were dialyzed 3
times against 1 L of 1  hepes buffer, 0.9% saline or distilled water for 1 hour. The purity
of the SAgs was assessed by SDS PAGE and the concentration of the SAgs was assessed
by BCA assay (Thermo Scientific, Rockland, IL, USA). Proteins were diluted to the
correct concentration in either 1  hepes buffer or 0.9% saline, aliquotted and stored in 20C. For antibody production proteins dialyzed into water were lyophilized.

2.7.2. Trichloroacetic acid streptococcal supernatant protein precipitation
Streptococcal cultures were subcultured into 100 ml pre-warmed THY broth and
grown to late exponential phase. The bacteria were pelleted and 90 ml of culture
supernatant was removed and 50% trichloroacetic acid (TCA) was added to reach a final
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concentration of 6%. The supernatant was chilled on ice for 30 minutes. Precipitated
supernatants were pelleted at 10,000  g for 10 minutes at 4C. The supernatant was
removed and the pellet was washed once in 10 ml of -20C acetone and spun at 10,000 
g for 10 minutes. The supernatant was removed and the pellet was dried and resuspended
in 900 l of 8M urea for a final concentration of 10:1.

2.8. Antibody generation
2.8.1. Antibody production
Purified and lyophilized SpeA, SpeC, SpeG, SpeL, SpeM, and SmeZ were sent to
ProSci Incorporated (Poway, California, U.S.A.). SAgs were resuspended in 0.9% saline
and were injected at a concentration of 200 g in complete Freund’s adjuvant at week 0.
Rabbits were boosted with 100 g of SAg in incomplete Freund’s adjuvant at weeks 2, 4
and 6. Serum samples were collected at week 0, 5 and 7 with a terminal bleed taken at
week 8. Serum samples were assessed for antibody titres, aliquoted and were stored at
minus 80C.

2.8.2. Antibody titres
Antibody titres were determined by enzyme-linked immunosorbant assay
(ELISA). SAgs were diluted to a concentration of 10 g/ml in 50 mM carbonate buffer
(Na2CO3 0.0015 M; NaHCO3 0.0349 M; NaN3 0.00307 M; pH to 9.5) in Costar ELISA
96-well plates (Costar, Corning, NY, USA). Coated plates were incubated at room
temperature wrapped in aluminum foil. Plates were washed twice with PBST wash buffer
and then blocked with blocking buffer [1% BSA (Sigma Aldrich Co., St. Louis, MO,
USA), 0.02% tween20 (Fisher Scientific, Fair Lawn, NJ, USA) in 1 x PBS] for 2 hours in
the dark at room temperature. Dilutions of serum were prepared in dilution buffer (0.1%
BSA, 0.02% tween20 in 1  PBS). Plates were washed twice after blocking with PBST
and flipped on Whatman paper to dry between washes. One hundred microliters of each
diluted sample was added to the plates in triplicate. Samples were incubated for 2 hours
at room temperature in the dark. Plates were washed three times with PBST, and three
times with distilled water.

Goat anti-rabbit antibody conjugated with horseradish

peroxidise (HRP) (Rockland, Gilbertsville, PA, USA) at a dilution of 1:10,000 in 1  PBS
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with 1% BSA, 0.02% Tween-20 was incubated in the plates for 2 hours at room
temperature in the dark. Plates were washed with PBST five times, followed by 5 washes
with distilled water. One hundred microliters of BD EIA 3,3’,5,5’ tetramethyl benzidine
(TMB) substrate reagent (Becton, Dickinson, Company, Sparks, MD, USA) developed
the reaction for 10 minutes at room temperature in the dark before being stopped by
adding 50 l of 1 N H2SO4. Plates were immediately read at OD450 with a reference of
OD570
2.9. Mouse housing and breeding
2.9.1. Housing
Mice were housed in an inclusion/exclusion facility during experimentation in
micro-isolator cages. Transgenic DR4, DQ8, and DR4/DQ8 breeding pairs were housed
and cared for at the West Valley Barrier Facility at Western University, Canada in
positive pressure microisolator system Micro-VENT System cages (model # MD75
Ju14OMVS PCD3, Allentown Inc., Allentown, New Jersey, USA).

2.9.2. Mice
A list of all mice used in this study can be found in Table 5. Human MHC class II
transgenic mice were bred from McCormick Laboratory colonies specifically for this
study and were in a C57BL/6 (B6) background. Transgenic H-2 null, MHC class II
human leukocytic antigen-DR4 (DR4) mice originated from a colony housed at Western
University, West Valley Barrier Facility and were a kind gift from Dr. Ewa Cairns.
Expression of the transgenic HLA-DR4 immunoreceptor was confirmed by flow
cytometry at regular intervals (data not shown). H-2 null, HLA-DR4/DQ8 transgenic
mice were a kind gift from Dr. M. Kotb at the University of Cincinnati, Cincinnati, OH,
U.S.A. HLA-DQA1*0301 and DQB1*0302 (DQ8) mice were originally developed by
the C.S. David group to examine the contribution of HLA-DQ type to the development of
human polyarthritis in a collagen-induced arthritis model [165]. The DQ8 alleles were
introduced into a mouse that was mouse class II-deficient H-2Ab0 by cosmid injection
into mouse embryos [165]. Mice were also developed to express DRB1*0402 in addition
to DQ8 are classified as DR4/DQ8 mice [166]. Mice were isolated in quarantine and
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Table 5. Mouse strains used in this study
Strain Name

Characteristics

MHC class II

Source

C57BL/6

Inbred black mouse

H-2b

The

Stock Number
Jackson

000664

Laboratory
BALB/cJ

Inbred white mouse

H-2d

Inbred white mouse

H-2

q

H-2

a

The

Jackson

000651

Laboratory
FVB/NJ

The

Jackson

001800

Laboratory
A/J

Inbred white mouse

The

Jackson

000646

Laboratory
DR4

Inbred homozygous
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were assessed for enteric pathogens before being transferred to the West Valley
Barrier Facility to be bred specifically for this study. All other mice were purchased from
The Jackson Laboratories. Mice were used between nine and thirteen weeks old for nasal
infection and both male and female mice were used in the study.

2.9.3. Genotyping
Transgenic HLA-DR4/DQ8 mice were genotyped to verify the presence of the
transgenes. The breeding colony was confirmed to be homozygous for the HLA-DQ8
allele but heterozygous for the HLA-DR4 allele. As such, all mice used were genotyped.
Unsuccessful attempts were made to establish a completely homozygous breeding colony.
Mice (10-14 days old) were ear punched to identify individuals and the ear punches were
used to isolate DNA from the tissue using the QIAGEN DNeasy blood and tissue kit
(QIAGEN Sciences, MD, USA) using the manufacturer’s directions. Resulting DNA
preparations were used with primers specific to the alpha and beta chains of the HLADR4 and HLA-DQ8 alleles (Table 4).

2.10. Streptococcal colonization and persistence in a mouse model
2.10.1. Bacterial preparation
Streptococcus pyogenes cultures that had been grown in serial culture in unautoclaved, 0.2 m-filtered THY media supplemented with 10% human serum for five
consecutive days before storage in -80C were started in 10 ml THY media in a 15 ml
falcon tube. Cultures were subcultured at 1:100 in THY broth daily for two days. On the
third day the culture of S. pyogenes was subcultured at 5% into a pre-warmed 150 ml
bottle of 100 ml of THY and grown for 3-4 hours at 37C, which allowed the cultures to
reach logarithmic phase which was considered to be when the OD600 was between 0.150
and 0.350. Optical density was measured at 600 nm and was used to calculate the number
of bacteria in a millilitre of culture. The volume of bacteria necessary to prepare the
inoculation was calculated, measured and spun at 3,000 RPM (Allegra 6 centrifuge;
Beckman Coulter) for 10 minutes. Supernatant was gently poured off without disturbing
the pellet. The pellet was transferred to a microfuge tube and the culture was spun at
21,130  g for one minute and the supernatant was drawn off and the pellet was washed
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in 1 ml of 1  Hanks Balanced Saline Solution without phenol red (HBSS; Hyclone
Laboratories, South Logan, UT, USA), S. pyogenes were re-pelleted and again the
supernatant was removed. The culture was prepared so that it was resuspended in 15 l
of HBSS per dose of bacteria at room temperature.

2.10.2. Mouse nasal inoculation
Mice between 9 and 13 weeks of age were anesthetized with isoflurane (Baxter
Corp., Mississauga, ON, Canada) and were monitored in accordance with the Western
University animal care and veterinary services post-operative/post-anesthetic care
protocol for rodents (standard operating procedure # 330-03). Mice were scruffed and 7.5
l of the bacterial preparation was used to inoculate each nostril of the mouse very slowly
so that there was no accumulation of inoculum on the nares of the mouse while the dose
was being given. The mouse was allowed to recover and was monitored for the duration
of the experiment.

2.10.3. Endpoint surgery
Mice were sacrificed at the end of the experiment as per the animal protocol
approved by the Western University Animal Ethics Board.

Endpoint timing was

determined by desired readout. To analyze the establishment of colonization data all
mice were sacrificed at 48 hours. To examine the persistence of colonization, mice were
sacrificed at 24, 48, 72, 96, and 144 hours post-infection.
At the desired endpoint mice were anesthetized with isoflurane until they were not
responsive to pain and anesthesia was maintained on a nose cone for the duration of the
surgery. Mice were opened down the ventral midline with small straight sterile scissors.
Organs were moved to the animal’s left exposing the dorsal abdominal wall. Blood was
drawn from the portal vein into a 1 ml syringe (Becton, Dickinson, and Co., Sparks, MD,
USA) with a 25 gauge needle coated with Heplean heparin (Organon Canada Ltd.,
Toronto, Ontario, Canada). After the blood draw, the animal was sacrificed by breaking
the diaphragm and decapitation with scissors.

The spleen, kidneys, liver (with

gallbladder removed), lungs and heart were harvested. Organs were surgically removed
into tubes containing 4 ml HBSS. Organs and blood samples were placed on wet ice until
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homogenization. To remove the complete nasal turbines including the NALT and the
maxillary sinuses, the head was positioned so that the snout of the head was facing the
surgeon upside down on the surgical platform. The head was stabilized using tweezers to
hold the lower jaw, gripping the tongue to the roof of the mouth. Sturdy large scissors
were inserted pointed end into the mouth all the way to the back and held so that they
were parallel to the soft palate and used to sever the lower jaw from the upper portion of
the head. Curved tweezers were then used to grip the cheek with the curve of the
tweezers pointing away from head. Large scissors were used to cut between the tweezers
and the head to cut away and remove excess cheek tissue from both cheeks, without
cutting the skull bones, all the way to the ears. Tweezers were subsequently used to grip
the tip of the nose and the sturdy scissors were used to cut behind the front teeth to
remove the nose and the front teeth. With the nose of the head still pointing directly at
the surgeon and the head positioned so that the soft palate is facing up, and cross-pinned
the head behind the palate. A fresh needle was used as a micro-scalpel to slice a very
shallow cut midline through the soft palate. The soft palate was peeled off using very
fine curved tweezers. Small curved scissors were inserted pointed side up shallowly into
one side of the curved jaw bone back to the back teeth. The NALT and maxillary sinuses
are attached to the ventral surface of the ethmoid turbinate, so it is important that the cut
of the curved part of the jaw bone is very shallow as to not disturb the ethmoid turbinates.
The bone was cut and the facial bone with remaining tissue was gently and slowly
rolled/pressed away from the septum. The entire nasal turbines including the NALT and
the maxillary sinus were removed without disturbing the septum by breaking and
removing the cartilage at the front of the tissue and breaking the ethmoid turbinates free
from the back. This harvested tissue will henceforth be referred to as the ‘complete nasal
turbinates’ (cNT). The other side cNT was removed in the same manner. The cNT were
collected in a microfuge tube with 500 l HBSS and stored on ice until processed (Figure
6).

2.10.4. Tissue processing and plating
Isolated tissues were processed by homogenization for determination of colony
forming units (cfu). Spleen, kidneys, liver, lung, and heart were processed with a
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Figure 6. Surgical removal of the murine complete nasal turbines. The head (A) was
prepared by the removal of the lower jaw (B) and cheek muscles on either side of the
head (C). The nostrils were removed by cutting posterior to the incisors (D). The head
was pinned down just ahead of the ear canals and a needle was used as a microsurgical
tool to make a very shallow cut in the centre of the palate (F) and the palate was peeled
off with fine smooth curved tweezers (G) to expose the top of the premaxilla on either
side of the septum (H). Very fine curved scissors are inserted very shallowly under the
top edge of the premaxilla all the way back to the back of the molars, the premaxilla was
cut and moved away from the tissue beneath it (I) which exposed the nasal turbines and
the ethmoid turbinate which were posterior to the more bony maxilloturbinate and
nasoturbinate (I, J). The maxilloturbinate and nasoturbinate can be distinguished from the
ethmoid turbinate as they appear to be redder in appearance and feel bony to the tweezers.
The maxilloturbinates and nasoturbinates were removed with the fine, smooth curved
tweezers. The tweezers were then placed posterior to the ethmoid turbinate and then
scooped out of the head without disturbing the septum (K). The other ethmoid turbinate
was then removed in the same manner.
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PRO200 electronic homogenizer (PRO Scientific Inc., Monroe, CT, USA). Between
samples, the homogenizer was cleaned by rinsing twice in 4 ml of water or HBSS, being
wiped with a tissue wipe, rinsed with 10% bleach, 70% ethanol, and finally rinsed twice
more in each of 4 ml sterile distilled water and 4 ml sterile HBSS. Samples were
homogenized until they appeared homogeneous. The cNT were homogenized in a 1 ml
glass homogenizer. Between samples, the glass homogenizer was cleaned three times
with 70% ethanol and rinsed twice with both sterile distilled water and sterile HBSS.
Tissues were plated both 100 l neat and serially diluted on TSAII plates containing 5%
sheep blood agar (Becton, Dickinson, and Co., Sparks, MD, USA). Bacterial growth was
observed after growth at 37C. Total bacterial growth and -haemolytic S. pyogenes
were assessed.

2.11. Histology
2.11.1. Organ isolation
Mice were fully anesthetized with isoflurane and the mouse was perfused through
the heart with sterile PBS containing heparin to flush the blood from the mouse using a
Gilson Minipuls 3 peristaltic pump (Middletown, WI, U.S.A) at a constant flow rate.
Mice were then perfused with 10% neutral buffered formalin (BDH, VWR, West Chester,
PA, USA) through the peristaltic pump at a constant flow rate until organs were fully
perfused with formalin. Organs were surgically removed without tool marks and were
placed in 10-volumes of fresh formalin.

The head was prepared for histology by

removing the lower jaw and tongue and the tip of the nose which was removed by cutting
behind the front teeth and then placed 10-volumes of formalin.

2.11.2. Histology tissue processing
Formalin-perfused soft tissues (spleen, kidneys, liver, lung and heart) were further
fixed in formalin for 48 hours at 4C, changed daily. Organs were rinsed in 1  PBS
before being resuspended in 10-volumes of 1  PBS twice a day for three days, and
washed in 10-volumes of 70% ethanol twice and stored in 70% ethanol until processed.
To process bony tissues, such as the head, the formalin-perfused mouse tissues were
soaked in 10 volumes of formalin for 24 hours and then the formalin was removed and
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the tissue was re-suspended in Shandon TBD-2 Decalcifier (TBD; Thermo Scientific,
Kalamazoo, MI, USA) for 96 hours.

The TBD-treated tissue was tested for

decalcification by cutting the back of the skull with a scalpel to determine whether or not
the bone could be sectioned smoothly after further processing. TBD-decalcified heads
were placed in formalin for 48 hours and washed with 1  PBS, and resuspended in 10volumes of 1  PBS twice daily for 4 days and washed in 70% ethanol twice and stored in
10-volumes of 70% ethanol until cassetted and processed.

2.11.3. Cassetting, embedding and sectioning fixed tissues
Fixed tissues were placed in 4 mm Fisherbrand TRU-Flow tissue cassettes. The
head was sectioned between the first and second molar and the front section of the head
was placed in one cassette and the back portion in a second for processing. Formalinfixed cassetted tissues in 70% ethanol were sent to The Robarts Research Institute
Molecular Pathology Core Facility for processing in preparation for embedding in wax.
Cassettes were processed in Leica ASP300 fully enclosed paraffin wax tissue processor
overnight in the bone program. Cassettes were transferred into a warm wax bath and
embedded in paraffin wax. Embedded tissues were stored at room temperature until
sectioning.
Tissues were sectioned on a microtome HM335E Microtome Leica in the Robarts
Research Institute Molecular Pathology Core Facility using MB35 Premier Microtome
blades (Thermo Scientific) into 5 micron sections. Serial sections were collected for head
sections, and representative sections were cut for the spleen. Sections were mounted on
Fisherbrand Superfrost Plus microscope slides (Fisher Scientific, Fair Lawn, NJ, USA)
and were dried at 45C for 48 hours prior to storage/staining.

2.11.4. Haematoxylin and eosin staining of processed tissue
Tissues were stained with haematoxylin and eosin in a Leica Autostainer XL.
Slides were allowed to dry and Fisher Finest Premium Cover Glass (Fisher Scientific,
Fair Lawn, NJ, USA) cover slips were affixed to the slides using Cytoseal 60 low
viscosity mounting medium (Richard-Allen Scientific, Kalamazoo, MI, USA). Cover
slipped slides were dried for at least 24 hours horizontally before vertical storage.
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2.11.5. Histology evaluation
Slides were blindly evaluated in collaboration with a pathologist. After all slides
were observed evaluation criteria were determined for each tissue type. The relative
amount of mucus present covering the epithelia, the presence of red blood cells, and the
presence of nucleated cellular debris on the surface of the epithelia was assessed. The
presence and severity of these findings were used to assign a score of zero to two points
to each of two sections per mouse. The scores were averaged to determine differences in
histological pathology in the mice.

2.12. Flow cytometry
2.12.1. Tissue isolation and processing
Mice were anesthetized as previously described. The cervical lymph nodes were
surgically removed and collected and suspended in RPMI 1640 (Gibco, Burlington,
Ontario, Canada) and the mouse was decapitated. The spleen was surgically removed and
placed into 5 ml of complete RPMI (cRPMI). The remaining lymph nodes were collected
into the lymph node collection tube. The cNT were removed as described above and
placed in a tube with 5 ml RPMI 1640. Cells were isolated by passing the organs through
40 m nylon cell strainers (BD Falcon, San Jose, CA, U.S.A) with the end of a syringe.
Cells were spun at 1,200 RPM (Beckman Coulter Allegra 6) for 5 minutes and the pellet
was resuspended into ACK lysis buffer (15 mM NH4CL, 10 mM KHCO3, 0.1 mM
EDTA) for five minutes with inversions every 30 seconds.

ACK lysis buffer was

neutralized with 10 ml cRPMI and the cells were pelleted as before. Cells were loosened
by racking and resuspended into filtered PBS with 5% fetal bovine serum (FBS). Cells
were enumerated and their viability was assessed by trypan blue (Gibco, Burlington,
Ontario, Canada).

2.12.2. Flow cytometry
Isolated cells were aliquoted at 500,000 cells per 5 ml tube. Cells were pelleted at
1,200 RPM (Allegra 6 centrifuge, Beckman Coulter) for 5 minutes and the supernatant
was carefully poured off. The pellet was gently racked to resuspend the cells. Cells were
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pre-treated with Fc block from hybridoma clone 2.4G2 cell culture supernatant (produced
by the Haeryfar lab) for 10 minutes prior to cell staining. A master mix of the antibodies
(Table 6) were used to stain the cells for each panel (Table 7) were added, the cells were
mixed and incubated on ice in the dark for 30 minutes. Cells were washed twice with 1 
PBS + 5% FBS, pelleting the cells at 1,200 RPM for 5 minutes between washes. Cells
were finally resuspended in 500 l of 1  PBS + 5% FBS. Stained cells were run on a
BD FACS Canto II flow cytometer, with capture of 100,000 events per sample. Standard
compensations were used for each tissue using FACSdiva software.

2.13. Cytokine analysis
2.13.1. Human peripheral blood mononuclear cell activation assay
Human blood was collected in heparinized vacuum tubes, diluted 1:1 with RPMI,
layered over pre-warmed ficoll and spun at 2,500 RPM for one hour. Peripheral blood
mononuclear cells (PBMC) were removed by pipetting and washed in 40 ml of warm
RPMI, pelleted for 5 minutes at 2,500 RPM, and resuspended in cRPMI. Cells were
assessed for viability by trypan blue and plated at 2  105 PBMCs per well in a 96-well
plate. Cells were stimulated with streptococcal culture supernatant so that the final
volume per well was 200 l. The potential mitogens were incubated at 37C with 5%
CO2 for 18 hours. Cell culture supernatant was removed and activation was assessed by
measuring IL-2 by ELISA.

2.13.2. Mouse splenocyte activation assay
The spleen was surgically removed from the mouse and was suspended in cRPMI.
The spleen was passed through a 40 m nylon cell strainer, spun at 1,200 RPM (Beckman
Coulter Allegra 6) for 5 minutes, and resuspended in ACK lysis buffer for five minutes
with inversions every 30 seconds before being neutralized with 10 ml cRPMI. Pelleted
cells were loosened by racking and resuspended into cRPMI. Cells were enumerated and
their viability was assessed by trypan blue. Cells were plated at 2  105 splenocytes per
well in a 96-well plate and were stimulated with either recombinant SAg (rSAg) or
streptococcal culture supernatant so that the final volume per well was 200 l. The
potential mitogens were incubated at 37C with 5% CO2 for 18 hours. Cell culture
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Table 6. Antibodies for flow cytometry
Target

Fluorochrome

Identifies

Order Number

Source

Mouse CD3

APC

Mature T cells

17-0031-82

eBioscience

Mouse CD3

PE Cy7

Mature T cells

25-0051

eBioscience

Mouse CD4

APC Cy7

CD4+ T cells

100414

Biolegend

Mouse CD8

PE Cy7

CD8+ T cells

25-0081

eBioscience

Mouse CD25

PE

Active and mature

12-0251-82

eBioscience

T cells and B cells
and regulatory T
cells
Mouse CD45

Alexafluor 700

Leukocytes

560510

BD Pharmigen

Mouse CD19

FITC

B cells

11-0191-81

eBioscience

Mouse NK1.1

PE

Natural killer and

12-5941-82

eBioscience

natural killer T cells
Mouse

CD1d

APC

tetramer, Unloaded
Mouse
tetramer,

CD1d

APC

Control for iNKT

NIH,

cell staining

Haeryfar

iNKT cells

NIH,

PBS-57

Dr.

Dr.

M.

M.

Haeryfar

Loaded
Mouse CD11c

APC Cy7

Dendritic cells

17-0114-82

eBioscience

Mouse F4/80

FITC

Macrophages

11-4801

eBioscience

Mouse GR1

FITC

Neutrophils

53-5931

eBioscience

Dead cells

51-68981E

BD Pharmigen

Anti 7AAD
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Table 7. Flow cytometry staining panels
Panel

Tissues stained

Antibodies

Panel 1

Lymph nodes

7AAD

Spleen

CD45 Alexaflour700 (cNT only)

Complete nasal turbinates

CD19 FITC (cNT only)
CD3 APC
CD4 APC Cy7
CD8 PE Cy7
CD25 PE

Panel 2

Lymph nodes

7AAD

Spleen

CD1d APC (loaded and unloaded)
CD3 PE Cy7
CD19 FITC
NK 1.1 PE

Panel 3

Lymph nodes

7AAD

Spleen

F4/80 FITC
CD11c APC Cy7

Panel 6

Lymph nodes

7AAD

Spleen

CD45 Alexaflour700 (cNT only)

Complete nasal turbinates

CD11c APC
F4/80 FITC
NK 1.1 PE

Panel 7

Lymph nodes

7AAD

Spleen

CD45 Alexaflour700 (cNT only)

Complete nasal turbinates

GR1 FITC
CD11b PE
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supernatant was removed and activation was assessed by measuring mouse IL-2 by
ELISA.

2.13.3. Enzyme-linked immunosorbant assay
Human and mouse IL-2 ELISA kits were purchased from eBioscience, and were
used to assess primary cell culture supernatants stimulated for 18 hours. Kits were run as
specified by the manufacturer in Costar ELISA plates. Plates were read at OD450 and at
the reference OD570.
2.13.4. Multiplex cytokine analysis
Cytokines were analyzed in cNT homogenates isolated from mice treated by
either wild-type S. pyogenes MGAS8232 or S. pyogenes MGAS5005, isogenic SAg
deletion strains or saline at either 24 or 48 hours in DR4/DQ8 and FVB mice respectively.
The homogenates were analyzed in one of three way; by ELISA (eBioscience), Luminex
was performed by the Screening Lab for Immune Disorders (Lawson Health Research
Institute, London, Ontario, Canada) using the Bio-Rad BioPlex 200 to run a Millipore 12plex cytokine array, or with an eBioscience Flow Cytomix mouse Th1/Th2 10-plex
ready-to-use cytokine analysis kit (San Diego, CA, U.S.A) as per manufacturer
instructions.
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Chapter 3: Results
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3.1. Establishment of a murine model of mild nasal infection by Streptococcus pyogenes
3.1.1. Surgical removal of the complete nasal turbinates of mice
Mice are obligate nose breathers, and hence all inspired air passes through the
nasal passage, which is the first site of contact for inhaled infectious agents [143]. The
lymphoid tissue that lines the basolateral surface of the nasopharyngeal meatus is known
as the NALT, which is physiologically similar to the human tonsils [144]. The NALT has
been established as a site of colonization of S. pyogenes in mouse nasal infection model at
24 hours post-inoculation [149].
Although there is a good description of one method of NALT extraction and
processing in which the palate is excised around the perimeter with a small scalpel and
then carefully separated from the head to solely isolate the NALT which is attached to the
posterior of the palate [144]. This process differs from the removal of the complete nasal
turbinates (cNT) whose removal includes the NALT, the maxillary sinuses, and the
ethmoid turbinates. There was no previous existing detailed diagrammatic protocol of
surgical removal of the complete nasal turbinates before this work (Figure 6). The cNT
isolation procedure differs in that the palate is removed without first incising the
perimeter. The premaxilla was shallowly cut all the way to the molars and the cheeks
were separated away to reveal the cNT which is separated from the septum using fine
tweezers.
To illustrate the physiological location of the structures in the nasal passage
relative to the rest of the head, histological sections were prepared from 10% formalinperfused TBD decalcified mouse heads embedded in wax. Sequential cross-sections of
the mouse head were prepared between the T3 and T4 sections to demonstrate the
differences in the nasoturbinates throughout the head (Figure 7). Cross-sections of the
mouse heads, stained with haematoxylin and eosin, were visualized by microscopy and
have been used to indicate the location of the NALT in relation to the ethmoid nasal
turbinates at the T4 cross-section (Figure 8).
The surgical technique used for the isolation of the cNT in this work was learned
in the laboratory of Dr. P. P. Cleary (University of Minnesota), an established expert in
this model [149, 151-152, 168]. Despite the fact that in previous literature the primary
site of colonization has been established to be highly localized in the NALT [149], the
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Figure 7. Histological transition in the haematoxylin and eosin-stained murine head cross
sections from T4 to T3. The prepared sections of the fixed mouse head were scanned in
their entirety. The sections were taken at 200 m intervals from the T4 cross-section to
the T3 cross-section, a total of 1,400 m (A-G). At the T4 section the eye (E) and the
optical lobes of the brain (B) are visible. The nasal turbinates (NT) are distinct from the
nasopharyngeal meatus (M) and are divided by the septum (S). The oral cavity (OC) is
located at the base of the section and the molar teeth (T) are visible. Starting at 200 m
towards the anterior of the head (B) the NALT (*) is visible bilaterally throughout the rest
of the sections (B-G). At 300 m towards the anterior of the head the maxillary sinuses
(MS) are visible bilaterally through the rest of the sections (C-G). At 800 m (D), the
nasopharyngeal meatus connects to the nasal turbinates and the teeth are no longer
apparent.
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Figure 8. Haematoxylin and eosin-stained section of transected murine head indicating
the position of the NALT from a wild type S. pyogenes MGAS8232-infected mouse. The
40 magnification orients where the NALT (N) is located in relation to the rest of the
tissue in the head. The oral cavity (OC) and palate (HP) and optical lobe of the brain (B)
serve to orient the diagram. The septum (S) divides the two ethmoid turbinates (NT) of
the sinuses. The 200 magnification image shows the lymphoepithelium (LE) separating
the NALT from the nasopharyngeal meatus. The 600 magnification image highlights
the LE and identifies the ciliated (C) cells, goblet cells (G) and overlying mucus (M)
which is located on the basolateral surface of the nasopharyngeal meatus (NPM).
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surgical technique learned from the Cleary lab varies slightly from the documented
NALT surgical technique described in Asanuma et al. [144] in that it removes the cNT
(Figure 6). All surgeries in this work recovered the cNT which includes the ethmoid
turbinates along with the NALT and maxillary sinuses. This thesis has provided a
detailed pictorial diagrammatic protocol of how to perform the removal of the cNT
(Figure 6). Importantly, this technique resulted in reproducible streptococcal counts
within the expected range (described below).

3.1.2. Bacterial dose determination for streptococcal colonization in mice
To examine streptococcal colonization potential, mice were sacrificed at 48 hours
post-inoculation.

The 48 hour time point was chosen as the time point to assess

streptococcal colonization based on previous work by Park et al. [149], which described
that in a BALB/c mouse model of streptococcal nasal infection with an M1 strain of S.
pyogenes (strain 90-226), after an initial decrease in the streptococcal burden at four
hours post-infection, the population of streptococci in the cNT recovers and peaks at 48
hours.
To determine the optimal dose of bacteria to use in a mouse model of nasal
colonization, 107, 108 and 109 cfu of wild-type S. pyogenes MGAS8232 were prepared
and tested in B6 mice, or B6 mice transgenic for HLA-DR4 (hereafter referred to as
DR4). Mice were sacrificed at 48 hours and their blood, organs and cNT were assessed
for the presence of live S. pyogenes MGAS8232. The streptococci colonized B6 mice
very poorly at all dose concentrations tested; however, S. pyogenes MGAS8232
consistently colonized DR4 mice 2-3 logs higher compared with the B6 mice (Figure 9).
Ultimately, due to the viscosity and technical difficulty in the preparation of the 109 cfu
dose of S. pyogenes MGAS8232 (data not shown), it was decided to use a dose of 1  108
cfu for both S. pyogenes MGAS8232 and S. pyogenes MGAS5005 for colonization
experiments in the mice.
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Figure 9. Efficient nasal colonization in humanized mice by S. pyogenes is dependent on
human MHC class II. Mice expressing either mouse or transgenic human MHC class II
molecules were nasally inoculated with (A) S. pyogenes MGAS8232 (N=4-7) and (B) S.
pyogenes MGAS5005 (N=3-6). At 48 hours post inoculation mice were sacrificed and
the streptococcal burden in the cNT was assessed. DR4/DQ8* mice are F1 generation
mice of a cross of DR4/DQ8 and DR4 mice from the Western University colony.
Statistical differences were assessed by unpaired t-test. *, P <0.05; **, P <0.005; ***, P
<0.0005.
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3.1.3. Streptococcal nasal colonization varies depending on transgenic expression of
human MHC class II
Different human MHC class II haplotypes have been previously established to
alter susceptibility to streptococcal SAg-induced T cell proliferation and have been linked
to clinical outcomes in patients with severe streptococcal infection [29, 59, 112-114].
Human MHC class II was also found to contribute to the severity of streptococcal sepsis
in a transgenic mouse model [113]. To assess the sensitivity of mouse strain variation on
streptococcal colonization, S. pyogenes MGAS5005 or S. pyogenes MGAS8232 were
used to nasally inoculate B6 background mice which do not express mouse H-2 and
express different MHC class II molecules with a 1  108 cfu/dose of bacteria. At 48 hours
post-inoculation this resulted in strikingly different amounts of streptococci recovered. In
particular it was noted that DR4/DQ8 or DQ8 mice were colonized more effectively than
DR4 mice, and DR4 mice were colonized more effectively than the parental B6 mice,
with both streptococcal strains (Figure 9). Specifically, mice expressing DQ8, with or
without DR4, had counts that were ~ 4-5 orders of magnitude higher than B6 mice.
DR4/DQ8-expressing mice are thought to be neutral in their susceptibility to severe
streptococcal disease when compared to other human MHC class II and are responsive to
some streptococcal SAgs [113]. These data indicate that human MHC class II molecules
are critical host factors for the efficient colonization of cNT by S. pyogenes.

3.1.4. Streptococcal colonization is not dependant on the source of mice
The DR4/DQ8 mice are not available commercially and all transgenic mice were
bred and genotyped on site by the researcher using MHC class II sequencing primers
(Table 4) (data not shown). Because the DR4 and DR4/DQ8 mouse populations used in
this study were from two different sources, the two strains were crossed and the F1
generation expressing both DR4 and DQ8 was used in colonization experiments. The
DR4  DR4/DQ8 mice had similar levels of streptococcal colonization at 48 hours postinoculation with S. pyogenes MGAS8232 (Figure 9A., Right column denotes
DR4/DQ8*). This data indicates that the source of the mouse is not likely a factor in the
HLA-dependent colonization phenotype.
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3.1.5. Nasal colonization by S. pyogenes in mice expressing different murine MHC class
II is variable and S. pyogenes strain-dependant
Mice expressing different mouse MHC class II alleles (Table 5) were also assessed for
their ability to be colonized by different strains of S. pyogenes (Figure 10). The Friend
leukemia virus B-type (FVB) line of mice are albino inbred mice that were purchased
from The Jackson Laboratory. They express the mouse MHC class II H2 haplotype q
[169-170]. FVB mice were initially derived in 1966 from an outbred population of Swiss
mice at the National Institutes of Health in the United States of America to have
sensitivity to post-pertussis vaccination histamine challenge. These mice are reported to
be susceptible to asthma-like airway responsiveness and have higher than average
activity, anxiety and basal body temperature [169-170]. FVB mice infected with S.
pyogenes MGAS5005 had the highest yield of streptococci of all mouse strains tested at
48 hours. Inoculation with MGAS8232 did not result in a similarly high yield of S.
pyogenes in isolated cNT. Ultimately it was decided that HLA-DR4/DQ8 transgenic
mice would be used to assess S. pyogenes MGAS8232 isogenic deletion strains, and FVB
mice would be used to assess S. pyogenes MGAS5005 isogenic deletion strains.

3.1.6. Streptococcal superantigenic sensitivity varies with murine expression of MHC
class II
It has been well-established that streptococcal SAgs have different activities
depending on their interactions with MHC class II [29, 112-114, 171] and V TCR [86,
172], whose specificities can vary with concentration [87]. In general, streptococcal
SAgs do not interact with mouse MHC class II as efficiently as they do with human MHC
class II [59], which often results in poor murine response to streptococcal SAg
stimulation.
To assess the activation of murine lymphocytes by streptococcal SAgs, splenocyte
activation was used as an ex vivo readout to predict in vivo sensitivity to SAgs (Figures 11
and 12) in strains of mice with different murine and human MHC class II molecules
(Table 5). The activation of splenocytes was assessed by mIL-2 ELISA after 18 hours of
stimulation by rSAg. The activation potential of each SAg encoded in the genomes of S.
pyogenes MGAS5005 and S. pyogenes MGAS8232 is summarized in Table 8. None of
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Figure 10. Streptococcus pyogenes colonization variability in mice expressing murine
MHC class II. Strains of mice expressing different mouse MHC class II were assessed
for their ability to be colonized nasally by (A) S. pyogenes MGAS5005 wild type and (B)
S. pyogenes MGAS8232 wild type. All mice were infected for 48 hours before the
streptococcal burden was assessed in the cNT. FVB mice colonized with S. pyogenes
MGAS5005 were colonized more efficiently than any mouse strain tested. Statistical
differences were assessed by unpaired t-test. **, P <0.01 (N=2-4).
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Table 8. Summary of mouse strain-specific superantigen sensitivityA
Superantigen C57Bl/6 DR4 DR4/DQ8 BALB/c FVB

A

SpeA

Neg

+

+++

Neg

Neg

SpeC

Neg

Neg

NegB

Neg

Neg

SpeG

Neg

Neg

Neg

Neg

Neg

SpeJ

Neg

+

Neg

Neg

+

SpeL

Neg

Neg

Neg

Neg

Neg

SpeM

Neg

Neg

Neg

Neg

Neg

SmeZ

Neg

+

++++

++

+ +

Superantigen sensitivity was assessed by looking at the concentration of SAg in pg/ml

neccessary to result in the production of mIL-2 at 18 hours.
B

SpeC is considered a negative result because activation did not occur in concentrations

above 100 ng/ml.
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Figure 11.

Splenocyte activation of B6 and transgenic HLA-mice by recombinant

streptococcal superantigens. Splenocytes isolated from female B6, DR4, and DR4/DQ8
mice were treated with ten-fold serial dilutions of the pure recombinant streptococcal
SAgs encoded in S. pyogenes MGAS5005 and S. pyogenes MGAS8232 for 18 hours.
Activation of the splenocytes was assessed by determining the amount of mIL-2 produced
in the cell culture supernatants by ELISA. Results are representative of independent
experiments in at least two mice.
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Figure 12. Splenocyte activation of BALB/c and FVB mice by recombinant streptococcal
SAgs. Splenocytes isolated from female (A) BALB/c and (B) FVB mice were treated
with ten-fold serial dilutions of pure rSAg from S. pyogenes MGAS5005 and S. pyogenes
MGAS8232.

Activation of the splenocytes was assessed by determining the

concentration of mIL-2 in the cell culture supernatants after 18 hours of stimulation by
ELISA.
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the streptococcal rSAgs were found to efficiently stimulate B6 splenocytes at any
concentration tested (Figure 11A) and streptococcal SAgs only activated DR4 splenocytes
at the highest concentrations for SpeA, SmeZ, and SpeJ (Figure 11B). Splenocytes from
DR4/DQ8 mice were stimulated by recombinant SpeA, SpeL and SmeZ (Figure 11C).
White mice were also tested and were selected for their expression of different murine
MHC class II haplotypes. BALB/c mice express H2 haplotype d and were stimulated by
recombinant SmeZ and mildly stimulated by SpeA and SpeJ.

FVB mice express H2

haplotype q and were stimulated by recombinant SmeZ and SpeJ (Figure 12).

3.2. Streptococcus pyogenes MGAS8232 and MGAS5005 superantigen isogenic deletion
strain creation and characterization
3.2.1. Superantigen production by Streptococcus pyogenes
Streptococcal SAgs encoded in the genomes of S. pyogenes MGAS5005 and S.
pyogenes MGAS8232 were predicted by data mining their sequenced genomes which are
annotated in the NCBI genome database for superantigens [136, 138] (Figures 3 and 4).
The presence of four SAgs in S. pyogenes MGAS5005 and six SAgs in S. pyogenes
MGAS8232 were initially confirmed by PCR analysis with primers for all eleven
streptococcal SAgs (data not shown). Between the two strains of streptococci there are
seven unique SAgs encoded: speA, speC, speG, speJ, speL, speM, and smeZ.
Anti-SAg antibodies were generated against six SAgs produced in MGAS5005
and MGAS8232, noting that SpeC and SpeJ have cross-reactive epitopes [173].
Recombinant SAgs were expressed by induction of the proteins from pET expression
vectors in E. coli BL21 (DE3) (Table 2) and purified to apparent homogeneity
as previously described (data not shown) [102]. The chromatography-purified SAgs were
used as immunogens to generate polyclonal rabbit anti-SAg antibodies. The resulting
rabbit polyclonal anti-SAg antibodies in sera were assessed for antibody titres by ELISA
(data not shown) (Table 9), and tested for specificity against recombinant pure SAgs by
Western blot (Figure 13). There was no cross-reactivity between any of rSAgs when
probed with the polyclonal rabbit anti-SAg antibodies, which supports the notion that
individual superantigens are immunologically distinct.
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Table 9. Antibodies used for Western blot analysis
Antibody

Target

DilutionB

Source

Rabbit anti-SpeA

Polyclonal SpeA

1:32,000

Pro-Sci - This study

Rabbit anti-SpeCA

Polyclonal SpeC

1:32,000

Pro-Sci - This study

Rabbit anti-SpeG

Polyclonal SpeG

1:8,000

Pro-Sci - This study

Rabbit anti-SpeL

Polyclonal SpeL

1:32,000

Pro-Sci - This study

Rabbit anti-SpeM

Polyclonal SpeM

1:8,000

Pro-Sci - This study

Rabbit anti-SmeZ

Polyclonal SmeZ

1:8,000

Pro-Sci - This study

Human IgG

1:10,000

IRDye700 conjugated

Rockland Inc.

goat anti-human IgG

IRDye800 conjugated

609-130-123
Rockland Inc.
Rabbit IgG

1:10,000

donkey anti-rabbit IgG

611-732-127
Rockland Inc.

goat anti-rabbit HRP

Rabbit IgG

1:10,000
611-1302

A

SpeC antibody cross-reacts with SpeJ [173] and was used for detection of SpeJ at

1:8,000
B

The dilution was calculated by antibody titre ELISA and then tested by Western blot
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Figure 13. Anti-streptococcal superantigen antibodies are specific for their target proteins.
Polyclonal anti-streptococcal superantigen antibodies were tested by Western blot for
specificity against streptococcal SAgs. Rabbit anti-SpeC cross-reacts with SpeJ, which is
the only superantigen that is found in S. pyogenes MGAS5005 and not in S. pyogenes
MGAS8232 (data not shown).
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3.2.2. Construction of Streptococcus pyogenes MGAS5005 and Streptococcus pyogenes
MGAS8232 superantigen deletion mutants
To assess the potential contribution of SAgs to the establishment and persistence
of colonization by S. pyogenes in mouse nasal colonization, isogenic deletion strains of S.
pyogenes were created with individual and complete SAg deletion profiles (Figure 14).
To construct the isogenic deletion strains pG+host5-based plasmids were constructed with
a truncated version of the SAg flanked by 500 bp homologous regions upstream and
downstream of the SAg. The presence of the electroporated plasmid was confirmed by
PCR before the clone was grown under antibiotic selection at a temperature that was not
permissive for free-living plasmid replication (Figure 5).

After shifting the growth

temperature to the non-permissive plasmid replication temperature under antibiotic
selection, the integration of the plasmid was confirmed by PCR in clones that grew at
40C and were erythromycin-resistant (data not shown). Subculture without antibiotic
selection at the permissive growth temperature encourages a second recombination event
which excises the integrated plasmid from the genome. The plasmid was subsequently
cured by growth at 30C. Erythromycin sensitivity and growth at 30C was an indicator
that S. pyogenes transformants had lost the pG+host5 plasmid. Erythromycin-sensitive
clones were further tested with primers that were outside of the homologous
recombination areas flanking the SAg (Figure 15).

The lack of SAg genes in the

respective deletion strains was also confirmed using primers internal to the SAgs as listed
in Table 4 (Figure 16).

3.2.3. Complementation of speA into the S. pyogenes MGAS8232 complete superantigen
deletion strain.
S. pyogenes MGAS8232 SAg was complemented by speA with its native
promoter.

The native promoter was determined from published data [174] and by

scanning the upstream regions for putative (Lactococcal-like) SigmaA binding sites using
PPP software (http://bioinformatics.biol.rug.nl/websoftware/ppp) [164].

This speA

cassette was ‘knocked in’ to the non-coding transgenic region between genes encoding
endopeptidase O (pepO) and EF-Ts (tsf; involved in translational protein elongation
[175]). The intergenic region between pepO and tsf has been used previously for the
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Figure 14.

Streptococcal superantigen deletion strategy for individual and entire

superantigen deletion strains. (A) S. pyogenes MGAS8232 encodes six SAgs. Each
superantigen was disrupted to generate single deletion strains in S. pyogenes MGAS8232.
The speL and speM genes were deleted in tandem, as they are encoded adjacent to one
another on a bacteriophage. Each subsequent round deleted an additional superantigen
until, after five rounds, a complete isogenic superantigen deletion strain was created. (B)
S. pyogenes MGAS5005 encodes four SAgs. The SAgs are deleted in a manner similar to
those in MGAS8232. The one notable difference was that the final round of superantigen
disruption resulted in an isogenic knockout with speA, speJ and smeZ deleted.
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Figure 15. Strategy to evaluate the superantigen deletion strains. Primers were designed
to create and screen for all of the integration and subsequent clearing stages of the
pG+host5 superantigen deletion plasmids within the streptococcal genomes. Similarly
located primers were designed for all of the superantigen deletion and complementation
constructs. The primer sequences are listed in Table 4. All PCR templates were total
DNA preparations isolated from S. pyogenes cultures. PCR products from primers 2 & 4,
and 3 & 5 were cut, ligated together and cloned into pG+host5 to create the superantigen
deletion and complementation construct plasmids. Primers 2 and 5 were used in PCR to
confirm the presence of the superantigen deletion construct in electroporated clones of S.
pyogenes by the presence of two different sized PCR products.

Integration of the

pG+host5 constructs was confirmed by PCR using primers 1, 6, 7, and 8. The final
superantigen deletion was confirmed by PCR with primers 1 and 6 and by primers
internal to the wild type SAgs. Internal superantigen primers 9 and 10 were used to
screen for the presence of wild type SAgs in the isogenic mutant deletion strains.
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Figure 16. Confirmation of superantigen deletions in mutant strains of Streptococcus
pyogenes. Superantigen deletions were confirmed by PCR with primers internal to the
superantigen genes for all (A) S. pyogenes MGAS5005 and (B) S. pyogenes MGAS8232
strains.

97

98

successful insertion of genes into streptococcal strains in our laboratory. This location
was initially chosen because the pepO and tsf genes are oriented in opposite directions
facing each other, and there are two hairpin structures present between the two genes
which implies that there is no transcriptional read through in that area (Brent Armstrong,
personal communication). The presence of the speA gene in the complemented clone was
confirmed by PCR (Figure 16).

3.2.4. Superantigen deletion did not induce significant growth defects
Streptococcus pyogenes MGAS5005 and MGAS8232 SAg deletion mutants were
assessed for growth both by manual (data not shown) and Bioscreen automated growth
analysis (Figure 17). There were no gross differences in the in vitro growth between the
parental wild type MGAS5005 and MGAS8232 and the individual and complete isogenic
SAg deletion mutant strains of MGAS5005 and MGAS8232.

3.2.5. Superantigen protein production by in vitro cultured isogenic streptococcal deletion
mutants confirms superantigen deletion
The production of SAgs from wild type S. pyogenes MGAS5005 and S. pyogenes
MGAS8232 and isogenic SAg deletion mutants grown in vitro was assessed.

The

precipitated culture supernatants were concentrated 10-fold by TCA precipitation and
analyzed by SDS PAGE and Western blot analysis. Western blot using polyclonal rabbit
anti-streptococcal SAg antibodies with rSAg used as a positive control (Figure 18). Of
the four SAgs encoded in S. pyogenes MGAS5005 only SpeA was detectable by Western
blot (Figure 18A).

Of the six SAgs encoded within the genome of S. pyogenes

MGAS8232, SpeC was produced in the greatest quantity, and SpeA and SpeL were also
detectable by Western blot. SpeG, SpeM and SmeZ were not detectable (Figure 18B).
Western blot analysis additionally confirmed that in the S. pyogenes deletion strains there
was no production of the superantigens when the superantigens were otherwise produced
and detected in the in vitro expression.

3.3. Role of superantigens in nasal colonization of Streptococcus pyogenes MGAS5005 in
FVB mice.
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Figure 17. Assessment of the growth of isogenic streptococcal superantigen
deletion strains. (A) S. pyogenes MGAS5005 and (B) S. pyogenes MGAS8232 were
assessed for growth defects potentially introduced by the superantigen deletion and
complementation processes by growth in the Bioscreen assay.
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Figure 18.

Expression analysis of streptococcal superantigens in the isogenic

superantigen deletion strains. TCA protein precipitation of all streptococcal supernatants
from cultures grown to late exponential phase were assessed for superantigen production
by Western blot. (A) S. pyogenes MGAS5005 produced similar amounts of detectable
SpeA in all strains with the exception of the deletion strains. (B) S. pyogenes MGAS8232
produced detectable SpeA, SpeC and SpeL that was of similar concentration in all
isogenic strains unless the respective gene was deleted.
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3.3.1. Streptococcal superantigens influence the colonization of Streptococcus pyogenes
MGAS5005 in the nasal passage of FVB mice
Wild type S. pyogenes MGAS5005 efficiently colonized FVB mice with ~8 logs
of streptococci recovered from the cNT of the mice at 48 hours post-inoculation. FVB
mice that were inoculated with the MGAS5005 speA and MGAS5005 speG isogenic
deletion strains had no significant decrease in streptococcal burden recovered from the
cNT of mice sacrificed 48 hours post-inoculation. Inoculation of FVB mice with S.
pyogenes MGAS5005 speJ, smeZ and speA/speJ/smeZ resulted in significantly fewer
streptococci recovered from the cNT (Figure 19). There was also a striking difference in
the amount of piloerection, which is indicative of stress in mice, observed in wild type
MGAS5005-treated mice at 48 hours, which was notably absent in the saline-treated, and
MGAS5005 speA/speJ/smeZ-treated mice (Figure 20), and there were no significant
differences in the amount of S. pyogenes recovered from the other organs (Figure 21).
Mice inoculated with MGAS5005 speA and speG were piloerected similar to wildtype-treated FVB mice, and MGAS5005 speJ-, and smeZ-treated mice were not
piloerected (data not shown), which corresponds to the streptococcal load assessed in the
mice at 48 hour post-inoculation.

3.4. Role of superantigens in nasal colonization of Streptococcus pyogenes MGAS8232 in
DR4/DQ8 mice
3.4.1. Streptococcal superantigens produced by S. pyogenes MGAS8232 contributed to
the colonization of the nasal passage at 48 hours post-inoculation
Wild type MGAS8232 colonized the cNT of DR4/DQ8 mice at ~6 logs at 48
hours. Although most of the individual SAg deletions did not impact the colonization
potential of MGAS8232, MGAS8232 speA and MGAS8232 SAg both had dramatic
reductions in the ability to colonize nasal tissue. Although there was some variation in
the number of streptococci recovered from the other isogenic mutant streptococci, there
were no statistically significant differences between those groups and the wild-type
MGAS8232-treated mice (Figure 22).
Streptococcus pyogenes MGAS8232 SAg was complemented with a copy of
speA integrated into the streptococcal genome between the pepO and tsf genes to create S.
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Figure 19. Specific superantigens are critical for successful colonization of cNT by
Streptococcus pyogenes MGAS5005 in FVB mice. Nine week-old FVB mice were
inoculated with wild type MGAS5005 and isogenic superantigen deletion mutants as
indicated. The cNT samples were homogenized and the bacterial burden of S. pyogenes
strains was assessed at 48 hours. Shown are the data points from individual mice, with
the average ( SEM) log10 cfu/cNT. (*, P < 0.05, and ***, P < 0.0005 as assessed by
unpaired t-test) (N=4-8).
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Figure 20. Piloerection of FVB mice in Streptococcus pyogenes MGAS5005-treated
mice. Nine week old FVB mice were inoculated nasally with 1  108 S. pyogenes
MGAS5005.

Mice were photographed under anesthesia at 48 hours post-infection,

immediately prior to sacrifice. Photographs are representative of three mice per group.
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Figure 21. Streptococcus pyogenes MGAS5005 recovered from the organs of nasallytreated FVB mice.

There were no streptococci recovered from the S. pyogenes

MGAS5005-deletion mutants the blood, the kidney or the spleen.

There were no

significant difference in the number of streptococci recovered from the liver, and heart.
There were significantly fewer streptococci recovered from the lungs of S. pyogenes
MGAS5005 SpeJ and SpeA/SpeJ/SmeZ-treated mice. Statistics were assessed by
unpaired t test. *, P <0.05, and **, P <0.005 (N=4-8).
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Figure 22. Nasal colonization by isogenic superantigen deletion strains of Streptococcus
pyogenes MGAS8232. DR4∕DQ8 transgenic mice were treated nasally with 1  108 cfu S.
pyogenes MGAS8232 wild type and isogenic superantigen deletion mutant and were
sacrificed at 48 hours post-infection.

Recovered cNT were homogenized and the

concentration of S. pyogenes was assessed as the number of colonies that were haemolytic on TSAII sheep blood agar plates.

There was a statistically significant

decrease in recoverable S. pyogenes in the speA and the complete superantigen deletiontreated mice. speA complementation in the genome resulted in a statistically significant
increase in recoverable S. pyogenes. Shown are the data points from individual mice,
with the average ( SE) log10 cfu/cNT. (**, P <0.005, and ***, P <0.0005 as assessed by
unpaired t-test) (N=5-8).
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pyogenes MGAS8232 SAg + SpeA. Nasal infection with the complementation strain of
S. pyogenes MGAS8232 SAg + SpeA resulted in a significantly greater recovery of
streptococci at 48 hours post-inoculation as compared to the S. pyogenes MGAS8232
SAg, and it was not statistically significantly different in the recovery from the S.
pyogenes MGAS8232 wild type.

3.4.2. Streptococcal burden in the organs of Streptococcus pyogenes MGAS8232-infected
transgenic DR4/DQ8 mice
There were fewer streptococci recovered from the organs of S. pyogenes MGAS8232
mutant-infected DR4/DQ8 mice as compared to S. pyogenes MGAS5005 mutant-infected
FVB mice (Figure 23). Streptococci were detected in the lungs and livers and hearts of
some mice. However, there were no statistically significant difference in the amounts of
streptococci recovered from the organs of mice inoculated with the wild type and mutant
S. pyogenes MGAS8232.

3.4.3. Superantigen deletion impacts streptococcal burden at 48 hours, but not the
persistence of S. pyogenes in DR4/DQ8 nasal passage
The kinetics of S. pyogenes MGAS8232 infections in transgenic DR4/DQ8 mice
were addressed by nasally infecting mice and assessing the streptococcal burden in the
cNT at one, two, three, four, and six day time points. Both the wild type and complete
SAg deletion strains of S. pyogenes MGAS8232, at 24 hours, were cleared to a level that
was lower than the inoculating dose and there was no significant difference in the
streptococcal burden recovered from the cNT at this time point. At 48 hours, MGAS8232
SAg colonization was dramatically decreased in comparison to wild type MGAS8232.
However, despite the inability of the mutant to recover to wild-type levels at 48 hours it
still persisted in the cNT of the transgenic DR4/DQ8 mice for the same length of time as
the wild-type S. pyogenes MGAS8232, and was not recovered in statistically significantly
different amounts between groups between days three and six (Figure 24). This suggests
that streptococcal SAgs play a role in the initial establishment of colonization in this
model, but not in the kinetics of clearance.
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Figure 23. Streptococcus pyogenes MGAS8232 recovered from the organs of nasallytreated DR4/DQ8 mice. There were no detectable streptococci in the blood, spleen,
kidney and heart of DR4/DQ8 mice nasally treated with S. pyogenes MGAS8232. Some
streptococci were detected in liver and lung homogenates. Shown are the data points
from individual mice, with the average ( SEM) log10 cfu/organ. There was no statistical
significance between groups as assessed by unpaired t test.

114

115

Figure 24. Kinetics of nasal colonization by Streptococcus pyogenes MGAS8232 wildtype and SAg strains in DR4/DQ8 mice. DR4/DQ8 mice were inoculated with S.
pyogenes MGAS8232 wild type and SAg and were sacrificed at day 1, 2, 3, 4, and 6 and
the streptococcal burden in the cNT was assessed. Statistically different amounts of S.
pyogenes MGAS8232 wild type and S. pyogenes MGAS8232 SAg were recovered at
day 2. There were no statistically significant differences in the number of streptococci
recovered at any other time point assessed. Shown is the average of individual mouse
data points, with the average ( SEM) log10 cfu/cNT. (***, P < 0.0005 as assessed by
unpaired t-test) (N=4-8).
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3.4.4. Infection with a superantigen-competent strain of S. pyogenes MGAS8232 results
in greater mucus production and cellular debris in the nasopharyngeal meatus
Two representative haematoxylin and eosin-stained histological sections of the
heads of three mice in each treatment group were examined along the entire length of the
respiratory

epithelial

lining

in

the

nasopharyngeal

meatus,

including

the

lymphoepithelium covering the NALT and over the entire length of the neuroepithelium
in the ethmoid turbinates for the presence of mucus, cellular debris, tissue damage and
other abnormalities by two independent researchers in a blinded fashion. Scores between
zero to two points were assigned to each sample depending on the presence and amount
of mucus, red blood cells and nucleated cellular debris along the respiratory (including
lymphoepithelium) and the neuroepithelium in the nasal turbinates. Scores were averaged
and assessed statistically by unpaired t test. There were no statistically significant
differences between the treatment groups in the neuroepithelium (Figure 25B). In the
respiratory epithelial lining of the nasopharyngeal meatus there was a greater incidence of
red blood cells and nucleated cells in the mucus covering the respiratory epithelium in the
nasopharyngeal meatus in wild type S. pyogenes MGAS8232-treated mice as compared to
the saline- or S. pyogenes MGAS8232 SAg-treated mice (Figure 25A). There was no
visible damage or break in the continuity of the either the neuroepithelium or the
respiratory epithelium observed in any of the sections examined, hence we were unable to
attribute the cellular debris to a specific epithelial damage.

3.4.5. Immunophenotyping of spleen, lymph node, and nasal cells in S. pyogenes
MGAS8232-treated mice
Transgenic mice expressing HLA DR4/DQ8 were inoculated with either saline,
wild type S. pyogenes MGAS8232, or S. pyogenes MGAS8232 SAg were sacrificed at
48 hours and the spleen, pooled lymph nodes and cNT were collected. The cells were
stained for differential markers for immune cells and analyzed by flow cytometry. Gating
strategies for flow cytometry are detailed in Figures 26, 28, and 30.
One hundred thousand events were captured for each treatment. Both the spleen
and lymph nodes were gated on live cells based on 7AAD staining and were assessed for
the presence of different cellular types based on staining. Cellular concentrations were
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assessed as the proportion of cells that were live. Although there were subtle changes in
the cell populations detected in the spleen, there were no statistically significant
differences in the immune cell populations between treatment groups (Figure 27). The
pooled lymph nodes included the cervical, the axillary, iliac and the popliteal lymph
nodes. There was a statistically significant increase in the F4/80+ macrophage population
between the S. pyogenes MGAS8232 wild type and isogenic deletion-treated mice (Figure
29).
One hundred thousand events were captured for each sample. The samples were
gated on the live cell populations based on 7AAD staining. The live cells were further
gated on the CD45+ cell population. Live CD45+ cell populations in the cNT were
assessed by flow cytometry for various immune cell populations. There was a significant
decrease in the CD11c+ DC cell populations in the cNT with S. pyogenes MGAS8232
wild type-treated mice as compared with the S. pyogenes MGAS8232 SAg-treated mice,
and lower than the saline-treated mice (Figure 31). The S. pyogenes MGAS8232 SAgtreated mouse cNT CD11c+ cell population was not significantly different from the
saline-treated mice. There were no other significant differences in any of the other cell
populations assessed in the cNT.
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Figure 25. Histological assessment of nasal tissue sections. Difference in the pathological
severity in mice inoculated with saline, S. pyogenes MGAS8232 wild type and SAgtreated mice sacrificed at 48 hours post-infection were assessed by examination of
haematoxylin and eosin stained sections. Sections were assessed for the presence and
severity of mucus, red blood cells, and nucleated cellular debris on the surface of the (A)
respiratory epithelium and the (B) neuroepithelium. There was a significantly greater
amount of mucus and cellular debris observed in the S. pyogenes MGAS8232 wild typetreated mice as compared to the saline- and SAg-treated mice. Shown is the average of
individual mouse data points, with the average ( SEM). (*, P <0.005 as assessed by
unpaired t-test).
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Figure 26. Splenocyte gating strategies to assess the proportions of immune cells in mice
treated with S. pyogenes. Splenocytes were isolated from mice treated with HBSS, S.
pyogenes MGAS8232 wild type or S. pyogenes MGAS8232 SAg.

Representative

gating strategies are shown for all panels used to determine proportions of immune cells
in the spleen. Splenocytes in all panels were first separated by forward and side scatter
and gated on the lymphocyte population, and then further gated on the live cell
populations based on 7AAD staining.

Immune cells were assessed based on

immunoreceptor staining. One hundred thousand events were captured for each sample.
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Figure 27.

Nasal infection with wild type and superantigen deletion strains of

Streptococcus pyogenes MGAS8232 does not result in changes in the lymphocyte
population in the spleen. Mice were inoculated with HBSS (empty bar), 1  108 cfu S.
pyogenes MGAS8232 wild type (black bar) or S. pyogenes MGAS8232 SAg (grey bar).
Mice were sacrificed at 48 hours post-infection. The spleen was harvested and cells were
stained to identify immune cell sub-populations by flow cytometry. There were no
statistically significant differences in (A) any of the immune cells assessed (N=6)
including the (B) GR1+ and GR1+CD11b+ populations (N=2). Shown is the average of
individual mouse data points, with the average ( SE).
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Figure 28. Lymph node gating strategies to assess the proportions of immune cells in
mice treated with S. pyogenes. Total pooled lymph nodes were isolated from mice treated
with HBSS, S. pyogenes MGAS8232 wild type or S. pyogenes MGAS8232 SAg.
Representative gating strategies are shown for all panels used to determine proportions of
immune cells in the lymph nodes. Cells in all panels were first separated by forward and
side scatter and gated on the lymphocyte population, and then further gated on the live
cell populations based on 7AAD staining.

Immune cells were assessed based on

immunoreceptor staining. One hundred thousand total events were captured for each
sample.
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Figure 29. Nasal infection with wild type and superantigen deletion strains of
Streptococcus pyogenes MGAS8232 results in significantly more macrophages in the
pooled lymph nodes.

Mice were inoculated with HBSS (empty bars), 1  108 S.

pyogenes MGAS8232 wild type (black bars) or S. pyogenes MGAS8232 SAg (grey
bars). The mice were sacrificed at 48 hours post-infection. Cells were stained to identify
immune cell sub-populations by flow cytometry. A statistically significant difference was
detected in the F4/80+ macrophage population between S. pyogenes MGAS8232 and
isogenic knockout-treated mice (P=0.0357) as assessed by unpaired t-test (N=4). Shown
is the average of individual mouse data points, with the average ( SE). (*, P = 0.05 as
assessed by unpaired t-test).
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Figure 30. Gating strategies to assess the proportions of immune cells in mice treated
with S. pyogenes in the complete nasal turbinates. The complete nasal turbinates were
isolated from mice treated with HBSS, S. pyogenes MGAS8232 wild type or S. pyogenes
MGAS8232 SAg at 48 hours post-infection. Representative gating strategies are shown
for all panels used to determine proportions of immune cells in the complete nasal
turbinates. The complete nasal turbinates cells were first separated based on 7AAD
staining and gated on live cells only. The live cells were further gated on CD45 positive
population before being assessed for the proportion of immune cells. One hundred
thousand total events were captured for each sample.
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Figure 31. Nasal infection with wild type deletion strains of Streptococcus pyogenes
MGAS8232 results in a decrease in CD11c+ cells in the cNT.

Mice were inoculated

with HBSS (clear bars), 1  108 cfu S. pyogenes MGAS8232 wild type (black bars) or S.
pyogenes MGAS8232 SAg (grey bars). Mice were sacrificed at 48 hours post-infection
and the cNT including NALT were harvested and stained to identify immune cell subpopulations in the various tissues by flow cytometry. All samples were gated to exclude
7AAD positive cells (dead cells). Additionally, cells from the cNT were gated on all
CD45-positive cells to indicate the lymphocytic population. Immune cell populations
assessed in (A) had an N of ≥ 4. (B) The CD11b+ cell marker marks myeloid progenitor
cells (N=2). A statistically significant difference in the CD11c+ DC cell populations in
the cNT was observed between the wild-type and isogenic knockout-treated (P=0.0304).
Shown is the average of individual mouse data points, with the average ( SEM). (*, P <
0.05 as assessed by unpaired t-test).
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Chapter 4: Discussion
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The bacterial SAg toxins have evolved to target two critical receptors of adaptive
immunity, and although the role of these toxins in severe disease is well established, little
is known about why so many different SAgs are encoded within the S. pyogenes genome,
and why ultimately these genes are maintained in the genome as the bacteria evolve. The
natural lifecycle of S. pyogenes is a state of colonization in the pharynx, where most
carriers do not develop symptomatic pharyngitis. In fact, ~20% of school children in the
winter and spring may be asymptomatic chronic carriers of S. pyogenes [176]. Thus, we
believe that SAgs have evolved in the context of “colonization”, rather than “virulence”,
and therefore their true evolutionary role is likely important for the state.
There are eleven identified streptococcal SAgs [116, 123-125] and to date, every
sequenced strain of S. pyogenes encodes multiple SAgs within its genome [35, 57-58,
126, 136, 138, 177-184]. Despite the impressive body of work focused on streptococcal
SAgs as potent virulence factors, there have been no efforts made to understand the
physiological function of streptococcal SAgs in the transmission, establishment of
colonization, and persistence of S. pyogenes within the human population. In addition,
there are very few studies that have examined the role of streptococcal SAgs using
defined genetic deletion strains [2, 59, 88, 112-113], and even fewer that are coupled with
live in vivo infections in appropriate animal models [185], and none have examined the
role of SAgs in colonization and mild infection in an appropriate mouse model.
Superantigens have been shown, indirectly, to play a role in the early stages of mild
pharyngeal infection as examined by transcriptome analysis of Streptococcus-infected
macaques [82].

Although there is a lack of mechanistic studies to address these

questions, a role for SAgs in the persistence of S. pyogenes in humans with mild infection
or colonization is supported by the existence of many healthy adults who have not had
severe or invasive streptococcal infections, and yet have antibodies against streptococcal
SAgs [133-134].
Group A streptococci are obligate human pathogens [3], and their primary site of
colonization is the human tonsils and S. pyogenes is often found in surgically excised
tonsils [147]. Human tonsils, or Waldeyer’s ring, are composed of the adenoid, bilateral
tubular, palatine, and lingual tonsils [142]. Physiologically similar structures have been
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identified in other mammals [145], and in mice the functionally analogous tissues are the
NALT, which are located bilaterally along the base of the nasal passage in mice [143].
The streptococcal colonization model of nasal infection has been previously
established as a model to mimic human colonization or pharyngeal infection [149]. The
surgical technique used in this work to isolate cNT was learned directly from the
laboratory of Dr. P. Patrick Cleary at the University of Minnesota (Figure 6). Use of this
technique deviates from other NALT extraction techniques published in the literature
[144]. This technique resulted in consistent and highly reproducible streptococcal and
bacterial counts from S. pyogenes colonized mice (Figures 9 and 10), and when assessed
for immune cells by flow cytometry, gave consistent proportions of subsets of live
CD45+ immune cells (Figure 31). Together, these results validate the surgical method as
an alternate method for the removal of cNT which includes the NALT along with the
ethmoid turbinates and maxillary sinuses. The details of this model and the surgical
method, as described in this thesis, which represents a significant contribution to this field
of research.
The genetic makeup, innate defenses, cytokine levels and the potential presence of
underlying health conditions which may alter the immune responsiveness of the host may
influence the course of a streptococcal infection [186]. Also, the ability of the MHC class
II to determine the clinical outcome of severe or invasive streptococcal infection has been
previously established [112-115, 135].

We found that murine lineages expressing

different murine or human MHC class II molecules respond differently to nasal challenge
by different S. pyogenes strains, as assessed at 48 hours post-infection (Figures 9 and 10).
Mouse lineages that expressed human MHC class II colonized much more effectively
than the parental B6 lineage (Figure 9); B6 mice did not colonize well with either strain
of S. pyogenes tested. Mice expressing MHC class II HLA-DR4 colonized better than B6
mice but not as well as the mice expressing HLA-DQ8 or HLA-DR4/DQ8 (Figure 9).
These experiments demonstrate clearly that host genetics can have an enormous influence
on the ability of S. pyogenes to colonize the nasopharynx.
To assess whether the colonization phenotypes were due to divergent evolutionary
differences in the DR4 and the DR4/DQ8 lineages of mice, DR4/DQ8 mice were backcrossed with the DR4 mice and infection of the F1 generation (DR4/DQ8*) resulted in
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similar levels of colonization to the DR4/DQ8 mice when tested with the S. pyogenes
MGAS8232 serotype (Figure 9). This experiment supports our findings that the human
MHC class II molecules are responsible for the colonization differences.
Mice expressing different murine MHC class II (Table 5) were also assessed for
their potential colonization with two strains of S. pyogenes (Figure 10). In general, the
mice were found to have low levels of S. pyogenes recovered after 48 hours of
colonization, with the exception of FVB mice. Strikingly, FVB mice infected with S.
pyogenes MGAS5005 had the highest recovery of S. pyogenes of any group of mice
tested with any strain of S. pyogenes, yet these mice were only poorly colonized by S.
pyogenes MGAS8232, the main difference between the superantigen complement
encoded in these strains being the presence of speJ in S. pyogenes MGAS5005, which is a
streptococcal superantigen that is immunostimulatory in FVB mice but not in transgenic
DR4/DQ8 mice. These experiments strongly suggest that the strain of S. pyogenes can
also have a major influence on the ability to colonize, and that this is also linked with host
genetics, specifically MHC class II.
To study infectious organisms, it is important to use a model system that is
sensitive to the virulence factors produced by the pathogen being assessed. SAg research
in mice has commonly utilized external sensitizing agents, such as D-galactosamine:
However, this agent could mask or exaggerate significant pathogenic effects of the
bacterial infection on the animal [140]. Theoretically, a naturally sensitive model is
critical to the proper understanding of the course of pathogenesis and the interactions
between pathogen and host. Streptococcal SAgs interact with human MHC class II with
higher affinity than to murine MHC class II molecules [139].

The demonstrable

sensitivity of a mouse to streptococcal SAgs, either with transgenic human MHC class II
expression or sensitive mouse H-2 for the SAgs in question is important in the study of
any streptococcal infection.
In order to understand the role of MHC class II in the nasal colonization model,
recombinant SAgs were evaluated on the different mouse splenocyte cells ex vivo. Mice
that expressed different MHC class II molecules were found to have different sensitivities
to rSAg as judged by the ability of their splenocytes to secrete IL-2 in response to various
SAgs (Figures 11 and 12). Mice expressing transgenic human MHC class II were more
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sensitive to rSAg than B6 mouse splenocytes which demonstrated little to no activation
by any of the toxins. Splenocytes from mice expressing DR4/DQ8 were more sensitive
than splenocytes from mice expressing only DR4 (Figure 11). It is important to note that
DR4/DQ8 mice were stimulated by SpeA and SmeZ, with SmeZ being 100-fold more
potent than SpeA (Figure 11).

This supports previous findings that SpeA is more

responsive in DQ-expressing mice [59, 113]. Overall the reactivity to SmeZ in all mice
with the exception of B6 was not unexpected as SmeZ has been reported to be, in general,
at least 10 times more potent in its T cell stimulating ability [187].
splenocytes were also stimulated by both SpeJ and SmeZ (Figure 12).

FVB mouse
Given the

universally poor superantigenic activity of streptococcal SAgs in B6 mice it may be
concluded that B6 mice are not an appropriate murine model with which to study
streptococcal SAgs. Additionally, B6 mice may not be appropriate murine models with
which to study streptococcal pathogenesis, despite the availability of many interesting
deletion strains in mice, as they are not reactive to streptococcal SAgs, which are
considered to be major streptococcal virulence factors.
Streptococcus pyogenes MGAS5005 encodes four SAgs [79], and S. pyogenes
MGAS8232 encodes six SAgs [136]. To evaluate the level of SAg expression from these
strains, recombinant SAgs were used to generate SAg-specific polyclonal rabbit
antibodies against the streptococcal SAgs encoded in both serotypes of S. pyogenes used
in this study (Figure 13). The amount of SAgs produced by S. pyogenes MGAS8232 and
S. pyogenes MGAS5005 in vitro were assessed by Western blot using the rabbit anti-SAg
antibodies (Figure 18). S. pyogenes MGAS5005 produced detectable amounts of SpeA,
and S. pyogenes MGAS8232 produced detectable amounts of SpeA, SpeC and SpeL.
However, it is important to note that S. pyogenes may have distinctively different protein
expression profiles in vitro depending on the medium or condition that they are grown in
and the transcriptome also varies based on growth phase [188]. There is evidence that
SAgs are produced in vivo at different points in the infection [82] and that the production
of SAgs in vivo has been linked to the selective pressure exerted by the innate immune
system [79, 189]. Previously, S. pyogenes MGAS5005 was grown in human blood and
the transcriptome was analyzed at various time points. It was found that the SAgs SpeA,
SpeJ, SpeG, and SmeZ were all upregulated within the first thirty minutes of growth in
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blood [186]. In a macaque model of pharyngitis that was used to evaluate changes in the
streptococcal transcriptome it was determined that the temporal upregulation of SAgs
coincided with a successful infection and inflammatory reaction and that SpeA, SpeJ and
SmeZ were expressed during distinct disease phases and in general were associated with
the colonization phase [82]. This suggests that there may be changes in SAg protein
expression profiles during nasal infection of the mouse which could affect virulence and
colonization potential of the streptococci. Thus, the SAgs produced in vitro may not
necessarily reflect the production of SAgs in vivo, but even if the SAg is produced, if the
mouse is not sensitive to SAg stimulation then the SAg may not necessarily have an
impact. Based on that premise it was surmised that the streptococci that will successfully
infect a mouse nasally will express SAgs that are immunostimulatory to that mouse, and
that it will not be able to effectively infect mice that are not stimulated by the SAgs
expressed in that strain. As a result of both the initial nasal colonization experiments and
the splenocyte sensitivity experiments it was ultimately decided to use the DR4/DQ8
transgenic mice to assess the colonization of the S. pyogenes MGAS8232 isogenic SAg
deletion strains and FVB mice to assess the nasal colonization potential of S. pyogenes
MGAS5005 isogenic SAg deletion strains.
Isogenic SAg deletions were created for S. pyogenes MGAS5005 and S. pyogenes
MGAS8232 (Figure 14) to address the role that streptococcal SAgs play in colonization
in a mouse model of nasal infection. The isogenic SAg deletion mutants were made as
in-frame markerless deletions using Gram-positive temperature-sensitive plasmids
(Figure 6). In-frame, markerless deletions have the advantage that they are stable and
likely non-polar, and result in the deletion of the central portion of the gene, which
maintains the genetic reading frame [163] (Figure 5).

The resulting isogenic SAg

deletion mutants were confirmed by PCR using primers that were located internally to the
SAg gene (Figure 16), Western blot for deletion of protein production (Figure 18), and by
growth curve to ensure that there were no serious growth defects introduced from the
genetic manipulations (Figure 17). A similar scheme was used to complement wild type
speA into the genome of the complete SAg deletion strain of S. pyogenes MGAS8232
between the pepO and tsf genes.
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Streptococcus pyogenes MGAS5005 encodes 4 SAgs that were disrupted to make
four single SAg isogenic deletion strains and one strain with deletions of three of four
SAgs, speA/speJ/smeZ (Figure 14A). Nasal inoculation of FVB mice with wild-type S.
pyogenes MGAS5005 resulted in approximately log10 7 recovery of S. pyogenes at 48
hours post-infection. The S. pyogenes MGAS5005 speA and speG strains resulted in
S. pyogenes recovery that was not significantly different from that of wild type S.
pyogenes MGAS5005. There was a significantly lower recovery from the single isogenic
S. pyogenes MGAS5005 speJ and smeZ deletions (Figure 19), which corresponds to
the superantigens that are immunostimulatory in the FVB mice (Figure 12B). Similarly,
FVB splenocytes stimulated with in vitro S. pyogenes MGAS5005 isogenic SAg deletion
culture supernatants and assessed for splenocyte activation showed a profile that indicated
that the disruption of speA/speJ/smeZ resulted in an absence of splenocyte activation
(Appendix 4B). FVB mice inoculated with S. pyogenes MGAS5005 wild type became
piloerected by 48 hours, the S. pyogenes MGAS5005 speA/speJ/smeZ deletion-treated
mice did not show any piloerection at 48 hours, similar to the saline-treated mice (Figure
20), as did the speJ and smeZ deletion-treated mice (data not shown). Taken together
this data indicates that in S. pyogenes MGAS5005 SpeJ and SmeZ play a significant role
in the establishment of colonization at 48 hours post-inoculation in FVB mice.
There were no significant differences in the number of streptococci recovered
from the blood, spleen, kidneys, liver or heart in any of the S. pyogenes MGAS5005 SAg
deletion mutants in FVB mice sacrificed at 48 hours post-inoculation (Figure 21). There
were statistically fewer streptococci recovered from the lungs of mice infected nasally
with S. pyogenes MGAS5005 speJ and speA/speJ/smeZ-infected mice as compared to
the wild type-infected mice, which may reflect the fact that there were fewer streptococci
present in the nasal cavity of those mice, which resulted in fewer streptococci being
inspired into the lungs of the mice at this time point.
Transgenic DR4/DQ8 mice infected nasally with wild type S. pyogenes
MGAS8232 resulted in approximately log10 6 recovery of S. pyogenes at 48 hours (Figure
22). There were significantly fewer S. pyogenes MGAS8232 speA and S. pyogenes
MGAS8232 SAg isogenic deletion mutants recovered from the cNT. When speA was
complemented into the genome of the S. pyogenes MGAS8232 SAg strain there was a
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significant recovery in the colonization potential (Figure 22). DR4/DQ8 splenocytes
stimulated with in vitro S. pyogenes MGAS5005 isogenic SAg deletion culture
supernatants assessed for splenocyte activation showed that the deletion of speL/M, and
speA resulted in a decrease of mIL-2 produced, and that the complete deletion of all of the
SAgs in S. pyogenes MGAS8232 resulted in an absence of splenocyte activation
(Appendix 4C), which is in accordance with the superantigens produced by this bacterium
in vitro (Figure 18B) and the superantigens that are immunostimulatory in the DR4/DQ8
mice (Figure 11C). This was a critical experiment, as it established that the phenotypes
observed for both the MGAS8232 speA and SAg strains are not due to secondary
mutations introduced through the mutagenesis process.

There were no statistically

significant differences in the numbers of streptococci recovered from the organs of
infected mice (Figure 23). This indicates that the superantigen deletions in S. pyogenes
MGAS8232 did not affect the invasiveness of S. pyogenes in the nasal infection of
DR4/DQ8 mice.
A time-course study was performed in which wild type and the isogenic SAg
deletion strains of S. pyogenes MGAS8232 were inoculated at the same initial
concentration of 108 cfu per animal, and streptococcal burden was assessed over the
course of a week (Figure 24). There was an initial drop in streptococcal recovery 24
hours after inoculation. Although there was a significant difference in the recovery of
wild type and SAg S. pyogenes MGAS8232 at 48 hours, both strains ultimately took the
same time to clear from the nasal passages of the mice. Both the S. pyogenes MGAS8232
wild type and S. pyogenes MGAS8232 SAg were not recovered at significantly different
concentrations after the 48 hour time point up to when the streptococci were cleared from
the cNT after day six. The results of colonization kinetics with wild type S. pyogenes in
DR4/DQ8 mice were similar to what was previously documented in streptococcal nasal
infections in BALB/c mice inoculated with five-times the streptococcal burden with S.
pyogenes 90-226 [149]. In the S. pyogenes 90-226-infected BALB/c mice, the infection
initially appeared to clear but then recovered to reach peak colonization at 48 hours postinfection and was detected in the nasal cavity of the mice for greater than 72 hours and up
to seven days [149].
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Haematoxylin and eosin stained histological sections of nasal turbinates from
mice nasally treated with saline, S. pyogenes MGAS8232 wild type, and S. pyogenes
MGAS8232 SAg were assessed along the respiratory epithelium and neuroepithelium
for production of mucus, nucleated cellular debris, and red blood cells along the
epithelium.

There was a significant increase in the pathological severity in the S.

pyogenes MGAS8232 wild type-treated mice as compared to the saline and the S.
pyogenes MGAS8232 SAg-treated mice (Figure 25A).

There were no significant

differences in the pathophysiology along the neuroepithelium between groups (Figure
25B). This indicates that the histological severity of the infection at the level of the T4
cross-section (Figure 2) was significantly different along the respiratory epithelium in the
nasopharyngeal meatus. This may be due to the fact that mice are quadrupedal and that
inspired antigens, mucus, and bacteria gravitationally settle in the nasopharyngeal meatus
where they are subsequently cleared by cilia [143]. This may be the practical
physiological reason for the location of the NALT being located on the basolateral
surface of the nasopharyngeal meatus in mice.
Investigation into how SAgs alter host immunity during the establishment of
colonization revealed that there were no significant differences in the number of T cell or
B cell populations amongst various treatment groups in the splenocyte, pooled lymph
nodes and cNT cell populations (Figures 27, 29, and 31). Flow cytometric analysis
revealed that there was an increase in the number of F4/80+ cells in the lymph nodes of
mice treated with wild type S. pyogenes MGAS8232 (Appendix 2), which indicated that
there was an increase in the macrophage population in mice infected with wild type S.
pyogenes MGAS8232 compared to the S. pyogenes MGAS8232 SAg treated mice.
Macrophages are able to rapidly recognize and internalize pathogens and can further
recruit immune cells by producing chemokines and can also serve as APCs. Macrophages
can play a critical role in streptococcal infections as previous work found that the
depletion of macrophages within the first 24 hours post-infection rendered resistant mice
susceptible to streptococcal intraperitoneal infection with higher bacterial loads and
mortality [190]. The presence of increased numbers of macrophages in the lymph nodes
of wild-type infected mice may indicate an active immune response to S. pyogenes. As
there were significantly fewer macrophages in the lymph nodes of mice infected with S.
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pyogenes MGAS8232 SAg at 48 hours, this may indicate the SAg activity has altered
this response. Further study on the kinetics of the macrophage response to Streptococcus
pyogenes infection with and without superantigens focusing mainly on the cervical lymph
nodes will allow us to draw further conclusions about the role of superantigens in
macrophage response.
Conventional DCs circulate within the peripheral tissues, take up antigens, and
become activated upon contact with pathogens after which they become potent
stimulators of T cell responses in the peripheral lymphoid organs [191]. As such, DCs
play a major role in the identification and immune response to pathogens, and can be
detected with the use of anti-CD11c antibodies. There was a significant decrease in the
proportion of CD11c+ cells in the CD45+ live population in the cNT of wild type S.
pyogenes MGAS8232-treated mice (Appendix 3) indicating fewer dendritic cells present
in the cNT of these mice.

In addition to antigen presentation and T cell activation DC

cells can also produce IL-6 and TGF-, which in the abscence of IL-12, IL-4 and IFN-
stimulate the differentiation of Th17 cells [191]. It has previously been reported in the
literature that there were fewer CD45+ live cells that stained with anti-CD11c antibody in
mice infected with S. pyogenes, than mice inoculated with Lactobacillus murinus, a
commensal bacterium in mice [153]. Although it was suggested that the presence of S.
pyogenes induced a migration of DC cells from the NALT to the lymph nodes or blood
[153], we did not observe such an increase in the DC cell population in the lymph nodes.
It is important to note that in S. pyogenes MGAS8232 wild type-treated mice, there was a
statistically insignificant, but potential trend, for an increase in the GR1+CD11b+ cell
population in the CD45+ live cells in the cNT of two mice (Appendix 3). GR1 and
CD11b together are markers of myeloid progenitor cells, and potentially myeloid-derived
suppressor cells (MDSC) in mice [192]. MDSCs are a heterogeneous cell population of
myeloid origin, are in an immature state and have the potential to suppress T lymphocyte
and adaptive immune responses [192].

The expansion of MDSCs is triggered by

prostaglandin, macrophage colony stimulating factor, IL-6, granulocyte-macrophage
colony stimulating factor and capsular endothelial growth factor [192]. It has been
suggested that some diseases can block or partially block the differentiation of immature
myeloid cells into granulocytes, macrophages or dendritic cells [192].

MDSCs are
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considered part of the regulatory arm of the immune system, and may induce the
expansion of the T regulatory cells [192]. Further study is needed to better characterize
the cellular immune response to S. pyogenes, and the SAg deletion strain, to better
understand the contribution of SAgs to the cellular immune response.
Cytokines can be classified as regulatory, anti-inflammatory or pro-inflammatory
and are often produced in a balance that is important for a controlled functional immune
response [108]. Streptococcal superantigens have been shown to elicit different cytokine
expressions depending on the concentration of superantigens used [87]. In vitro SAgs
have been reported to induce a Th1 proinflammatory response that results in the release of
IFN- and TNF [83]. Similarly, mice with severe streptococcal infections had high serum
levels of inflammatory cytokines including IFN- , IL-12 and IL-1, which strongly
indicates a Th1 response [193-194]. Cytokine profiles were assessed by Luminex and
Multiplex on homogenized cNT supernatants from FVB mice inoculated with either
saline, S. pyogenes MGAS5005 or S. pyogenes MGAS5005 speA/speJ/smeZ at 48 hours
(Appendix 1) and by Luminex on cNT homogenates from transgenic DR4/DQ8 mice
infected with saline, S. pyogenes MGAS8232 or S. pyogenes MGAS8232 SAg at 24 and
48 hours (Appendices 5 and 6). At 24 hours there were no statistically significant
differences in the cytokines between the saline-, S. pyogenes MGAS8232 wild type-, and
S. pyogenes MGAS8232 SAg-treated samples in the DR4/DQ8 mice. At 48 hours postinfection in both FVB mice treated with S. pyogenes MGAS5005 and DR4/DQ8 mice
treated with S. pyogenes MGAS8232 there were notable differences in the amount of IL1, IL-6, IL-17, MCP-1, MIP-1 in the samples from both mice. Additionally, FVB mice
also had significantly more IL-10, IFN-, and TNF- produced in the S. pyogenes
MGAS5005 wild type-treated mice. The luminex cytokine analysis of the cNT tissue
homogenate supernatant, and particularly the FVB experiments which produced more
inflammatory cytokines, suggests that the mice could have potentially been mounting a
Th17 response [191] in the FVB mice treated with S. pyogenes MGAS5005 wild type.
The mice treated with the wild type streptococci had a stronger cytokine response than the
saline-, S. pyogenes MGAS5005 speA/speJ/smeZ-, and S. pyogenes MGAS8232 SAgtreated mice indicating that this response is likely SAg driven and likely contributes to the
enhance survival of S. pyogenes.
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One potential immunomodulatory route that has been suggested to be induced in
streptococcal nasal infection is the development of Th17 T cells by TGF-1 assisted
generation [195]. IL-17-producing T cells have been reported to enhance the infiltration
of neutrophils and macrophages in infected tissue which aids in pathogen clearance [196].
In the literature, the frequency of NALT cells with a Th17 phenotype is similar to the
number of CD4+IL-17+ cells that have been characterized in human tonsils [197]. The
Th17 population of T cells (CD4+IL-17+) was not directly examined in the cNT of S.
pyogenes-infected mice by flow cytometry in this study; however, we did detect a low but
statistically significant increase in IL-17 in DR4/DQ8 mice that were inoculated with
wild-type S. pyogenes MGAS8232 as compared to saline-treated mice. There was a
lower trend, but not statistically significant decrease in the amount of IL-17 between the
wild-type- and SAg deletion-treated mice. In the S. pyogenes MGAS5005-treated FVB
mice there was a significantly higher amount of IL-17 produced in the wild-type-treated
mice as compared to the saline- and speA/speJ/smeZ-treated mice (Appendix 1). Future
experiments to examine cells producing IL-17, by flow cytometry doing ICS staining for
IL-17 or RORT at different time points, are needed to better characterize the significance
of S. pyogenes SAgs to the Th17 response in the mouse model of cNT colonization.
In all instances we observed a striking increase in the amount of IL-6 in all wildtype streptococci-treated mice compared to the other two treatment groups. IL-6 is
necessary, along with TGF-1, which was not assessed in this study, TNF- and IL-1 to
contribute to Th17 cellular expansion in mice [198]. In the S. pyogenes MGAS5005treated FVB mice there was an increase in both IL-1 and TNF- that was not observed
in either the saline or SAg deletion-treated mice. This indirectly suggests that there is an
up regulation of the Th17 population of cells in the mice that are infected with SAgcompetent S. pyogenes that is absent in mice treated with SAg-disrupted S. pyogenes.
It is tempting to draw broad sweeping conclusions about the contributory role of
streptococcal SAgs in the immune response by comparing the immunological results of S.
pyogenes MGAS8232-treated DR4/DQ8 mice (Figures 27, 29, 31, and Appendix 2 and 3)
and S. pyogenes MGAS5005-treated FVB mouse data (Appendix 1). Both data sets
assess the contributory role of SAgs in nasal colonization of mice at the 48 hour time
point, in different strains of S. pyogenes that produce different virulence factors which
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may play a contributory role in the overall colonization potential in their different, and
respective, mouse models, and despite this both models yielded similar results indicating
that superantigens played a contributory role in the establishment of murine nasal
colonization. Further studies examining the cell populations and cytokines within the
cNT at various time points in one strain of mouse infected with one serotype of S.
pyogenes is necessary to elucidate a clear mechanism by which SAgs contribute to
mediating the establishment of colonization in the murine nasal passage.
There are multiple strains of S. pyogenes circulating globally at any given time,
and these strains vary in prevalence region-to-region [11], and different strains are
associated with the different incidences of S. pyogenes-related diseases in a regional
manner [11]. Different subsets of SAgs are produced by different strains of S. pyogenes,
which may affect the persistence of the strain within a population of people who encode
MHC class II that optimally binds the superantigens in the particular strain of S.
pyogenes. Future studies examining the immune response to S. pyogenes with different
SAg complements naturally within the human population, will help us better understand
the differences in sensitivity to superantigens within the human population. Specific
immune cell responses may be examined by cellular depletion, and cytokine
neutralization in a murine model of colonization to help further elucidate the mechanism
by which superantigens subvert the immune system to allow S. pyogenes to establish
colonization.
To apply Koch’s postulates to microbial pathogenesis, Stanley Falkow’s
“molecular Koch’s postulates’ suggests that the (1) phenotype or factor under
investigation should be associated with pathogenic organisms, (2) the virulence genes
should be identified, and isolated (3) an inactivation of the virulence factor should result
in a decrease in pathogenicity and (4) the re-introduction of the wild type gene should
restore pathogenicity [199]. Based on this bacterial pathogenesis application of Koch’s
postulates, the role of streptococcal SAgs in severe and invasive disease has been welldocumented [18]. Secondly, SAg genes have been identified in the genomes of all S.
pyogenes strains sequenced [57, 116, 123-125], and these streptococcal SAgs have been
isolated

and

recombinantly produced

and

mutagenized

to

characterize

their

immunoreceptor interfaces [160-161]. Thirdly, in this work streptococcal SAgs were

146

completely inactivated by markerless in-frame deletions of all of the streptococcal SAgs
in S. pyogenes MGAS8232, and three of four SAgs in S. pyogenes MGAS5005, the
resulting SAg deletion strains revealed decreased ability to establish colonization in a
nasopharyngeal-associated lymphoid tissue murine model of infection in strains with the
SAgs that were immunostimulatory to the mouse model employed in the colonization.
Finally, the re-introduction of the wild type speA into an alternate location within the
genome of S. pyogenes MGAS8232 SAg restored the pathogenicity of the strain by
recovering its ability to establish colonization in a similar manner to wild type S.
pyogenes MGAS8232. Therefore having satisfied Koch’s postulates, as they can be
applied to microbial pathogenesis, it can be said that in regards to the hypothesis that the
results indicate that streptococcal SAgs play a role in the establishment in the
colonization of a nasopharyngeal-associated lymphoid tissue model of murine
streptococcal infection.
In summary, this work has provided important evidence that the true evolutionary
function of the bacterial SAgs, at least those produced by streptococci, is to aid in the
establishment of nasopharyngeal infection in SAg-sensitive mice, and potentially the
persistence of S. pyogenes within human populations. The role of SAgs in the life-cycle
of bacterial pathogens has remained an enigma, and this work will contribute to a more
complete understanding of this interesting and important family bacterial toxins.
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Appendix 1.

Cytokine analysis of complete nasal turbinate tissue homogenate

supernatants from FVB mice inoculated with Streptococcus pyogenes MGAS5005 at 48
hours. The cNT homogenates were assessed for cytokine production by luminex and
multiplex analysis (N=3). Shown is the average of individual mouse data points, with the
average ( SE). (*, P <0.05, and ***, P <0.0005 as assessed by unpaired t-test).
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Appendix 2.

Cytokine analysis of complete nasal turbinate tissue homogenate

supernatants from DR4/DQ8 mice infected with Streptococcus pyogenes MGAS8232 at
24 hours. The homogenates were assessed for cytokine production by luminex. There
were no statistically significant differences between groups (N=4). Shown is the average
of individual mouse data points, with the average ( SE). Assessed by unpaired t-test.
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Appendix 3.

Cytokine analysis of complete nasal turbinate tissue homogenate

supernatants from DR4/DQ8 mice inoculated with Streptococcus pyogenes MGAS8232
taken at 48 hours. The cNT homogenates were assessed for cytokine production by
luminex analysis (N=3). Shown is the average of individual data points, with the average
( SEM). (*, P <0.05, and **, P <0.005 as assessed by unpaired t-test).
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Appendix 4.

Activation of human PBMCs and murine splenocytes by

Streptococcus pyogenes wild-type and isogenic mutant bacterial culture
supernatants. (A) Human PBMCs were treated with S. pyogenes MGAS5005 and
MGAS8232 bacterial supernatants. Mouse splenocytes were treated with (B) S.
pyogenes MGAS5005 and (C) MGAS8232 bacterial supernatants. Cells were
treated with serial dilutions of bacterial culture supernatants for 18 hours. The
amount of IL-2 detected in human PBMC cultures stimulated with wild type S.
pyogenes serotype supernatants was in general higher than mIL-2 produced by
murine splenocytes stimulated with the same wild type streptococcal supernatants.
The superantigen complete knockout strain in S. pyogenes MGAS8232 and the
triple deletion mutant in S. pyogenes MGAS5005 supernatant-treated splenocytes
did not produce mIL-2.
ELISA.

Mouse and human IL-2 cytokines was assessed by
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Appendix 5. Human PBMC stimulated with isogenic Streptococcus pyogenes mutant
supernatants. Human PBMCs were treated with (A) S. pyogenes MGAS5005 and (B) S.
pyogenes MGAS8232 bacterial culture supernatants for 18 hours. Human IL-2 was
assessed by ELISA. There was a significantly lower amount of IL-2 produced between
the wild-type S. pyogenes MGAS5005 and the speJ, smeZ and the speA/speJ/smeZ
isogenic knockout supernatant-treated PBMCs. There was statistically significant lower
amount of IL-2 produced between the S. pyogenes MGAS8232 wild-type and the speC,
SAg and the SAg + speA-treated PBMCs. Shown is the average of individual data
points, with the average ( SE). (*, P <0.05, and **, P <0.005, and ***, P <0.0005 as
assessed by unpaired t-test).
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Appendix 6. Animal protocol ethics approval.
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Appendix 7. Human ethics approval.

173

174

Curriculum Vitae
KATHERINE JESSICA KASPER
Education:
2007-2013

Ph.D. Candidate (Microbiology and Immunology), The University of
Western Ontario, London, Ontario.

2004-2007

M.Sc. (Microbiology and Immunology) The University of Western
Ontario, London, Ontario.

1998-2004

B.MSc. Honors (Microbiology and Immunology, Minor Biochemistry)
The University of Western Ontario, London, Ontario.

Employment Experience:
May 2007-Jan. 2013

Ph.D. candidate
The University of Western Ontario, London, Ontario
Successfully completed Ph.D. candidacy examination in March 2008.

May 2004-Apr. 2007

Masters Student
The University of Western Ontario, London, Ontario.

Sept. 2003-May 2004 4th Year Honors Project Student
The University of Western Ontario, London, Ontario.
Nov. 2000-May 2004

Work Study Student
Department of Biochemistry, The University of Western Ontario,
London, Ontario.

Sept. 2002-Sept. 2003 Internship Student, Quality Control Manager
Labatt Breweries, Packaging Q.C. Dept., London, Ontario.
May 2002-Aug. 2002

Summer Student (Summer Studentship)
Samuel Lunenfeld Institute, Casper Lab, Toronto, Ontario.

175

Teaching Experience:
Sept. 2007-Dec. 2010

Laboratory Teaching Assistant, Microbiology 2100a
The University of Western Ontario, London, Ontario
-Nominated for “Graduate Student Teaching Award” by students in all
three years.

Sept. 2005-Dec. 2005

Laboratory Teaching Assistant, Microbiology 2100a
The University of Western Ontario, London, Ontario
-Microbiology and Immunology introductory lab course. Nominated for
“Graduate Student Teaching Award”

Sept. 1995-Dec. 1997

Continuing Education Instructor and Coordinator
Waterloo County Board of Education, Kitchener, Ontario.
-Ran and coordinated the “Toy Box Theatre” program.

Awards:
Jan. 2013

John A. Thomas Award ($1000)
The Department of Microbiology and Immunology, Western University

May 2011-Apr. 2012

Ontario Graduate Scholarship ($15,000)

May 2011

Drs Charles & Madge Macklin Award for Teaching and Research ($3000)

Schulich School of Medicine and Dentistry
May 2008-Apr. 2011

Doctoral Research Award ($63,000)
Canadian Institute for Health Research.

May 2005-Apr. 2011

Western Graduate Research Scholarship ($28,000)
The University of Western Ontario, London, Ontario.

May 2009

Drs Charles & Madge Macklin Award for Teaching and Research ($3000)

Schulich School of Medicine and Dentistry
Sept. 2007-May 2008

Schulich Graduate Enrichment Scholarship Research Award ($12,000)

176
Schulich School of Medicine and Dentistry
Oct. 2008

Travel Award ($500)
Gram-positive Pathogens Conference in Omaha, Nebraska, U.S.A.

Oct. 2006

Travel Award ($1,000)
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.

Oct. 2006

Travel Award ($500)
Gram-positive Pathogens Conference in Omaha, Nebraska, U.S.A.

Summer 2002

Summer Studentship ($5,000)
The Samuel Lunenfeld Institute, Mount Sinai Hospital, Toronto, Ontario

Publications:
1.

Rahman, A. K. M. N., D. A. Bonsor, C. A. Herfst, F. Pollard, M. Peirce, A. W. Wyatt, D. M.
Mazzuca, K. J. Kasper, J. Madrenas, E. J. Sundberg, and J. K. McCormick. 2011. The T
cell receptor -chain second complimentarity determining region loop (CDR2β) governs T
cell activation and Vβ-specificity by bacterial SAgs.

Journal of Biological Chemistry

286(6):4871-81.
2.

Hayworth J. L.*, Kasper, K. J.*, Leon-Ponte, M., Herfst, C. A., Yue, D., Brintnell, W. C.,
Mazzuca, D. M., Heinrichs, D. E., Madrenas, J., Hoskin, D. W., McCormick, J. K., and S. M.
Haeryfar. 2009. Attenuation of massive cytokine response to the staphylococcal enterotoxin
B superantigen by the innate immunomodulatory protein lactoferrin. Clinical Experimental
Immunology. 157(1):60-70. *Equal contribution.

3.

Chau, T. A., McCully, M. L., Brintnell, W., An, G., Kasper, K. J., Vines, E. D., Kubes, P.,
Haeryfar, S. M., McCormick, J. K., Cairns, E., Heinrichs, D. E., and J. Madrenas. 2009.
Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigeninduced T cell activation and prevent toxic shock syndrome. Nature Medicine. 15(6):641-8.

4.

Kasper, K. J., W. Xi, A. K. M. N. Rahman, M. Kotb, J. Madrenas, E. J. Sundberg, and J. K.
McCormick. 2008. Molecular Requirements for MHC Class II α-Chain Engagement by the
Group IV Bacterial Superantigen SpeC. Journal of Immunology. 181(5):3384-92.

177

5.

Günther, S., Varma, A. K., Moza. B., Kasper, K. J., Wyatt, A. W., Zhu, P., Rahman, A. K.
M. N., Li, Y., Mariuzza, R.A., McCormick, J.K. and E.J. Sundberg. 2007. A novel loop
domain in SAgs extends their T cell receptor recognition site. Journal of Molecular Biology.
371(1):210-21.

6.

K.J. Kasper. 2007. Functional Characterization of Streptococcal Superantigen Low-Affinity
MHC Class II Binding Interfaces. The University of Western Ontario. (Master’s thesis)

Oral Presentations At Professional Meetings:
January 2013 “Superantigens dictate host-specific nasopharyngeal infection by Streptococcus
pyogenes”. PhD public lecture. Western University, London, Ontario.
November 2007 “Functional Mapping of the Low-Affinity MHC Class II Site of the
Streptococcal Superantigen SpeC”. Infection and Immunity Research Forum. The University of
Western Ontario, London, Ontario.

Poster Presentations At Professional Meetings:
1. Kasper, K. J., Xu, S. X., Mazzuca, D. M. Baroja, Land McCormick, J. K. Development of a
model to assess the role of streptococcal virulence factors in nasal-associated lymphoid tissue
colonization in mice. London Health Research Day. London, Ontario. March, 2012.
2. Kasper, K. J., Xu, S. X., Mazzuca, D.M. and McCormick, J. K. Development of a model to
assess the role of streptococcal virulence factors in nasal-associated lymphoid tissue
colonization in mice.

Canadian Society of Microbiology Conference. St. Johns,

Newfoundland. June 2011
3. Kasper, K. J., Mazzuca, D. M., and J. K. McCormick. Development of a model to assess the
role of streptococcal SAgs in nasal-associated lymphoid tissue colonization in mice. Margaret
Moffat Research Day, London, Ontario. March, 2011.
4. Kasper, K. J., Mazzuca, D. M., and J. K. McCormick. Development of a model to assess the
role of streptococcal SAgs in nasal-associated lymphoid tissue colonization in mice. Banff
Conference on Infectious Diseases, Banff, Alberta. May, 2010

178

5. Patterson K. G., Dixon, J. L., Bastedo, P. S., Gupta, S. S., Kasper K. J., and J. K. McCormick.
Development of superantigen-derived anti-cancer immunotherapeutics. Infection and
Immunity Research Forum. London, Ontario. November 2009.
6. Kwon, T., Kasper, K. J., Pollard, F., and J. K. McCormick. Allium sativum as a potential
antimicrobial against group A streptococcal infections. The Infection and Immunity Research
Forum. London, Ontario, Canada. November 2009.
7. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick. Inhibition of streptococcal
SAgs by IVIG. The Third Annual Infection and Immunity Research Forum. London, Ontario,
November 2008.
8. Patterson K.G., Dixon, J.L., Bastedo, P.S., Gupta, S.S., Kasper K.J., and J.K. McCormick.
Development

of

superantigen-derived

anti-cancer

immunotherapeutics.

Infection

and Immunity Research Forum. London, Ontario. November 2008.
9. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick. Inhibition of streptococcal
SAgs by IVIG. The Third Annual Canadian Society for Life Sciences Research Conference.
Toronto, Ontario, November 2008.
10. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick. Inhibition of streptococcal
SAgs by IVIG. The National Conference for Gram-positive Pathogens. Omaha, Nebraska,
U.S.A. October 2008.
11. Patterson K. G., Dixon, J. L., Bastedo, P. S., Gupta, S. S., Kasper K. J., and J. K. McCormick.
Development of superantigen-derived anti-cancer immunotherapeutics. Canadian Society of
Microbiology Conference. Calgary, Alberta. June 2008.
12. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick. Low-affinity MHC class II
binding of streptococcal SAgs.

The National Conference for Gram-positive pathogens.

Omaha, Nebraska, USA. October 2006.
13. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick. Low-affinity MHC class II
binding of streptococcal SAgs. Canadian Society of Microbiologists Annual Meeting Student
Poster Competition. London, Ontario. June 2006.

179
14. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick. Low-affinity MHC class II
binding of streptococcal SAgs. Margaret P. Moffatt Graduate Research Day. University of
Western Ontario, London, Ontario. May 2006.
15. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick. Low-affinity MHC class II
binding of streptococcal SAgs. Lawson Health Research Day. London, Ontario. March 2006.
16. McCormick, J. K., C. A. Herfst, J. M. Laughton, J. L. Dixon, J. N. W. Herbert, A. K. M. N.
Rahman, C. M. Kerr, K. J. Kasper, I. Gryski, N. Brouillard, and S. A. Cuozzo. Molecular
biology of Gram-positive bacteria: toxins, islands, communication, and in vivo expression
technology. The Canadian Institutes of Health Institute for Infection and Immunity New
Investigator Forum. Toronto, Ontario. April 2005.
17. Kasper, K., and J. K. McCormick. Evolution of pathogenicity islands in Streptococcus
pyogenes.

University of Toronto Microbiology and Infectious Diseases Research Day.

Toronto, Ontario. July 2004.
18. Kasper, K., and J. K. McCormick. Evolution of pathogenicity islands in Streptococcus
pyogenes. 15th Annual Sister Mary Doyle Research Day. London, Ontario. March 2004.
19. Kasper, K., Detmar, J., and R. Casper. The role of Bax in apoptosis in mouse placenta and
the creation of an inducible mouse model for preeclampsia. Samuel Lunenfeld Institute
Summer Studentship Poster Competition. August 2002.

Scholarly and Professional Activities:
Student Mentorship and Supervision
Feb. 2008 –Jan. 2013

Actua Student Mentor
Actua Science Mentorship Program, CIHR.

Sept. 2010-May 2011

Direct Supervisor and Mentor to 4th year Honors Thesis Student
Supervised and mentored a 4th year honors thesis student in day-to-day
lab work.

Nov. 2007-Aug. 2010

Supervisor and Mentor High School Student
Mentored a high school student (Tony Kwon) who worked on science fair
projects. He placed first in the local science fair for three years, which

180
allowed him to participate in Canada-Wide Science Fair. In 2009 he
placed first at The National Science Fair and was invited to present his
work at an international science fair in Tunisia in the summer of 2009. In
2010 was named one of the top 20 under 20.

Roles in Conferences
Nov. 2012

Volunteer
Infection and Immunity Research Forum Organizing Committee.
The Department of Microbiology and Immunology, Western University
London, Ontario.

Nov. 2009-Jan 2011

VP of Donor/Sponsor Relations
Infection and Immunity Research Forum Organizing Committee.
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.

Nov. 2009-Jan. 2010

Past Chair
Infection and Immunity Research Forum Organizing Committee.
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.

Nov. 2008-Jan. 2009

Chair
Infection and Immunity Research Forum Organizing Committee.
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.

May 2007–2008

VP Advertising and Event Promotion
Infection and Immunity Research Forum Organizing Committee
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.

June 2006

Student Volunteer
The Canadian Society of Microbiologists Annual Meeting

Memberships in Professional Societies
2009-Present

Society for Industrial Microbiology and Biotechnology

181

2007-Present

American Society for Microbiology

2006-Present

Canadian Society of Microbiologists

University Committees
May 2007-Sept. 2010

Student Representative
Infection

and

Immunity

Seminar

Series

Committee

Student

Representative. The Department of Microbiology and Immunology, The
University of Western Ontario, London, Ontario.
Sept. 2009-Sept. 2010 Graduate Student Representative
Student Liaison to the Faculty Committee
The Department of Microbiology and Immunology, The University of
Western Ontario, London, Ontario.
Sept. 2004-Sept. 2008 Social Committee Member
Department of Microbiology and Immunology Social Committee
The University of Western Ontario, London, Ontario.

Outreach and Volunteer Work
March 2012

Science Fair Judge
Orchard Park Public School

Oct. 2010

Representative of Schulich School of Medicine and Dentistry
Represented The Schulich School of Medicine and Dentistry at a graduate
training recruitment event at The University of Toronto at Mississauga
Campus.

March 2010

Science Fair Judge
London District Science and Technology Fair, London, Ontario.

March 2010

Representative at Faculty of Science March Break Open House
The University of Western Ontario, London, Ontario.

March 2009

Science Fair Judge and Assistant Division Chair
London District Science and Technology Fair, London, Ontario.

182
March 2009

Representative at Faculty of Science March Break Open House
The University of Western Ontario, London, Ontario.

April 2008

Science Fair Judge
London District Science and Technology Fair, London, Ontario.

March 2007

Representative at Faculty of Science March Break Open House
The University of Western Ontario, London, Ontario.

Professional Development
2012

Alternative Curriculum Delivery (Schulich School of Medicine and Dentistry)

2012

Rethinking Multiple Choice (Schulich School of Medicine and Dentistry)

2011

Microsoft Access 2010 Level 1 (Schulich School of Medicine and Dentistry)

2011

Microsoft Excel 2010 Level 2 (Schulich School of Medicine and Dentistry)

2011

Microsoft Powerpoint Level 2 (Schulich School of Medicine and Dentistry)

2011

Teamboard Instruction (Schulich School of Medicine and Dentistry)

2010

WHMIS (The University of Western Ontario

2010

Radiation Safety (The University of Western Ontario)

2009

Gas anesthesia training (UWO ACVS)

2009

Rodent Handling (UWO ACVS)

2009

Basic animal care and use (UWO ACVS)

